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Abstract 
 
 This PhD thesis describes research into the structure and function of 
lysostaphin (EC 3.4.24.75), a glycylglycine endopeptidase secreted by 
Staphylococcus simulans biovar staphylolyticus ATCC 1362. Lysostaphin is a 
member of the M23/M37 zinc metalloprotease family and is a pre-pro-enzyme. 
The mature form (after removal of the pro-region) contains two distinct 
domains, the C-terminal cell wall targeting domain of lysostaphin (termed 
LssTdom in the thesis) facilitates binding to Staphylococcus aureus cells. The 
endopeptidase domain (termed LssEdom in the thesis) cleaves the 
pentaglycine crosslinks in the peptidoglycan resulting in cell death through 
cell rupture of S. aureus.  
Lysostaphin is a potential therapeutic antibiotic for Methicillin-
resistant Staphylococcus aureus (MRSA) for which new antibacterials are 
required owing to the widespread occurrence of multi-drug resistant strains. To 
date, the structural requirements for enzymatic activity and the target in the 
cell wall for lysostaphin have not been fully elucidated. Thus a structure might 
enable rationally guided design of lysostaphin variants for the generation of 
new enzymes which would also cleave the non-canonical crosslinks and would 
thus overcome bacterial resistance.  
Thus, one approach was to obtain the lysostaphin structure using 
homology modelling. Lysostaphin shares significant homology with the ALE-
1 (83 % identity) and LytM (48 % identity) bacteriocins, and modelling the 
structure of lysostaphin was achieved using the recently released structures of 
LytM and ALE-1 derived from X-ray crystallography as templates. In 
 v
addition, we report the successful production of active recombinant 
lysostaphin (as well as the endopeptidase and the targeting domains) and initial 
characterisation of their secondary structure by Fourier-transform infrared 
spectroscopy.  
Initially, advanced spectroscopic techniques including X-ray and NMR 
methods were investigated for molecular interaction studies between Lss and 
its putative ligands. Significant problems were encountered with these 
methods and mass spectrometry studies proved more amenable. Lysostaphin 
targeting domain-ligand complexes have been identified, along with their 
stoichiometry. The strength of the protein-ligand interactions has also been 
quantified. Lysostaphin was shown to bind in vitro Gly5 (mimicking the 
pentaglycine cross-bridge) and Lys-D-Ala-D-Ala (mimicking the stem peptide) 
with low affinity, but not NAM-L-Ala-D-iGln-Lys. It was also shown that 
lysostaphin targeting domain affinity for Gly5 was significantly reduced by 
addition of Gly-Gly-Ser-Gly-Ser (found in the host bacteria resistant to 
lysostaphin action – S. simulans) in solution. From these studies it could be 
concluded that resistance due to the incorporation of serine residues in the 
crossbridge were a result of the endopeptidase domain being unable to cleave 
this sequence and not due to the targeting domain being unable to bind it.  
 
 
 
 vi
Acknowledgements 
 
I dedicate this work to my parents. A maman, Alex, Fred et Manu pour 
leur amour. 
I would like to thank several people who helped in completing this 
thesis. My supervisors past and present: Dr F. Villalba gave me fundamental 
skills and Dr S. Blanquet was exemplary in many ways, Prof N.R. Thomas and 
Prof R. James gave me the great opportunity to do a PhD in England. I 
appreciated their flexibility as they helped me go and learn from other 
institutes and groups. 
 I also would like to thank the University of Nottingham for funding my 
PhD and the School of Chemistry for awarding me a competitive BEST 
(Business, Engineering and Science, and Travel) scholarship to fund my 
participation in the Cold Spring Harbour Laboratory Workshop entitled Phage 
Display of Proteins and Peptides. 
Dr M. Paoli and his student Dr S. Schneider, have contributed to the 
crystallisation studies and Dr N. Oldham and his student J. Hopper to the 
interaction studies. I am indebted to Dr J-P. Duneau and M. Mazanetz for their 
altruistic contributions to the structural studies.   
A particular thank to Dr R. Warfield, for her kindness, for providing 
me with substrate, and for correcting my English, Dr J. Long for running 
preliminary NMR studies, J. Heep and G. Coxhill for technical support and Dr 
P. Bardelang, J. Sharpe, Dr M. Vankemmelbeke, Prof P. Soultanas, Prof M. 
Searle for useful advice. A special thank you to W.Chen, the M.Sci. student 
who worked on the project, for her dynamism and her curiosity.  
 vii
My friends Anne, Aurélie, Delphine, Isabelle and Rebecca deserve 
great credit for sticking with me throughout my studies and they did not deny 
me their moral support. Anne-Laure, Cristina, Karin, Laetitia, Stephanie and 
Stephan deserve a special thank for helping me in my final year. My door will 
always be open for them.  
Manuel kept me on track with his advice and ideas, his sense of 
humour and “art de vivre”. If it was not for his love and his care, I could not 
have gotten so far.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii
Abbreviations 
 
AA   amino acid 
Abs, A   absorbance 
Abz   N-(2-aminobenzoyl) 
ATR   attenuated total reflection 
B. anthracis  Bacillus anthracis 
C   concentration 
CD   circular dichroism 
(L-R) CPL  (left-right) circularly polarised light 
Da   Dalton 
DMSO  dimethyl sulfoxide 
DN   scale down 
DNA   deoxyribonucleic acid 
DSC   differential scanning calorimetry 
DTT   dithiothreitol 
E. coli   Escherichia coli 
EDDnp  N-(2,4-dinitrophenyl) ethylene 
E. faecalis  Enterococcus faecalis LMG2333 
EnlA   enterolysin A 
Epr   endopeptidase resitance factor 
ESI   electrospray ionisation 
FPLC   fast protein liquid chromatography 
FRET   (Föster) fluorescence resonance energy transfer 
FT-IR   Fourier-transform infrared 
 ix
GCP   gel permeation chromatography 
GISA   glycopeptide-resitant Staphylococcus aureus 
GFP   green fluorescent protein 
GST   glutathione S-transferase 
HPLC   high performance liquid chromatography 
HSQC   heteronuclear single quantum coherence 
IC50   half maximal inhibitory concentration 
IMAC   immobilised metal affinity chromatography 
IPTG   isopropyl-ȕ-D-thiogalactopyranoside 
ITC   isothermal titration calorimetry 
KD   dissociation constant 
KM   Michaelis constant 
[L]   free ligand 
L   ladder 
LB   Luria-Bertani 
Lif   lysostaphin immunity factor 
Lss   lysostaphin 
LssEdom  lysostaphin endopeptidase domain 
LssTdom  lysostaphin targeting domain 
LTA   lipoteichoic acid 
M   molar 
M. luteus  Micrococcus luteus 
(M9)MM  M9 minimum medium 
MRSA   methicillin-resistant Staphylococcus aureus 
MS   mass spectrometry 
 x
NAG, G  N-acetylglucosamine 
NAM, M  N-acetylmuramic acid 
NMR   nuclear magnetic resonance 
NTA   nitrile acetate agarose 
OD   optical density (absorbance per unit distance) 
(o-)ToF  (orthogonal) time of flight 
[P]   free protein 
[PL]   protein-ligand complex 
PAGE   polyacrylamide gel electrophoresis 
PBP   penicillin-binding protein 
PCR   polymerase chain reaction 
PDB   protein database 
PEG   polyethylene glycol 
PEP   phosphoenol pyruvate 
pep3   tripeptide 
pep5   pentapeptide 
PGRP   peptidoglycan recognition protein 
QMC   Queens medical centre 
RFU   relative fluorescence unit 
RMSD   root mean square deviation 
RNA   ribonucleic acid 
S. aureus  Staphylococcus aureus 
S. capitis  Staphylococcus capitis 
S. carnosus  Staphylococcus carnosus 
SDS   Sodium Dodecyl Sulphate 
 xi
S. epidermidis  Staphylococcus epidermidis 
S. gordonii  Streptococcus gordonii 
SH3   Src homology 3 domain 
S. mutans  Streptococcus mutans 
SPR   surface plasmon resonance 
S. pyogenes  Streptococcus pyogenes 
S. saprophyliticus Staphylococcus saprophylyticcus 
S. simulans Staphylococcus simulans biovar staphylolyticus 
ATCC1362 
S. zooepidemicus Streptococcus equi subsp. zooepidemicus 
TFA   trifluoroacetic acid 
TLN   thermolysin 
UDP   uridine diphosphate 
UP   scale up 
UV   ultra violet 
VISA   vancomycin-intermediate Staphylococcus aureus 
VRSA   vancomycin-resistant Staphylococcus aureus 
Vmax   maximal velocity 
v/v   volume per volume 
w/v   weight per volume 
WTA, TA  wall teichoic acid 
Zif   zoocin immunity factor 
 
 
 
 xii
List of amino acids and their code:  
A, Ala   alanine 
C, Cys   cysteine 
D, Asp   aspartic acid 
E, Glu   glutamic acid 
F, Phe   phenylalanine 
G, Gly   glycine 
H, His   histidine 
I, Ile   isoleucine 
K, Lys   lysine 
L, Leu   leucine 
M, Met  methionine 
N, Asn   asparagine 
P, Pro   proline 
Q, Gln   glutamine 
R, Arg   arginine 
S, Ser   serine 
T, Thr   threonine 
V, Val   valine 
W, Trp  tryptophan 
Y, Tyr   tyrosine 
 
 
 1
1. Introduction 
1.1. Peptidoglycan structure and biosynthesis 
1.1.1. Targeting bacterial cell wall 
Peptidoglycan is a vital component of virtually all bacterial cells and 
accounts for approximately 50% of the weight of Gram-positive 
(staphylococci, streptococci) bacterial walls. Figure 1 shows a schematic of the 
cell envelope of a typical Gram-positive bacterium. The peptidoglycan 
polymer is responsible for the shape, mechanical strength and integrity of 
bacterial cells. If the peptidoglycan is disrupted or its synthesis is selectively 
blocked by antibiotic action, bacteria undergo a number of changes in shape 
and they ultimately die as a result of cell lysis. As mammalian cells do not 
possess a cell wall or macromolecular structure that ressembles peptidoglycan, 
antibiotics that act on peptidoglycan have excellent selective toxicity.  
 
In this study, we focused on staphylococci and particularly on 
Staphylococcus aureus, because it is a pathogenic Gram-positive bacterium 
that is a significant cause of healthcare infections. S. aureus is a spherical 
bacterium (coccus) which on microscopic examination appears in pairs, short 
                                                 
 }Adapted from: http://student.ccbcmd.edu/courses/bio141/lecguide/uniH/prostruct/gpcw.html 
Figure 1: Schematic of the cell wall envelope of a typical Gram-positive bacterium
}
.  
 2
chains, or bunched, grape-like clusters. It is found on the mucous membranes 
and on the skin of approximately a third of the human population and owes its 
name (aureus) to the golden colour of its colonies when grown on solid media. 
In susceptible hosts: neonates, immunologically suppressed and post-operative 
patients, S. aureus can cause serious hospital-acquired infections including: 
pneumonia, endocarditis, osteomyelitis, skin and soft tissue infections. 
1.1.2. The main constituents of peptidoglycan 
The peptidoglycan of S. aureus contains glycan chains, which are 
cross-linked by short peptide bridges. Alternating units of N-
acetylglucosamine (NAG; G) and N-acetylmuramic acid (NAM; M) joined by 
ȕ-1,4 glycosidic linkages constitute the glycan chains (20 disaccharides in 
length) (Schleifer and Kandler, 1972). Each M unit has a short “stem” peptide 
chain attached and this is cross-linked by a short bridging peptide chain. These 
peptide chains are species specific. In S. aureus, the short stem peptides are 
composed of L-alanine, D-isoglutamic acid, L-lysine and two D-alanine units 
(L-Ala-D-iGlu-L-Lys-D-Ala-D-Ala) and are linked via an amide bond to the D-
lactyl moiety of N-acetylmuramic acid (Figure 2). Neighbouring wall peptides 
are cross-linked between the free İ-amino group of L-lysine in one peptide and 
the carboxyl group of the penultimate D-alanine in another via pentaglycine 
cross bridges (-Gly5-), whereby the D-Ala in position 5 is split off during 
transpeptidation. Together, the glycan strands and cross-linked wall peptides 
generate the three-dimensional exoskeletal network of peptidoglycan. The 
recently reported NMR structure of peptidoglycan provided a right-handed 
helical conformation of the polysaccharide backbone producing a threefold 
 3
symmetry in the molecule (Meroueh et al., 2006). This result led to the 
proposed honeycomb pattern for the cell wall.  
 
 
 
The high cross-linkage (80%) of the peptides between the glycan 
chains gives the peptidoglycan macromolecule the mechanical strength needed 
to resist the high osmotic pressure that exists on bacterial cell membrane. It 
also acts as attachment site for various cell wall-sorted proteins, which are 
important in infection and virulence of this pathogen (Perry et al., 2002, Roche 
et al., 2003). 
1.1.3. Stages of peptidoglycan biosynthesis 
S. aureus peptidoglycan biosynthesis described by Schneider and 
coworkers (Schneider et al., 2004) can be divided into three stages described 
                                                 
 $Adapted from: Arbeloa et al., 2004  
Figure 2: Structure of S. aureus peptidoglycan sheet 
$
.  
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in Figure 3. The first stage occurs in the cytoplasm starting with the 
nucleotide-linked sugar UDP-NAG, which is converted to UDP-NAM in two 
steps, catalysed by MurA and MurB. The pentapeptide is then sequentially 
elongated from the lactyl moiety of the UDP-NAM, one or two amino acids at 
a time, to produce the final cytoplasmic precursor, UDP-NAM- L-Ala-D-iGlu-
L-Lys-D-Ala-D-Ala.  These reactions are catalysed by MurC, MurD, MurE and 
MurF. The second stage occurs at the inner face of the cell membrane, starting 
with the transfer of phospho-NAM-L-Ala-D-iGlu-L-Lys-D-Ala-D-Ala from 
UDP to the lipid carrier undecaprenol-phosphate (C55-P) by the integral 
membrane enzyme MraY, forming lipid-I. In the last intracellular enzymatic 
step, MurG catalyzes the transfer of NAG from UDP-NAG to lipid-I, forming 
lipid-II, which contains the basic monomeric unit of the cell wall, the 
disaccharide pentapeptide, linked to the undecaprenol carrier.  To enter into 
the final stage of synthesis, lipid-II must be flipped so that the disaccharide-
pentapeptide is exposed at the outer surface of the inner membrane and can be 
polymerised and cross-linked into the cell wall. This final stage involves two 
separate reactions: a transglycosylation reaction, in which linear non cross-
linked glycan chains are formed, and a transpeptidation reaction, where the 
peptide substituents are cross-linked on the glycan chains by a pentaglycine. 
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Extensive genetic analysis and characterisation of mutant cell walls 
suggested that the pentaglycine is synthesised in a sequential fashion by non-
ribosomal peptidyltransferases (Hegde and Shrader, 2001, Rohrer and Berger-
Bachi, 2003a). It has been shown that three proteins are involved in the 
formation of the pentaglycine crossbridge in S. aureus peptidoglycan. The 
factor catalysing the first step in its biosynthesis was found to be FemX, 
encoded by the essential gene fmhB (Rohrer et al., 1999). Chain formation also 
depends on the two proteins FemA and FemB, which are encoded by the 
operon femAB. FemA was proposed to catalyse the addition of the second and 
third glycines (Maidhof et al., 1991, Stranden et al., 1997), whereas FemB is 
thought to add glycines four and five (Henze et al., 1993) as shown in Figure 
4. 
                                                 
 hAdapted from Ton-That et al., 2004 
Figure 3: Overview of the pathway of cell wall synthesis
h
. The jagged line in the 
membrane represents undecaprenol-P. Names for the enzymes catalysing each step are 
given above the arrows. 
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 
 
 
 
 
 
Staphylococcal strains producing glycyl-glycine endopeptidases, such 
as lysostaphin (Thumm and Gotz, 1997) or ALE-1 (Sugai et al., 1997b) (cf. 
sections 1.3 and 1.4), protect their cell walls with FemABX-like immunity 
factors, termed Lif or Epr respectively, which insert serine in place of glycine 
in positions three and five in the interpeptide cross-bridge (Ehlert et al., 2000, 
DeHart et al., 1995). This protects the cell wall as lysostaphin and ALE-1 
cannot hydrolyse glycyl-serine or seryl-glycine bonds. It was found that, in 
order for Lif to operate, the functions of FemA and  FemB were required, 
which is in contrast to the previously postulated theory that Lif complements 
FemB in S. aureus femB mutant (Tschierske et al., 1997).  
 
 
                                                 
 jAdapted from Kopp et al., 1996 
Figure 4: Pentaglycine bridge formation
j
. Glycine is transferred to the free H-amino 
group of lysine by the activity of glycyl-tRNA synthetase. FemX is essential for addition 
of the first glycine, while FemA and FemB are needed for addition of glycine 2, 3, and 4,
5, respectively.    
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1.1.4. Peptidoglycan recognition in innate immunity 
Other major constituents of the bacterial cell wall are polyanionic wall 
teichoic acids (WTAs) and lipoteichoic acids (LTAs) (Ghuysen et al., 1965), 
as well as proteins (Navarre and Schneewind, 1999). Many surface proteins 
are anchored by a reaction catalysed by a sortase enzyme via the free amino 
group of uncross-linked pentaglycine side chains to the S. aureus cell wall 
(Ton-That et al., 2004). This ability to anchor to the cell wall requires a 35-
residue sorting signal that consists of an LPXTG motif, followed by a C-
terminal hydrophobic domain and a tail of mostly positively charged residues. 
Cell wall sorting consists of serial steps, which lead to the proteolytic cleavage 
of the polypeptide chain between threonine and glycine of the LPXTG motif. 
The carboxyl of threonine is subsequently amide-linked to the free amino-
group in the pentaglycine crossbridge of the staphylococcal cell wall.  
WTAs, LTAs and surface proteins are involved in the adhesion and 
pathogenesis of S. aureus. Indeed, proteins on the cell wall surface interact 
with host matrix proteins to conceal the bacterial surface from attack by the 
host defence system (Mengin-Lecreulx and Lemaitre, 2005). 
1.2. Antibiotics that work on bacterial cell wall and 
resistance to them 
Since peptidoglycan plays a key role in maintaining the shape and 
structural integrity of the cell wall, interference with any stage in its synthesis 
and assembly is an effective means of inhibiting cell growth. Some of the most 
valuable antibiotics act in this way, including the ȕ-lactams and the 
glycopeptides. However, use of antibiotics selects for growth of rare resistant 
organisms in an otherwise susceptible population. Large numbers of bacteria 
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and the short generation time (approximately four hours) lead to emergence of 
resistance. Resistance genes collected on plasmids and transposable elements 
lead to rapid spread of multidrug resistance between bacterial species. 
S. aureus was the first bacterium in which penicillins G and V 
resistance was found in 1947. Methicillin then became the antibiotic of choice. 
The structures of penicillins G and V and methicillin are shown in Figure 5. 
Penicillins G and V and methicillin are ȕ-lactam antibiotics which irreversibly 
inhibit S. aureus transpeptidases by acting as alternative (suicide) substrates. 
They mimic the structure of D-alanyl-D-alanine residues and react with 
transpeptidases. Transpeptidases bind the ȕ-lactam ring of the antibiotic, thus 
preventing the pentaglycine crosslinks from being incorporated into the 
peptidoglycan layer. The transpeptidase enzymes are usually referred to as 
penicillin-binding proteins (PBPs) (Spratt, 1994). Expression of ȕ-lactamase 
enzymes is the most important mechanism by which organisms become 
resistant to ȕ-lactams. Other mechanisms by which resistance to ȕ-lactams can 
arise also exist. Methicillin-resistant strains of S. aureus (MRSA) display an 
altered pattern of PBPs in which an alternative PBP called 2a (or 2’) is 
produced. This PBP, the product of mecA gene, is a transpeptidase with a very 
low susceptibility to inhibition by methicillin or other ȕ-lactam antibiotics 
(Chambers et al., 1990). Methicillin-resistant S. aureus (MRSA) is a major 
problem in the world, causing the most common hospital and community 
acquired infections that appeared in the 1980s. Wilkinson and coworkers 
reported that the peptidoglycan of some MRSA strains had slightly diminished 
glycine levels compared with that of normal S. aureus strains (Wilkinson et 
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al., 1978). Thus a combination of modified peptidoglycan and expression of 
PBP2’ is responsible for the overall level of resistance expressed by MRSA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since 1997 there have been reports of strains carrying varying levels of 
resistance to glycopeptide antibiotics (glycopeptide intermediate S. aureus or 
GISA), in particular vancomycin (Koehl et al., 2004). Vancomycin, the 
structure of which is shown in Figure 6, has a different mode of action to that 
Figure 5: Penicillins G (structure A) and V (structure B) and methicillin (structure C)
are ȕ-lactam antibiotics. 
A: Structure of penicillin G 
B: Structure of penicillin V 
C: Structure of methicillin 
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of penicillins as it binds to the terminal D-alanyl-D-alanine on each 
pentapeptide side chain by formation of five hydrogen bonds, rather than 
interacting with the transpeptidase itself (Loll and Axelsen, 2000). The 
presence of the bulky glycopeptides on each D-alanyl-D-alanine residue 
prevents extension of the linear glycan peptide in the cell wall by denying 
access of the transpeptidases to the substrate. Boyle-Vavra and coworkers have 
described a spectrum of changes in peptidoglycan composition in different 
GISA strains (Boyle-Vavra et al., 2001). These changes in peptidoglycan 
composition include a decrease in the proportion of highly cross-linked 
peptidoglycan species. It has been proposed that GISA strains have an 
increased number of D-alanyl-D-alanine residues in their cell walls that form 
false targets that sequester vancomycin in the cell wall, preventing it from 
reaching its target D-alanyl-D-alanine in membrane-anchored lipid 
disaccharide-pentapeptide peptidoglycan precursors (Zygmunt et al., 1967). 
Increased levels of PBP2 have also been reported in VISA (vancomycin-
intermediate S. aureus) isolates (Moreira et al., 1997), leading to the 
conclusion that the bacteria synthesise more of these proteins which then 
compete more effectively with vancomycin for their substrate.  
 
 
 
 
 
 11
 
 
Lysostaphin, a lysin expressed by Staphylococcus simulans biovar 
staphylolyticus (Schindler and Schuhardt, 1964), has the capability to digest 
the cell wall of certain staphylococci when applied exogenously (cf. section 
1.3). It has gained renewed interest as an anti-staphylococcal therapeutic agent 
because of the growing emergence of multi-drug resistant S. aureus. The 
literature is inconclusive on lysostaphin susceptibility of MRSA. Zygmunt and 
coworkers found that over 400 strains of multiply resistant MRSA were lysed 
by lysostaphin (Zygmunt et al., 1967), while Sabath and coworkers reported 
diminished lysis of MRSA with lysostaphin (Sabath et al., 1969). Huber and 
Huber studied this question and concluded that lysostaphin susceptibility 
seems to be a reliable taxonomic criterion even in strains which have acquired 
methicillin resistance (Huber and Huber, 1989). Nevertheless, resistance to 
lysostaphin has been described among femAB null mutants of MRSA strains 
Figure 6: Structure of Vancomycin. 
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with alteration of the pentaglycine cross-bridge (Stranden et al., 1997). The 
interpeptide bridge is essential for the full expression of methicillin resistance 
in MRSA. Shortening of the pentaglycine chain impairs growth, leading to 
aberrant septum formation and lowered methicillin resistance level (Maidhof 
et al., 1991). The interpeptide is essential for S. aureus; survival with a 
shortened bridge reduced to only one glycine requires as yet uncharacterised 
compensatory mutations (Ling and Berger-Bachi, 1998). One possible solution 
to the problem of S. aureus becoming resistant to antibiotics is the co-
administration of a ȕ-lactam antibiotic with lysostaphin (Kiri et al., 2002). It 
has been observed that resistance to lysostaphin is usually coupled with an 
increase in the susceptibility to ȕ-lactams, which the strain was previously 
resistant to (Climo et al., 2001). Thus, the right combination of enzyme and 
antibiotic could help in the control of certain antibiotic resistant bacteria.  
Lysostaphin and the phage K lytic enzyme LysK were also tested to 
determine whether their simultaneous use was competitive or synergistic to 
kill MRSA (Becker et al., 2008). The results revealed a clear synergistic effect 
in the efficiency when both enzymes where used. Thus, in addition to more 
effective killing, the use of two different lysins to kill resistant S. aureus could 
retard the emergence of enzyme-resistant mutants significantly.     
1.3. Lysostaphin 
1.3.1. The characteristics of lysostaphin 
Lysostaphin was originally isolated by Schindler and Schuhardt in 
1964 from cell-free filtrates of the Gram-positive coccus, Staphylococcus 
simulans biovar staphylolyticus ATCC1362 (Schindler and Schuhardt, 1964). 
The name was given to a preparation that included a glycylglycine 
 13
endopeptidase, a glucosaminidase and an amidase, but the term was later used 
just to describe the endopeptidase (Iversen and Grov, 1973). Lysostaphin was 
reported as a potential anti-staphylococcal agent against S. aureus and, to a 
lesser extent, S. epidermidis (Wu et al., 2003). It was active against both live 
and autoclaved cells, indicating that it did not disrupt a biosynthetic pathway 
(Schindler and Schuhardt, 1964). The rate at which lysostaphin lysed bacterial 
cells was found to be dependent on the temperature, pH and ionic strength of 
the assay medium, and also on the concentration of the enzyme (Schindler and 
Schuhardt, 1965).  
The glycinase action of the endopeptidase was demonstrated further by 
Browder and coworkers by instant thin layer chromatographic separation and 
UV detection of the post-hydrolysis dansylated products from glycine peptides 
(Browder et al., 1965). This activity indicated that lysostaphin catalyses the 
hydrolysis of the pentaglycine crossbridge in the bacterial peptidoglycan, 
leading to osmotic rupture of the cell membrane and cell death. It has been 
suggested that lysostaphin cleaves specifically between the third and fourth 
glycine residues of the pentaglycine cross-bridge based on the release of 
staphylococcal surface proteins by lysostaphin (Schneewind et al., 1995), 
however analysis of lysostaphin cleaved muropeptides by mass spectrometry 
revealed that cleavage occurs between glycine residues 2 and 3, 3 and 4 and 4 
and 5, with preference for the latter cleavage site (Xu et al., 1997). Moreover 
lysostaphin was reported to bind tightly to elastin and to contain elastolytic 
activity (Park et al., 1995). It was also shown to catalyse transpeptidation of 
glycine peptides (Sloan et al., 1977). 
 14
Slightly different genes encoding lysostaphin, residing on the largest of 
the five plasmids of S. simulans, pACK1 (Recsei et al., 1987, Heath et al., 
1991), were cloned into Escherichia coli by two groups: Recsei and coworkers 
(Recsei et al., 1987) and Heinrich and coworkers (Heinrich et al., 1987) in 
1987. Using DNA sequencing, the open reading frame was determined by the 
first group to consist of 1167 base pairs, corresponding to a precursor of 389 
amino acids, with a calculated molecular weight of 42.2 kDa (Recsei et al., 
1987) and by the second group, to consist of 1440 base pairs, corresponding to 
a precursor of 480 amino acids, with a calculated molecular weight of 51.7 
kDa (Heinrich et al., 1987). Figure 7 shows the lysostaphin nucleotide and 
amino acid sequences of the gene and encoding gene product, respectively, in 
accordance with Recsei and coworkers (Recsei et al., 1987).  
 
 
 
 
 
 
 
 
 
                                                 
hAdapted from: Recsei et al., 1987 
Figure 7: Preprolysostaphin gene from S. simulans and amino acid sequence of the 
encoded gene product
h
. The N-terminal formylmethionine of the preprolysostaphin is 
designated as residue 143 and the N-terminal alanine of mature lysostaphin is 
designated as residue +1. Are underlined: in purple, the first residues of the signal peptide;
in orange, the seven tandem repeat sequences; in light green (+1/+139) and in dark green
(+154/+246), the endopeptidase and targeting domain respectively, of the mature lysostaphin.
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It was observed by amino acid sequence analysis of the encoding 
product that the preprolysostaphin is organised in three distinct regions. 
Commonly observed in preprolysostaphin, the N-terminal region contains a 
cluster of four positively charged residues followed by an uncharged, largely 
hydrophobic sequence. The N-terminal has the properties characteristic of a 
signal peptide directing the protein to the hydrophobic cell membrane. The 
Ala-Ser bond at position –121 and –120 or that at position –108 and –107, in 
the alternative gene, is the likely signal cleavage site that helps to transform 
preprolysostaphin into prolysostaphin. The second region is composed of 7 
tandem repeats of a 13-amino acid pattern (from the sequence obtained by 
Recsei and coworkers) (Recsei et al., 1987) or composed of 15 tandem repeats 
if the sequence obtained by Heinrich and coworkers is considered instead 
(Heinrich et al., 1987). The first repeats (six or fourteen) are identical, while 
the last one contains three amino acid substitutions. This portion of the 
molecule, called prolysostaphin, is highly ionic and has a net negative charge. 
The third region is the mature lysostaphin, which is made up of 246 amino 
acids. Prolysostaphin is secreted, and then activated (converted to the mature 
enzyme) extracellularly by a cysteine (sulfhydryl) protease, via cleavage of the 
N-terminal portion of the proenzyme (Neumann et al., 1993, Bunn et al., 
1998). The protease that converts prolysostaphin to the mature form is itself 
secreted as a proenzyme and then processed autocatalytically to provide the 
active form (Bunn et al., 1998).  
The mature lysostaphin is a zinc-containing metalloenzyme (it contains 
one zinc ion per molecule of protein), consisting of a single polypeptide chain, 
with a molecular weight, when determined by sedimentation equilibrium of 25 
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kDa, a calculated pI of 9.52 and a pH optimum for catalytic activity of 7.5 
(Browder et al., 1965, Trayer and Buckley, 1970). Lysostaphin contains no 
cysteine residues. The enzyme activity is inhibited by excess zinc cations 
(Zygmunt and Tavormina, 1972, Park et al., 1995). Figure 8 shows a 
representation of the arrangement of preprolysostaphin (Thumm and Gotz, 
1997).  
The biologically active structure sufficient for the binding of mature 
lysostaphin to the cell wall of S. aureus consists of the 92 C-terminal residues 
lysostaphin. A lysostaphin molecule lacking the C-terminal targeting domain 
was enzymatically active, but had lost its ability to distinguish between S. 
aureus and S. simulans cells, indicating that this domain functions to confer 
target cell specificity to the bacteriolytic molecule (Baba and Schneewind, 
1996). The targeting domain has been classified as belonging to the SH3b 
family, a prokaryotic homologue of the eukaryotic Src homology 3 (SH3) 
domain mediating protein-protein interactions (Koch et al., 1991). The mature 
lysostaphin lacking the targeting domain is called the endopeptidase domain 
and is classified as part of the M23/37 protease family in the MEROPS 
database (Rawlings et al., 2002). 
Figure 8: Schematic diagram of the amino acid regions of preprolysostaphin.  
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1.3.2. Zinc metalloprotease mechanism 
Zinc-containing metalloproteases constitute an expanding list of 
structurally related proteases that are widely distributed in Nature. 
Thermolysin (TLN) is a typical example from the zinc-metalloprotease 
superfamily. Isolated from Bacillus thermoproteolyticus (Endo, 1962), this 
extracellular endopeptidase catalyses the hydrolysis of the peptide bond 
specifically on the amino side of large hydrophobic residues (Rao et al., 1998). 
The X-ray crystal structure of the enzyme showed that the active site of the 
wild-type TLN had two histidines (His 142, His 146) and one glutamic acid 
(Glu 166) residue coordinating a zinc cation (Colman et al., 1972). The 
glutamic acid 143 formed, together with the above-mentioned two histidines, 
the consensus HExxH motif of the enzyme amino-acid sequence (Lipscomb 
and Strater, 1996). Hall and coworkers suggested an analogy between cryptic 
peptidase sonic hedgehog and thermolysin reaction mechanism (Hall et al., 
1995) and Bochtler and coworkers reported similarities between lysostaphin-
type enzymes, D-Ala-D-Ala metallopeptidases and the N-domain of cryptic 
peptidase sonic hedgehog (“LAS” proteins) (Bochtler et al., 2004). Although 
the active-site geometry might be different in lysostaphin, LytM (a member of 
the M23/37 family) (Firczuk et al., 2005, Bochtler et al., 2004) and 
thermolysin, we suggest some similarity of lysostaphin with thermolysin in 
terms of their hydrolysis of the peptide bond. 
A single-step reaction mechanism for thermolysin was obtained 
following a proposal by Pangburn and Walsh in 1975 (Pangburn and Walsh, 
1975), and refined by Kester and Matthews in 1977 (Kester and Matthews, 
1977). This proposal proceeds as shown in Figure 9 (Hangauer et al., 1984, 
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Holden et al., 1987). Starting from the unligated TLN 1, with a zinc-
coordinated water molecule, the wide groove separating the enzyme in two 
large domains accommodates an extended peptide chain, forming the 
Michaelis complex 2. The glutamic acid 143 activates the incoming 
nucleophilic water molecule, and the protonated histidine 231 that is located 
across the hypothetical position of the substrate, together with the zinc cation, 
enhances the nucleophilicity of the water oxygen that polarises the substrate 
peptide bond for nucleophilic attack on the peptide carbonyl carbon. The 
proton accepted by glutamic acid 143 is immediately shuttled to the peptide 
nitrogen. As a result, a tetrahedral gem-diolate intermediate 3 is formed, where 
zinc is penta-coordinated and the peptide carbon is tetrahedral. In the next 
step, a direct cleavage of the peptide C-N bond takes place, with the amine 
product proposed to be released in its protonated form 4, fitting the neutral pH 
conditions. Here, the glutamic acid 143 serves as a proton shuttle, abstracting 
the second proton from the water oxygen and delivering this proton to the 
amine nitrogen. The catalytic cycle is completed by carboxyl product release, 
probably mediated by incoming water molecule uptake (Pelmenschikov et al., 
2002). 
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 
1.3.3. Therapeutic applications 
Lysostaphin has been investigated as an alternative to conventional 
antibiotics since the 1960s. The drug company Mead Johnson tried to 
develop a product based on a natural extract from S. simulans, containing a 
glycylglycine endopeptidase, a glucosaminidase and an amidase (Zygmunt 
and Tavormina, 1972). It appeared, after experimental studies of 
lysostaphin’s effect on renal staphylococcal infection models in mice, that 
lysostaphin warranted further consideration as a potential 
antistaphylococcal agent for systemic use (Harrison and Zygmunt, 1967). 
Other parallel studies in animal models of oxacillin-susceptible S. aureus-
                                                 
 iAdapted from: Lipscomb et al., 1996 
Figure 9: Experimentally proposed reaction for thermolysin
i
. 
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induced infection indicated that lysostaphin was an effective treatment 
agent against experimental aortic valve endocarditis in dogs caused by S. 
aureus (Goldberg et al., 1967). It was also found that lysostaphin could be a 
potentially useful agent for the treatment of epidemiologically important 
nasal carriers of S. aureus (Quickel et al., 1971).  
However, the lysostaphin preparations used were only available in 
partially purified form, and as there were other anti-staphylococcal 
antibiotics widely available (Zygmunt and Tavormina, 1972), further 
development of lysostaphin for clinical use was halted until the recent 
introduction of recombinant lysostaphin (that is more than 90% pure) in the 
1980s enabled more extensive investigation. In 2000 lysostaphin was 
placed into clinical trials by the American company Biosynexus and large 
scale production of the protein was carried out by a partner company, 
Avecia (McCoy, 2004). The availability of recombinant lysostaphin has 
provided an opportunity to assess the efficacy of lysostaphin in an animal 
model of S. aureus endocarditis and to compare it to the efficacy of 
standard therapy with vancomycin (Climo et al., 1998, Patron et al., 1999). 
It was found that lysostaphin was effective whereas vancomycin performed 
poorly. A more extensive investigation of the clinical use of this form of 
lysostaphin to treat humans was reported in the case of a formulation of 
nasal cream containing lysostaphin (von Eiff et al., 2003). This cream was 
spread in the anterior nostrils: these are the primarily ecologic niche for S. 
aureus, to stop the nasal colonisation by this opportunist pathogen that 
increases the risk of development of a S. aureus infection (Kokai-Kun et al., 
2003). From these experiments it appeared that lysostaphin is not 
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inactivated by body fluids. The development of lysostaphin as an 
intravenous antibiotic has also been investigated, showing an increased 
effectiveness of lysostaphin over penicillin G in augmenting the survival 
rate of mice infected by staphylococci (Schaffner et al., 1967). Zygmunt 
and coworkers showed in an in vitro study that serum exhibited a minimal 
antagonizing effect on the antibiotic activity of lysostaphin (Zygmunt et al., 
1966). However, clinical use of bacterial enzymes systematically has been 
associated with some toxicity and hypersensitivity problems. It was found 
that conjugation by polyethylene glycol (PEG) significantly enhanced 
lysostaphin’s therapeutic value as an intravenous antibiotic against S. 
aureus, by increasing its tissue distribution and decreasing its 
immunogenicity (Walsh et al., 2003). It was found that the half life of 
lysostaphin in blood serum increased from one hour (when unconjugated) 
to a maximum of 24 hours upon conjugation with PEG.  
Another example of clinical use of lysostaphin was found by coating 
a catheter with lysostaphin to prevent catheter colonisation by several 
strains of  S. aureus (Shah et al., 2004). Staphylococcal biofilms can lead to 
infections in biomedical implants, which tend to be difficult to treat and are 
usually much more resistant to antibiotics than those in normal colonies; 
this may make it necessary to remove a pacemaker or an artificial joint and 
replace it. To solve the problem, the activity of lysostaphin on biofilms 
made up of colonies of S. aureus and S. epidermidis has been examined. 
Lysostaphin not only killed S. aureus in biofilms, which were resistant to 
very high concentrations of oxacillin, vancomycin and clindamycin, but 
also disrupted the extracellular matrix of biofilms in vitro on plastic and 
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glass surfaces (Wu et al., 2003). Unlike most antibiotics that interfere with 
the growth of bacteria, lysostaphin is highly effective in lysing both actively 
growing and dormant S. aureus cells (Schindler and Schuhardt, 1964), 
which gives it an additional therapeutic value.  
1.4. Endopeptidases related to lysostaphin: 
structure and function 
Bacteriocins are proteinaceous antibiotics produced by one bacterium 
that principally have killing activity against closely related bacteria (Jack et al., 
1995, Joerger, 2003). Bacteria produce various peptidoglycan hydrolases that 
include N-acetyl-glucosaminidases, N-acetyl-muramidases, N-acetyl-muramyl-
L-alanine amidases, endopeptidases, and transglycosylases (Ghuysen et al., 
1966). Sites of hydrolysis of various muralytic enzymes on the peptidoglycan 
of S. aureus are shown in Figure 10. Enzymes secreted by a number of 
different bacteria have been found to have similar activity to that of 
lysostaphin as described below.  
                                                 
 ?Adapted from: Navarre et al., 1999 
Figure 10: Sites of hydrolysis of various muralytic enzymes on the peptidoglycan of S. 
aureus
?
.   
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1.4.1. LytM 
A gene encoding an autolytic activity was identified in S. aureus by 
Mani and coworkers, in 1993 (Mani et al., 1993). Its open reading frame, 
designated LytM, is made of 948 base pairs that encode a polypeptide of 316 
amino acids. The calculated molecular mass of LytM corresponds to that of the 
autolytic activity protein detected: 36 kDa. A putative signal sequence, as well 
as a putative signal peptide cleavage site, is present within the first 26 amino 
acids. The signal sequence is strongly hydrophobic and characteristic of 
secreted proteins. Significant amino acid sequence homology was found with 
lysostaphin when compared with LytM: the C-terminal region of LytM 
showed significant homology (48%) with N-terminal region of the mature 
lysostaphin (Ramadurai and Jayaswal, 1997, Nilsen et al., 2003). Based on its 
similarity with lysostaphin, the enzyme would be expected to be specific for 
glycine rich sequences, a conclusion that is supported by experimental data 
(Ramadurai et al., 1999). It degrades the cell walls from S. carnosus and the 
Lyt- mutant of S. aureus, but not those from Micrococcus luteus, leading the 
authors to speculate that the enzyme is a glycyl-glycine endopeptidase 
(Ramadurai et al., 1999). 
They also suggested that LytM could be a member of the zinc-
metalloprotease enzyme group as it contains a 38 amino acid motif Y-x-H-
x(11)-V-x(12/20)-G-x(5-6)-H, homologous to other members (Sugai et al., 
1997a, Bochtler et al., 2004), and has conserved histidine residues, which are 
believed to bind the zinc cofactor (Ramadurai et al., 1999). Recently the X-ray 
crystal structure as been presented by Odintsov and coworkers in 2004 as the 
first structure of a lysostaphin-type peptidase (Odintsov et al., 2004). It 
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demonstrated that LytM is a two domain ȕ-protein. The N-terminal domain 
was found to make limited contact with the C-terminal domain (Figure 11).  
 
 
 
 
 
 
 
 
 
 
In the active LytM185-316 structure presented by Firczuk and coworkers 
in 2005, the zinc cation is tetrahedrally coordinated by the side-chains of His 
210, Asp 214 and His 293 and presumably the water molecule as the fourth 
ligand as shown in Figure 12 (Firczuk et al., 2005).They are part of two 
motifs, H-x(3)-D and H-x-H. The Nİ of histidine 210 and the Nį of histidine 
293 imidazole rings donate their free electron pairs to the zinc ion (Firczuk et 
al., 2005, Bochtler et al., 2004). The Nİ of histidine 210 and the Nį of histidine 
293 are therefore protonated and donate a hydrogen bond to a carbonyl oxygen 
of the main chain and a glutamine of the side chain, respectively. Histidine 260 
is assigned as the catalytic base that activates the water molecule together with 
the zinc cation (Bochtler et al., 2004). All active-site residues are located on or 
                                                 
 xAdapted from: Odintsov et al., 2004 
Figure 11: Ribbon representation of latent LytM structure (PDB code 1QWY)
x
.    
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around a ȕ-sheet scaffold. The core of this central ȕ-sheet consists of four 
antiparallel ȕ-strands (Firczuk et al., 2005).  
 
 
 
 
 
 
 
 
 
Interestingly, three consecutive glycine residues, 206 to 208, in one of 
the most exposed loops of the LytM structure, appeared to fill different parts 
of the LytM185-316 groove in two different crystal forms as a surrogate substrate 
analogue (Firczuk et al., 2005). It was shown that a tetraglycine chain, labelled 
with a dinitrophenyl group, had moderate (millimolar) binding affinity for the 
enzyme (Firczuk et al., 2005). 
1.4.2. ALE-1 
In 1997, Sugai and coworkers reported the purification of a new 
staphylolytic enzyme from the supernatant of a culture of Staphylococcus 
capitis EPK1, which was named ALE-1 (Sugai et al., 1997a). It was identified 
as a glycylglycine endopeptidase metalloenzyme that contained one atom of 
                                                 
 ŶAdapted from: Firczuk et al., 2005 
Figure 12: Representation of the selected residues of the active site of LytM185-316
x
. The 
zinc cation is shown as a black ball. All zinc cation coordinating interactions are 
represented by dotted lines.  H210, D214, H260, H291, H293 are residues essential for
activity. Q295 and P200 are orientated key residues.   
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zinc cation per molecule. The optimum pH range was from 7 to 9 and its pI 
was 9. Like lysostaphin, ALE-1 is synthesised as a precursor protein that is 
cleaved after the alanine residue at position 35. Mature ALE-1 consists of 362 
amino acid residues and has a molecular weight of 35.6 kDa. The primary 
structure was very similar to that of the lysostaphin proenzyme form (Nilsen et 
al., 2003), as it contains an N-terminal domain with tandem repeats of a 13 
amino acid sequence followed by a central catalytic domain and a C-terminal 
targeting domain of 92 amino acids. As with lysostaphin, the targeting domain 
of ALE-1 has been classified as SH3b, a prokaryotic homologue of the 
eukaryotic SH3 domain. One difference observed between ALE-1 and 
lysostaphin was that the N-terminal repeat domain in ALE-1 is not 
extracellularly processed as happens to prolysostaphin.  
The 1.75 Å crystal structure of ALE-1 targeting domain shown in 
Figure 13 as been presented recently (Lu et al., 2006). Like LytM, this is 
distinct from the catalytic domain that precedes it in the enzyme structure. It 
consists of eight ȕ-strands. Two anti-parallel multiple-stranded ȕ-sheets pack 
at approximately right angles: ȕ5- ȕ7 and the N-terminus of ȕ2 in sheet I; ȕ3- 
ȕ4, ȕ8, and the C-terminus of ȕ2 in sheet II, and give a narrow groove that can 
potentially accommodate an extended pentaglycine by forming ȕ-sheet-type 
interactions with strands ȕ1 and ȕ3. Lu and coworkers compared the binding 
of the ALE-1 targeting domain to various staphylococcal peptidoglycans with 
genetically modified interpeptide bridges and their isogenic parents (Lu et al., 
2006). The targeting domain also showed a strong preference for Gly5 in this 
study. Forms of ALE-1 that lacked the targeting domain had significantly 
decreased binding activity to S. aureus cells, confirming that this portion was 
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responsible for targeting the enzyme to the bacteria. The first nine residues in 
this domain are likely to be responsible for the specificity for S. aureus, as the 
truncated version of the targeting domain, lacking these residues, had 
drastically reduced binding to the bacterial peptidoglycan.  
 
 
 
 
 
 
 
 
 
 
 

S. capitis also carries a gene that is homologous to the femAB operon 
for the production of endopeptidase resistance factor, epr (Sugai et al., 1997b). 
This was found to have similarities to the amino acid sequence of FemA 
(Berger-Bachi et al., 1989) and FemB (Henze et al., 1993). Epr is similar to 
lif, in that it confers resistance to attack on S. capitis by serine-incorporation at 
position three and five in the pentaglycine crossbridge (Ehlert et al., 2000). 
 
                                                 
 &Adapted from: Lu et al., 2006 
Figure 13: ALE-1 targeting domain crystal structure with strands numbered
sequentially
&
. 
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1.4.3. zoocinA 
Simmonds and coworkers purified a proteinaceous bacteriocin-like 
inhibitory substance, named zoocin A, from cultures of Streptococcus equi 
subsp. zooepidemicus, in 1995 (Simmonds et al., 1995). Analysis of the 
nucleotide sequence revealed an open reading frame of 858 nucleotides. 
Zoocin A is synthesized as a 285 amino acid pre-peptide that is cleaved to 
release a 262 amino acid peptide into the environment (Simmonds et al., 
1997). The deduced molecular mass of the predicted peptide is 27.9 kDa, 
which is similar to the molecular mass of the purified peptide, as estimated by 
SDS-PAGE.  
The pre-peptide sequence is made of four characteristic regions. The 23 
amino acid leader sequence, as mentioned before, is a signal peptide to locate 
the protein at the cell surface. The N-terminal region shows strong homology 
to the N-terminal domain of lysostaphin (Simmonds et al., 1997) and in both 
cases contains the catalytic sites that bring about hydrolysis of the 
peptidoglycan. The mid-sequence region is a short threonine and proline-rich 
linker, and is attached to the C-terminal region, which is the cell wall 
recognition site, allowing zoocin A to be specific to its target bacteria. 
Evidence for this domain structure has also been found using NMR 
spectroscopy (Liang et al., 2004). The targeting domain was shown to still be 
able to bind sensitive cells when expressed on its own, but the catalytic 
domain, when treated similarly, only retained 2 % of the activity of the native 
enzyme. It was concluded that the loss of activity for the catalytic domain was 
likely therefore to be due to loss of targeting ability.  
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Zoocin A treated cells revealed that Streptococcus zooepidemicus 
strains other than the producer: Streptococcus pyogenes, Streptococcus 
gordonii and Streptococcus mutans, are sensitive to zoocin A (Simmonds et 
al., 1996). These are closely related to the producing strain, and include some 
of the main causative agents of group A streptococcal sore throat and dental 
caries. The C-terminal portion was found to be unique to zoocin A, explaining 
the difference in targets in between this enzyme and lysostaphin. In 1996, 
studies of the mode of action of zoocin A demonstrated that it was able to 
cleave a hexaglycine substrate with an efficiency comparable to that of 
lysostaphin, suggesting that like lysostaphin, zoocin A functions enzymatically 
as an endopeptidase (Simmonds et al., 1996). In 2004, Heath and coworkers 
demonstrated that purified zoocin A bound penicillin (ressembles D-alanyl-D-
alanine) covalently and that its peptidoglycan hydrolase activity was inhibited 
by penicillin (Heath et al., 2004). These results suggested that zoocin A is 
presumably a D-alanyl endopeptidase that controls the extent of peptidoglycan 
cross-linking.  
Reported by Beatson and coworkers, flanking the gene encoding 
zoocin A (zooA) in a back-to-back orientation was a gene zoocin A immunity 
factor (zif), responsible for protecting the producer strain from the otherwise 
lethal action of its own products (Beatson et al., 1998). zif has sequence 
homology to femA (factor essential for methicillin resistance) and lif 
(lysostaphin immunity factor). No differences were observed in amino acid or 
amino sugar compositions of peptidoglycan purified between zif containing 
and non-zif containing Streptococcus gordonii DL1 transformants. These 
results suggested that unlike FemA, FemB and Lif, Zif is not involved in 
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modifying the biosynthesis of the peptidoglycan precursor crosslink. 
Additionally, they suggested that the homology of zoocin A to lysostaphin and 
of Zif to Lif, the similarity in position and orientation of their encoding genes, 
and the similarity in the arrangement of the flanking insertion sequences, may 
be due to the horizontal transfer of large segments of DNA between 
staphylococci and streptococci (Beatson et al., 1998). 
1.4.4. Peptidoglycan Recognition Proteins 
Peptidoglycan recognition proteins (PGRPs) are innate immunity 
molecules conserved from insects to mammals. PGRPs have at least one C-
terminal PGRP domain which is highly conserved and homologous to 
bacteriophage and bacterial type 2 amidases (Kang et al., 1998). Insects have 
up to 19 PGRPs, classified into short (S) and long (L) forms (Werner et al., 
2000). Mammals have four PGRPs, which were initially named PGRP-S, 
PGRP-L, PGRP-IĮ and PGRP-Iȕ (for “short”, “long”, or “intermediate” 
transcripts, respectively) (Liu et al., 2001). Subsequently, their symbol was 
changed to PGLYRP-1, PGLYRP-2, PGLYRP-3, PGLYRP-4 respectively. All 
mammalian PGLYRPs are secreted, usually as disulphide-linked homo- and 
heterodimers. 
Almost all PGRPs have two closely spaced conserved cysteines in the 
middle of the PGRP domain that form a disulfide bond. These residues are 
thought to be essential as a mutation in one of these cysteines in human 
PGLYRP-2 (C419A) abolished its amidase activity (Wang et al., 2003). 
PGLYRP-2 is an amidase with a conserved zinc cation binding site in the 
peptidoglycan-binding groove which consists of two histidines, one tyrosine, 
and one cysteine. Few PGRPs structures have been released recently and have 
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revealed a general design similar to type 2 bacteriophage amidases (Guan et 
al., 2005, Guan et al., 2006). Crystallographic analysis of human PGLYRP-1 
and the C-terminal PGRP domain of PGLYRP-3 showed that the ligand 
binding groove accommodated N-acetylmuramic acid bound to three peptide-
bond amino acids (muramyl tri-peptide), which was the minimum 
peptidoglycan fragment hydrolysed by PGLYRP-2 (Wang et al., 2003). Those 
amidases also bound muramyl tetra-peptide and muramyl penta-peptide with 
higher affinity than muramyl tri-peptide (Kumar et al., 2005, Guan et al., 
2006). Moreover, binding of muramyl-pentapeptide (but not muramyl tri-
peptide) to the C-terminal fragment of PGLYRP-3 induced a conformational 
change in the molecule. In addition, PGLYRP-1 seemed to have high affinity 
for lipoteichoic acid and lipopolysaccharide (Tydell et al., 2006). It was not 
clear however, whether these other ligands bound specifically to the 
peptidoglycan-binding groove or unspecifically to hydrophobic regions of the 
molecule. 
1.4.5. Enterolysin A 
Enterolysin A, a class III bacteriocin of lactic acid bacteria, was 
originally isolated by Nilsen and coworkers from cell free filtrate of 
Enterococcus faecalis LMG 2333 (Nilsen et al., 2003). This bacteriocin is a 
heat-labile protein with a broad inhibitory spectrum, which breaks down the 
cell wall of lactobacilli, lactococci, pedicocci and enterococci.  The bacilli, 
listeria and staphylococci strains tested showed zones of growth inhibition 
only in the overlay assay. It is believed that the bacteriolytic activity of the 
bacteriocin is based on its ability to degrade the cell wall by hydrolysing the 
peptide bond of the sugar unit side chain.    
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Sequence analysis of enlA encoding enterolysin A revealed that the 
enzyme is translated as a 343-amino acid preprotein with a typical signal 
peptide of 27 amino acids directing the protein to the hydrophobic cell 
membrane and allowing its release in the periplasm, followed by a sequence 
corresponding to the N-terminal part of the purified protein.  The expression of 
enlA, the gene of enterolysin A amplified from E. faecalis II/1, has been 
achieved in Escherichia coli (Nigutova et al., 2008). The mature enzyme, 
product of activation of the preprotein, consisted of 316 amino acids, its 
molecular weight was close to 35 kDa on electrophoretic gel and it was overall 
a basic protein. Enteroysin A was predicted to exhibit a typical domain 
structure organisation with two separate domains. The N-terminal domain of 
the bacteriocin contains an amino acid motif HxxxD and HxH typical of 
metallopeptidase family M23 (Rawlings et al., 2008) and thus was predicted to 
have a catalytic activity similar to lysostaphin, zoocin A, LytM and ALE-1 
(Nilsen et al., 2003). The C-terminal domain is linked by a threonine and 
proline-rich region to the former one and has significant sequence homology to 
a lysine from bacteriophage A2 and an N-acetomuramoyl-L-alanine amidase 
from bacteriophage PL-1, both of which are bacteriophages of Lactobacillus 
casei (Nilsen et al., 2003).  Both of those domains where reported to cooperate 
to yield a functional protein (Nigutova et al., 2008). A deletion mutant of 
enterolysin A lacking 58 amino acid C-terminal domain had lost biological 
activity and was presumed to have an important role in the cell-wall binding of 
enterolysin A.     
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1.4.6. Bacteriophage endolysins 
Nonfilamentous bacteriophages (bacterial viruses) have developed 
specific lytic enzymes for the release of their progeny from bacterial cells. 
Enzymatic cleavage of peptidogolycan is conducted by a holin-endolysin 
system (Young et al., 2000, Tabac et al., 2005). Many lysins are produced as a 
single polypeptide but contain two functional domains, a catalytic domain, 
which cleaves peptidoglycan bonds, and a cell wall binding module, which 
may bind specific features in the cell wall (Loessner, 2005). The modular 
structure of endolysins enabled alteration of their binding specificity and 
enzymatic activity independently by replacing either domain with the 
corresponding domain from another enzyme (Sheehan et al., 1996), but there 
are several other strategies for engineering enzymes, for instance, random 
mutagenesis and targeted mutagenesis (Cedrone et al., 2000, Bloom et al., 
2005). There are many data supporting the hypothesis that host and phage 
murein hydrolases share common ancestry and moreover, in some organisms 
the proteins have co-evolved by interchanging their functional domains (Lopez 
and Garcia, 2004). Such postulated evolutionary relationship between 
endolysins and autolysins may be the consequence of horizontal gene transfer 
between bacteriophages and their host bacterial cells (Hambly and Suttle, 
2005).   
Very recently the catalytic module of PlyB, an endolysin encoded by 
phage BcpI, which displays potent lytic activity against the Bacillus anthracis-
like strain ATCC 4342 has been reported (Porter et al., 2007). PlyB comprises 
an N-terminal catalytic module that shares sequence similarity with the 
members of the glycosyl hydrolase family 25 (GH-25) and cell wall binding 
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module homologous to bacterial SH3b domains. It was suggested that PlyB 
cleaved the ȕ-1,4-glycosidic bond between N-acetylmuramic acid and N-
acetylglucosamine units. It has also been shown that the SH3b domain played 
an important role in PlyB activity. It is unlikely that SH3b from PlyB 
recognises inter-peptide pentaglycine bridges as was shown for ALE-1 (Lu et 
al., 2006) because its target, the bacilli, do not possess pentaglycine cross-
bridges. The crystal structure of another B. anthracis phage endolysin, PlyL, 
has also been described (Low et al., 2005). PlyL, the endolysin of the Ȝ 
prophage Ba02, is also composed of an N-terminal catalytic module and a C-
terminal cell wall binding domain. The structure of the catalytic domain 
revealed that its fold is similar to the Drosophila PGRP-LB (Kim et al., 2003) 
and may have a NAM-amidase function. Remarkably, the presence of the cell 
wall binding domain within the full-length PlyL inhibits the lytic activity of 
the catalytic module (Low et al., 2005). A possible explanation could be that 
the C-terminal domain might inhibit the catalytic activity of the N-terminal 
domain when not bound to the cell wall.  This inhibitory effect might be 
relieved on high-affinity binding to the cell wall by the C-terminal domain. 
1.5. Aims and objectives 
Eighty years ago a mouldy Petri dish changed the face of medicine, and 
Alexander Fleming's discovery of penicillin opened a golden age of antibiotic 
research. But today, so-called superbugs are front page news and the antibiotic 
development pipeline is very poor.  Some of the largest pharmaceutical 
companies have simply given up on what has become a tricky market. Experts 
now say that without improved approaches, along with better regulation and 
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controlled use of antimicrobials, the future of antibiotic development could be 
in jeopardy.  
The industry has been looking at the genomes of these bacteria and has 
been screening potential antibacterial agents against targets essential for 
bacterial survival. This has failed for all types of targets, because bacteria have 
had billions of years of evolution to cope with harsh environments. The limited 
number of antibiotic classes means that all drugs in use continue to target the 
same group of mechanisms, attacking four chinks in the bacterial armour: cell 
wall synthesis; protein synthesis; DNA/RNA precursor synthesis and 
DNA/RNA synthesis. Since some bacterial strains have developed resistance 
to all these methods of attack, new tactics are desperately needed.   
Lysostaphin is considered a good alternative to antibiotics, although it 
is unlikely to replace it, because it has the properties of cleaving specifically 
the cross-linking pentaglycine bridges in the cell walls of staphylococci and 
thus display a narrow spectrum of lytic activity. Unlike most antibiotics that 
interfere with the growth of bacteria, lysostaphin is highly effective in lysing 
both actively growing and dormant S. aureus cells. Nonetheless, S. simulans 
produces and protects itself from lysostaphin. Production of the endopeptidase 
appears to act as a selective pressure that removes the susceptible cells in the 
population, as the enzyme appears in the medium. The FemAB-like factors: 
lysostaphin immunity factor (Lif) and lysostaphin endopeptidase resistance 
factor (Epr), confer resistance to lysostaphin by replacing a glycine by a serine 
in the peptidoglycan crosslink. Thus, we can predict that other staphylococcal 
strains (not to mention the example of S. aureus) could acquire, by horizontal 
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transfer, the genes (lif or related gene) that confer S. simulans resistance to 
lysostaphin. 
The aim of this project was to investigate the mechanism by which 
lysostaphin interacts with its substrate. With this knowledge, in future studies, 
we wished to evolve this bacteriocin to give it new binding and catalytic 
properties to thwart the lif mechanism of resistance. By anticipating the 
resistance of staphyloccocal cells to wild-type lysostaphin and providing 
mutants able to bypass the mechanisms of resistance, we would tackle 
superbugs.  
Thus, the approach described in this thesis was to obtain the 
lysostaphin catalytic domain (termed LssEdom in the thesis) structure, so that 
in future studies, by using structure-based enzyme engineering, we could 
modify the amino acids in interaction with the substrate to expend its substrate 
specificity. An additional approach described in this thesis was to define the 
targets of the lysostaphin targeting domain (termed LssTdom in the thesis) on 
the bacterial cell wall. In future studies, by directing its evolution using the 
phage display technique, we hoped that lysostaphin would acquire altered 
binding properties.  
One strategy adopted was to perform crystallisation trials on active 
LssEdom with the aim of producing highly ordered crystals that diffract X-
rays at high resolution to determine peptide structure by X-ray crystallography. 
To conduct crystallisation trials, the endopeptidase domain of lysostaphin was 
sub-cloned and expressed as a His-tagged peptide in order to facilitate its 
purification. Optimisations of both, LssEdom activity and LssEdom 
crystallisation process were investigated by modifying the protocol of 
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purification and by removing the His-tag of the peptide, respectively. As well, 
a structure model of LssEdom in silico was investigated. Considering the 
difficulties encountered to crystallise LssEdom, another strategy to obtain its 
structure emerged. Fourier-transform infrared (FT-IR) spectroscopy technique 
was explored for the determination of protein secondary structure in solution. 
Finally, to define the targets of the lysostaphin targeting domain (LssTdom) on 
the bacterial cell wall, we looked at protein-ligand interactions using mass 
spectrometry (ESI-ToF).  
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2. Materials and methods 
2.1. Techniques of molecular biology 
2.1.1. Bacterial strains and media 
Strains used with their relevant genotypes and sources are listed in 
Table 1. Chemically competent E. coli were transformed by the heat-shock 
transformation technique (Sambrook et al., 1989).  
Table 1: List of strains with their relevant genotypes and sources. 
E.coli strains Relevant 
genotypes 
Source 
DH5Į lacZǻM15 recA1 Invitrogen 
BL21 (DE3) araB::T7 Invitrogen 
 
Recombinant clones that acquired resistance to ampicillin were selected 
on LB or 2YT agar plates supplemented with ampicillin (75 µg.ml-1, final 
concentration). Bacterial cultures were grown in LB or 2YT broth (Sambrook 
et al., 1989) supplemented with ampicillin (50 µg.ml-1, final concentration). 
Isopropyl-ȕ-D-thiogalactopyranoside (IPTG) was added to a final 
concentration of 1 mM to induce expression of T7 RNA Polymerase in BL21 
cultures. Protein for NMR studies was obtained by expression in M9 
Minimum Medium (Na2HPO4 (10 g), KH2PO4 (3 g), NaCl (0.5 g), 
MgSO4.7H2O (0.3 g), CaCl2 (0.015 g), NH4Cl (1 g), glucose (4 g), biotin (10 
mg), thiamine (10 mg) in 1 L milliQ grade H2O). Protein uniformly labelled 
with isotope 15N was obtained by expression in 15N-enriched minimum media 
(15N NH4Cl, 1 g.l
-1). 
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2.1.2. Plasmids 
The pET21a(+) vector (Novagen) contains a multiple restriction site, 
shown in Figure 14, in which the protein sequence of recombinant lysostaphin 
(Lss) and lysostaphin endopeptidase domain (LssEdom) were inserted at the 
NdeI/XhoI restriction sites by Dr E. Antoniadou and Dr P. Bardelang (Centre 
for Biomolecular Sciences, University of Nottingham, U.K.). The vectors built 
in this way were called respectively pEA3 (pET21a(+)-Lss248-493) and 
pETedom (pET21a(+)-Lss248-385). The protein sequence of recombinant 
lysostaphin targeting domain (LssTdom) was sub-cloned in  pET21d(+) vector 
(Novagen) at the NcoI/XhoI restriction sites by Dr E. Antoniadou. The vector 
built in this way was called pEA7 (pET21d(+)-Lss401-493). Expression was 
under control of strong bacteriophage T7 transcription and translation signals. 
The C-terminal His-tag fused to the recombinant proteins enabled rapid 
purification by metal-affinity chromatography. The calculated molecular 
weight* of this C-terminal His-tagged Lss is 28,141 Da and its pI is 9.6. For 
the endopeptidase domain the calculated molecular weight* is 16,386 Da and 
the pI is 8.8 and for the targeting domain the calculated molecular weight* is 
11,623 Da and the pI is 9.7. 
 
 
 
 
 
 
                                                 
* Calculated with Expasy software: http://www.expasy.org/tools/pi_tool.html 
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Figure 14: pET-21a-d(+) cloning/expression region. 
 
The pGAT2 plasmid (originally constructed by Dr. M. Hyvönen, 
University of Cambridge, U.K.) (Peranen et al., 1996), shown in Figure 15, 
carries a T7 promoter inducible with IPTG and a sequence coding for a His-
tag, which is fused to the N-terminal region of the protein when expressed. 
Notably, this vector contains a sequence coding for a thrombin cleavage site in 
between the sequence coding for a His-tag and the multiple restriction site. 
pSGAT2 is a pGAT2 vector for which the GST sequence has been removed by 
restriction with SpeI. The third glycine (Gly+18 downstream of Met+1) in the 
pentaglycine sequence has been mutated into a serine to give a pSGAT2GlyĺSer 
vector. The protein sequences of recombinant Lss and LssEdom have been 
inserted in this vector, in two parallel experiments, at the BamHI/HindIII 
restriction sites. For N-terminal His-tagged Lss the calculated molecular 
weight* is 29,668 kDa and the pI is 9.7 and for the endopeptidase domain the 
calculated molecular weight* is 17,914 kDa and the pI is 9.3. 
 
 
 41
 
2.1.3. Electrophoresis, DNA extraction and 
quantification 
Agarose gel electrophoresis was completed as detailed by Sambrook and 
coworkers (Sambrook et al., 1989). DNA ladder standards (New England 
Biolabs) were loaded alongside DNA samples to enable estimation of their 
length and concentration.   
Extraction of DNA from agarose gels was completed using the QIAEX 
II kit (Qiagen) as directed by the manufacturer’s instructions.  
To determine DNA concentrations, a sample of 1 µl was analysed by 
NanoDropTM 1000 spectrophotometer (Thermo Scientific). The resulting 
spectral diagram showed the absorbance of the solution in the 220-350 nm 
range of wavelength. Concentration was confirmed by UV absorbance at 260 
nm. An approximate conversion factor estimates that duplex DNA is about 50 
µg/A(260nm).  
 
 
Figure 15: pGAT2 cloning/expression region. 
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2.1.4. Plasmid restriction, ligation, transformation 
Endonuclease digestion of DNA was completed as detailed by 
Sambrook and coworkers (Sambrook et al., 1989). Ligation of DNA fragments 
into plasmids was performed using the Rapid DNA Ligation Kit (Roche 
Diagnostics GmbH). Transformation of competent E. coli cells was completed 
as detailed by Sambrook and coworkers (Sambrook et al., 1989). 
2.1.5. Polymerase Chain Reaction (PCR) 
PCR was completed using an Eppendorf Mastercycler Personal. Taq 
DNA Polymerase (Roche, Penzberg, Germany) was used for standard 
reactions and Pwo DNA Polymerase (Roche, Penzberg, Germany) was used 
for high fidelity reactions. The PCR cycles were realised according to a 
standard program that consisted of a hot start at 94°C for 2 minutes, followed 
by 30 cycles of denaturation (94°C for 30 seconds), hybridisation (TM
 for 30 
seconds),  extension (72°C for n seconds) and finished with a final extension 
at 72°C for 10 minutes. Products of reaction were conserved at 4°C. Details of 
the oligonucleotides used (synthesised by MWG-Biotech, U.K.) are shown in 
Table 2. Oligonucleotide secondary structures were predicted utilising 
software found in http://mfold.bioinfo.rpi.edu/.  
 
 
 
 
                                                 
† Melting temperature (TM) is the temperature at which an oligonucleotide duplex is 50% in 
single-stranded form and 50% in double-stranded form, which depends on its nucleotide 
content.  
 
‡ n corresponds ideally to 2 minutes extension for the amplification of 1 DNA kilobase with 
high fidelity polymerase. 
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Oligonucleotide ID 
(restriction site) 
Sequence (5ĺ3) 
LssForw (BamHI) GAGATATAGGATCCGCTGCAACACAT 
LssRev (HindIII) GTGGTGAAGCTTACTTTATAGTTCC 
Use: Lss sequence amplification in pEA3 for sub-cloning in pSGAT2 
LssForw (BamHI) GAGATATAGGATCCGCTGCAACACAT 
LssEdomRev (HindIII) GTGGTGAAGCTTACTTTATAGTTCC 
Use: LssEdom sequence amplification in pEA3 for sub-cloning in pSGAT2 
T7PP TAATACGACTCACTATAGGG 
Gly3mutpSGAT2 (BamHI) 
AGCGGATCCCCTCGGAACCAGGCGGCCGCCAGAA
CCACCAGATCC 
Use: Mutate G18 to S in pSGAT2-LssEdom and pSGAT2-Lss 
pSGAT2EdomFor (BamHI) CCGAGGGGATCCGCTGCAACACAT 
pSGAT2EdomRev (HindIII) ATACTCAAGCTTATCCTGCGCTCTT 
Use: Insert a Stop codon in pSGAT2-Ser-LssEdom 
T7PP CCGAGGGGATCCGCTGCAACACAT 
T7TP ATACTCAAGCTTATCCTGCGCTCTT 
Use: Sequencing 
WC1 GCATAGACAATTCTATATGCATCTAAGTAAAT 
WC2 GATGCATATAGAATTGTCTATGCACTCCATC 
T7For (NdeI) GCATATGGCTGCAACACATGAACATTC 
T7Rev (XhoI) GCTCGAGTCCTGCGCTCTTTAAGAAAGG 
Use: Mutate W80 to F in pETedom 
WC3 GTTGAAGCTGGTTTCAGTAATTACGGAGGAGGT 
WC4 GTAATTACTGAAACCAGCTTCAACTATTTTTCC 
T7For (NdeI) GCATATGGCTGCAACACATGAACATTC 
T7Rev (XhoI) GCTCGAGTCCTGCGCTCTTTAAGAAAGG 
Use: Mutate W59 to F in pWC3 
Table 2: List of oligonucleotide primers used in cloning. 
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2.1.6. Site-directed mutagenesis 
Site-directed mutagenesis was completed in a two-step PCR modified 
method (Sarkar and Sommer, 1990). The method utilised four oligonucleotides 
(cf. section 2.1.5), two flanking oligonucleotides and two internal 
oligonucleotides carrying the mutation of interest, to perform two parallel 
rounds of polymerase chain reaction (cf. section 2.1.5). The two megaprimers 
generated were used to polymerise the complete DNA sequence with the 
desired mutation. Mutation W80 to F in pWC3 and mutations W59/80F in 
pWC5 were performed by W. Cheng (Centre for Biomolecular Sciences, 
University of Nottingham, U.K.) under my supervision. Mutation H114 to A in 
pEA3 was performed by Dr E. Jarvis (Centre for Biomolecular Sciences, 
University of Nottingham, U.K.).  
2.1.7. DNA sequencing and sequence analysis 
To prepare the sequencing reaction, 1 µl of the template, DNA plasmid, 
was used at a concentration of 100 ng.µl-1. To this template was added 5 µl of 
forward (T7PP) or reverse (T7TP) primers, 30 pmol.µl-1. DNA sequencing 
reactions were completed using the Applied Biosystems BigDye® Terminator 
v3.1 Cycle Sequencing Kit and 96-Well GeneAmp® PCR System 9700. The 
reaction involved 25 cycles of 96ºC for 10 seconds, 50ºC for 5 seconds and 
60ºC for 4 minutes. The DNA was ethanol precipitated and reactions were run 
on a 3130xl Genetic Analyzer (Applied Biosystems) by sequencing technician, 
S. Ouadi, at the Queens Medical Centre (QMC) University DNA sequencing 
laboratory (Nottingham, U.K.). 
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The results of the sequencing were analysed with ClustalW software§ 
(Thompson et al., 1994) for alignment studies of biopolymer sequences. 
2.1.8. Protein expression 
2.1.8.1. Experimental plan for expression 
A volume of 4 ml of a 3 hour 2YT broth culture of E. coli BL21 cells, 
transformed with the relevant plasmid, was used to inoculate 400 ml 2YT 
broth.  When an OD600nm of 0.6 was reached, the cells were transferred from a 
37°C to a 30°C incubator and induced by addition of IPTG to 1mM.  After two 
hours of induction at 30°C the cells were harvested by centrifugation at 
10,000g for 2 x 10 minutes in a Beckman Avanti J-20 centrifuge. Cells were 
stored at -20°C.    
Expression of LssEdom for NMR studies was realised at an analytical 
scale according to an outlined experimental plan (Abergel et al., 2003). Three 
temperatures (20ºC, 25ºC, 30ºC) and three media (M9MM (section 2.1.1), 
M9MM with added 1mM zinc chloride, M9MM with added 200 mM sodium 
chloride) were tested as shown in Table 3. A volume of 150 µl of a 4 ml over-
night LB broth culture of E. coli BL21 cells, transformed with the relevant 
plasmid, was used to inoculate 4 ml of the media cited.   
Table 3: Experimental plan for expression of LssEdom for NMR studies. 
Medium 
Bacterial strains 
20ºC 25ºC 30ºC 
BL21 (DE3) M9MM + NaCl M9MM + ZnCl2 M9MM 
BL21 (DE3) M9MM + ZnCl2 M9MM M9MM + NaCl 
BL21 (DE3) M9MM M9MM + NaCl M9MM + ZnCl2 
 
 
 
                                                 
§ http://www.ebi.ac.uk/clustalw/ 
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2.1.8.2. Cell lysis 
Frozen cells were resuspended in 30 ml buffer A (20 mM sodium 
phosphate (pH 7.4), 5 mM imidazole, 0.5 M sodium chloride, 5% (v/v) 
glycerol) with 300 µl phenyl methyl sulfonyl fluoride (1 mM) and disrupted in 
a French Press. Cell lysates was separated from insoluble cell debris after two 
successive 30 minute centrifugations at 10,000 rpm.   
2.2. Analytical methods 
2.2.1. Protein purification 
2.2.1.1. Metal affinity chromatography 
   A standard metal-affinity chromatography protocol was employed for 
the purification of His-tagged Lss, LssEdom and LssTdom and their mutants. 
Proteins were purified using HiTrapTM chelating HP columns (Amersham 
Biosciences) connected to a BiologicLP low-pressure liquid chromatography 
system (BioRad). The column was charged with nickel or zinc ions using a 12 
ml injection of 50 mM nickel sulfate or a 24 ml injection of 50 mM zinc 
chloride, washed in water and equilibrated in buffer A (20 mM sodium 
phosphate (pH 7.4), 5 mM imidazole, 0.5 M sodium chloride, 5% (v/v) 
glycerol). The sample was applied to the column at a flow-rate of 1 ml.min-1. 
The loaded column was washed in 5% buffer B (95% buffer A) (20 mM 
sodium phosphate (pH 7.4), 0.5 M imidazole, 0.5 M sodium chloride, 5% (v/v) 
glycerol) until no further unbound proteins were eluted from the column. 
Bound proteins were eluted from the column using a linear gradient of 5-85% 
buffer B in a total volume of 40 ml. The change in absorbance at 280 nm of 
the protein eluted was recorded over time. Fractions containing the required 
protein, identified by SDS-PAGE, were pooled and dialysed overnight (4oC) in 
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the appropriate buffer. His-tagged Lss and LssEdom were diluted 10-fold into 
cold buffer iexA (10 mM Tris-HCl (pH 7.4), 50 mM sodium chloride, 5% 
(v/v) glycerol) and dialysed in buffer iexA overnight (4oC), ready for ion-
exchange chromatography.  
2.2.1.2. Ion-exchange chromatography 
Lss (pI~9) or LssEdom (pI~9), with or without His-tag, were subjected to 
cation-exchange chromatography. This step allowed thrombin (pI~6) and 
contaminants to be washed away. A 5 ml HiTRAP SP column (Pharmacia 
Biotech) connected to a BiologicLP low-pressure liquid chromatography 
system (BioRad) or a Mono S 5/50 GL (TricornTM) column connected to an 
ÄKTA™ purifier liquid chromatography system (Amersham Biosciences) 
were used. All the columns were equilibrated in iexA buffer (10 mM Tris-HCl 
(pH 7.4), 50 mM sodium chloride, 5% (v/v) glycerol). Lss or LssEdom in 
solution in iexA buffer were loaded on to the column at a flow-rate of 1 
ml.min-1 and the column washed with 25 ml buffer iexA. Proteins bound to the 
column were eluted using a linear gradient of 0-100% buffer iexB (10 mM 
Tris-HCl (pH 7.4), 1 M sodium chloride, 5% (v/v) glycerol) in a volume of 60 
ml. The change in absorbance at 280 nm of the protein eluted was recorded 
over time. Fractions containing the required protein, identified by SDS-PAGE, 
were pooled and dialysed overnight (4oC) in the appropriate buffer. 
2.2.1.3. Gel filtration chromatography 
A SuperdexTM 75 10/300 GL or SuperdexTM 200 10/300 GL 
(TricornTM, Amersham Biosciences) column with an optimum separation 
range of 3,000 – 70,000 Da or 10,000 – 600,000 Da respectively, attached to 
an ÄKTA Explorer FPLC system (Amersham Biosciences), were equilibrated 
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with two column volumes of 50 mM sodium phosphate (pH 7.4), 150 mM 
sodium chloride (0.2 µm filtered and degassed with helium) at a flow rate of 
0.8 ml.min-1. Sample protein was then loaded onto the column at a flow rate of 
0.5 ml min-1.  The change in absorbance at 280 nm of the protein eluted was 
recorded over time. Fractions containing the required protein, identified by 
SDS-PAGE, were pooled and dialysed overnight (4oC) in the appropriate 
buffer. 
2.2.1.4. His-tag removal 
Cleavage of proteins at the excision site Leu-Val-Pro-ArgĻGly-Ser for 
His-tag removal was complete following 16 h treatment with thrombin, at 
19oC, with 3 units of thrombin per mg of protein, in iexA buffer (10 mM Tris-
HCl (pH 7.4), 50 mM sodium chloride, 5% (v/v) glycerol).    
2.2.2. Electrophoretic analysis 
Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-
PAGE) was completed using a mini gel system (Atto).  Stacking (6%) and 
resolving (16%) gels were prepared as described by Sambrook and coworkers 
(Sambrook et al., 1989). Protein samples were loaded onto a gel after 1 minute 
denaturation at 95oC in an equal volume of 2 x loading buffer (100 mM Tris-
HCl (pH 6.8), 4% (w/v) SDS, 0.2% (w/v) bromophenol blue dye, 200 mM 
DTT).  Protein molecular weight standards (New England Biolabs) were 
loaded alongside protein samples to enable estimation of molecular weights.   
Gels were stained over 30 minutes using Coomassie blue stain (0.2% 
bromophenol blue dye, 45% methanol, 10% acetic acid) and destained twice in 
fast destain solution for 10 minutes  (40% methanol, 10% acetic acid) followed 
by slow destain solution over-night (10% methanol, 10%  acetic acid).   
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2.2.3. Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) measurements were carried out on a 
Zetasizer Nano S from Malvern Instruments. Each sample was filtered through 
a 0.2 µm filter (Millipore) prior to measurements, which were made at room 
temperature. The particle size was taken as the mean value of three 
measurements. LssEdom, LssEdomW80F and LssEdomW59/80F (15 µM), 
buffer exchanged in 1 mM sodium phosphate (pH 7.0) buffer, were measured.  
2.2.4. Mass Spectrometry    
2.2.4.1. Principles of Mass Spectrometry 
Mass spectrometry (MS) was the analytical technique chosen to 
identify proteins and protein/ligand interactions on the basis of the mass-to-
charge ratio of the charged particles. The mass spectrometer was designed 
with three essential modules (Figure 16): an electrospray ion source, which 
generated intact, positively charged ions, in the form of [M+nH]n+; an 
orthogonal-time-of-flight (o-ToF) analyser, which focused and sorted the ions 
along their intended flight path and separated them according to their mass-to-
charge (m/z) ratio; and a detector, which measured the value of indicator 
quantity and thus provided data for calculating the abundances of respective 
ions.  
 
 
 
Figure 16: Schematics of a mass spectrometer with an ESI source combined with a TOF 
analyser, using a combination of quadrupole filters orthogonally coupled to a TOF tube, 
for the transmission and analysis of protein complexes. 
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Electrospray ionisation (ESI) was the technique chosen to produce ions 
from proteins and protein non-covalent complexes without disrupting them in 
the gas-phase. ESI is a commonly used ionisation method for MS studies of 
protein complexes (Fenn et al., 1989, Kebarle, 2000, Wilm and Mann, 1996). 
Pressure is applied to deliver an appropriate flow of liquid through a needle 
maintained at kilovolt potential. By passing through a high electric field 
density the emerging liquid droplets become charged. This charging leads to 
droplets with an elongated minuscus (Taylor cone) (Mora et al., 2000, 
Kebarle, 2000).  These residual charges are subsequently transferred to 
proteins during their desolvation under a stream of dry gas in the sample 
chamber, often in the form of inorganic ions (e.g. triethylammonium ions) 
(Peschke et al., 2002, Lemaire et al., 2001). These excess charges are 
transferred to basic sites on the surface of globular proteins. Gas-phase ions 
are produced when the coulombic repulsion in the reduced droplet size 
generates droplet fission into even smaller droplets (Rayleigh, 1882). This 
ionisation process takes place at atmospheric pressure and is, therefore, very 
gentle. The most efficient electrospray are carried out in a certain proportion of 
organic solvent at relatively high temperatures to aid the spray, charging and 
desolvation processes. 
Once the molecular species ([M+nH]n+) are produced they are 
transferred through the quadrupole, trap, drift tube and transfer regions to the 
mass analyser by a series of rf and dc voltages. A discrete pulse of molecular 
ions is injected into a field-free “drift tube”, measuring the time taken for ions 
to reach the detector. With instruments incorporating an orthogonal time-of-
flight (o-ToF) mass analyser, the trajectories of ions are determined not only 
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by the acceleration imparted in the orthogonal extraction source but also by the 
axial velocity of the ions as they enter this region. Direct measurement of the 
velocity (ȣ) of the charged molecules is used in the time-of-flight (ToF) 
technique (Tang et al., 1994). Non-covalent complexes can be examined as a 
result of the coupling of time-of-flight analysis with electrospray ionisation, 
achieved through the use of an orthogonal acceleration process with a mass 
range up to 20,000 m/z. The detector records ions as a function of m/z where m 
is the mass of the ion and z is the ion charge 
 When representing data, we used the dimensionless m/z, where z is the 
number of elementary charges (e) on the ion (z=Q/e). This quantity represents 
the ratio of the mass number and the charge number, z. 
2.2.4.2. Analysis 
Electrospray mass spectrometry (ESI-MS) of protein samples was 
carried out on a Bruker MicroTOF instrument using direct infusion of the 
sample solutions via a syringe pump at a flowrate of 4 µl.min-1 by G. Coxhill 
(School of Chemistry, University of Nottingham, Nottingham). Thoroughly 
desalted proteins were supplied as 5 µȂ solutions in the appropriate buffer, 
containing methanol (buffer:methanol 1:1 (v/v)) and acetic acid, 1%. 
2.2.4.3. Interaction studies 
Of the different buffers tested, triethylammonium acetate (25 mM, pH 
7.4), was the buffer chosen to dissolve LssTdom. The following ligands: Gly5 
(G5), Gly4 (G4), Gly3 (G3), Gly2 (G2) Gly-L-Ser (GS), L-Ser (S), N-
acetylmuramyl-Ala-D-isoglutaminyl-Nİ-stearoyl-Lys (NAM-Ala-iGlu-Lys), 
acetyl-Lys-D-Ala-D-Ala (KA2), were obtained from Sigma-Aldrich (Poole, 
UK). The ligand Gly-Gly-L-Ser-Gly-L-Ser (G2SGS) was synthesised at the 
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Queen Medical Centre University synthesis laboratory (Nottingham, UK). 
Gly5 (14.53 mg) was dissolved in 5 µl trifluoroacetic acid (TFA), evaporated 
by Speed Vacuum. The sample was resuspended in 1 ml milliQ water and 
lyophilised three times in the presence of 0.1 M HCl, directly replacing TFA 
counterions with chloride ions (Andrushchenko et al., 2007). All the ligands 
cited were resuspended in milliQ water.  For KD measurements, the thoroughly 
desalted LssTdom protein was used at a concentration of 5 µȂ in buffer with 
added methanol (10%). Ligands interacting non-covalently with LssTdom 
were titrated into the protein solution to give final (total) concentrations in the 
range of 10-40 µM, whilst the protein concentration was held constant. Upon 
mixing, samples were allowed to equilibrate for 30 min before measurement.  
ESI-MS of LssTdom in interaction with small ligands was carried out 
on a SYNAPTTM High Definition Mass SpectrometryTM (HDMSTM) System 
(Waters, MA) equipped with an ESI source and an orthogonal acceleration 
time-of-flight (o-ToF) mass analyser. The conditions within the mass 
spectrometer were adjusted to preserve non-covalent interactions. Samples 
were infused into the Mass Spectrometer from a gas-tight syringe at a flowrate 
of 5 µl.min-1. MS experiments were performed at a capillary voltage of 2.5 kV, 
desolvation gas flow of 587 L.h-1 and desolvation gas temperature of 50ºC. 
The quadrupole allowed the detection of ions at over 8000 m/z mass range. 
Data were analysed using MassLynxTM software. 
Spectra were acquired in the range m/z 500 to 4000 at a rate of 1 scan.s-
1 for 116 scans. Averaged spectra were smoothed (smooth window ± 8; 
number of smooths 4) and the signal intensities of the two largest charge states 
([M+4H]4+ and [M+5H]5+) combined. The apparent concentrations of free 
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proteins ([P]), protein-ligand complex ([PL]) and free ligand ([L]) were 
calculated from the concentration of total protein and ligand used, and the 
signal intensities. It was assumed that P and PL gave the same linear detector 
response. Plots of [PL]/[L] vs. [L] were used to determine KD for the ligands 
employed. Plots of [PL] vs. [inhibitor] were used to determine IC50 in the 
competitive binding experiments.   
2.2.5. Determination of protein concentration 
   To determine protein concentrations, a 2 Pl sample was analysed by 
NanoDropTM 1000 spectrophotometer (Thermo Scientific). The resulting 
spectral diagram showed the absorbance of the solution in the 220-350nm 
range of wavelength. The concentration was confirmed by UV absorbance at Ȝ 
280 nm. The expression of Beer’s law: A = İ280nm.l.C, was applied to deduce 
the concentration (C) of the sample from the absorbance value (A), with a 
pathlength for the cell of 1 cm. The molar absorption coefficients of the 
proteins were determined using their tryptophan (W), tyrosine (Y) and cysteine 
(C) amino acid composition, as described in the following equation (Gill and 
vonHippel, 1989, Pace, 1995): 
)125()1490()5500( uuu CnYnWnH  
where n is the number of each residue and the stated values are the amino acid 
molar absorptivities at 280 nm. The calculated molar extinction coefficients of 
the purified proteins used in this thesis are listed in Table 4.  
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Table 4: List of the molecular weights, isolelectric points and molar extinction 
coefficients of purified proteins used in this thesis. 
Protein 
Calculated 
molecular 
weight (Da) 
pI 
Molar extinction 
coefficient  
(M
-1
.cm
-1
) 
Lss-H6  
(pEA3) 
28,141 9.6 67,840 
LssEdom-H6 
(pETedom) 
16,386 8.8 36,900 
LssTdom-H6 
(pEA7) 
11,623 9.7 29,450 
H6-Lss  
(pSGAT2-Lss) 
29,668 9.7 67,840 
H6-LssEdom  
(pSGAT2-LssEdom) 
17,914 9.3 36,900 
LssEDW80F-H6 
(pWC3) 
16,347 8.8 31,400 
LssEDW59/80F-H6 
(pWC5) 16,308 8.8 25,900 
LssH114A-H6 
(pEJ1) 
28,074 9.5 67,840 
 
To obtain a higher concentration of proteins, centrifugation of protein 
solutions using 5ml Vivaspin Vertical filter tubes (VivaScience) with a 
molecular weight cut off of 3,000 Da or 10,000 Da when appropriate was 
performed. 
2.2.6. Determination of protein activity 
2.2.6.1. Substrate for protein activity determination 
A figure of the protein sequence MV11 is shown in Figure 17. Dr M. 
Vankemmelbeke (Centre for Biomolecular Sciences, University of 
Nottingham, Nottingham) designed this protein. The 57 residue N-terminal 
domain of MV11 was originated from the translocation domain of colicin E9 
and the C-terminal domain was made of a green fluorescent protein (GFP), 
fused to it by a 7 residue linker. Additionally, MV11 contained a 6 residue C-
terminal His-tagged sequence and a lysostaphin cleavage site (pentaglycine 
sequence) introduced by mutating the colicin E9 sequence. The introduction of 
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a N44C mutation in the recombinant protein allowed derivatisation with 
AlexaFluor 546 to result in a biological FRET substrate in which the 
AlexaFluor 546 would quench the fluorescence emission of GFP. The relative 
molecular mass of this biological substrate, in which a lysostaphin cleavage 
site has been introduced, is 33,800 Da (not included AlexaFluor 546).  
 
2.2.6.2. Pentaglycine cleavage assay 
   Lss and LssEdom activity was tested on MV11 substrate. The enzyme, 
1 PM, was mixed with MV11, 1 PM, in buffer (25 mM sodium phosphate (pH 
7.0), 150 mM sodium chloride). The cleavage reaction was stopped after 1 h, 2 
h and 3 h by chilling the reaction vessel in ice. The cleavage reaction was 
analysed by SDS-PAGE. 
 
 
Figure 17: Internally quenched MV11 substrate for peptide activity determination. 
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2.2.7. Kinetic parameters 
2.2.7.1. Principles of Föster Resonance Energy 
Transfer (FRET) 
Föster Resonance Energy Transfer (FRET) describes an energy transfer 
mechanism between two chromophores. A donor chromophore in its excited 
state transfers energy by a non-radiative, long-range dipole-dipole coupling 
mechanism to an acceptor chromophore in close proximity. The FRET 
efficiency (E) is described by the Föster equation and depends on the donor-to-
acceptor separation distance r with an inverse 6th power law due to a dipole-
dipole coupling mechanism (Förster, 1948):  
 
 
with R0 being the Föster distance of this pair of donor and acceptor at which 
the FRET efficiency is 50%.  
The Föster distance depends on the overlap integral of the donor 
emission spectrum with the acceptor absorption spectrum, highlighted in 
Figure 18, and their mutual orientation as expressed by the following equation:  
 
where ț2 is the dipole orientation factor, n is the refractive index of the 
medium, Q0 is the fluorescence quantum yield of the donor and J is the 
spectral overlap integral. 
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The FRET effect was employed as a technique for monitoring the rate 
of hydrolysis of the pentaglycine bond by lysostaphin and its endopeptidase 
domain and thus for determining the kinetic constants for hydrolysis, Vmax and 
KM. Figure 19 outlines the mechanism by which the rate of increase in donor 
fluorescence is proportional to the rate of cleavage of the linker.    
 
 
 
 
 
 
 
 
 
 
Figure 19: Fluorescence Resonance Energy Transfer prior and following cleavage of a
linker chain. 
Figure 18: Overlap (J) of the donor emission with the absorbance spectrum of the
acceptor in a FRET pair. 
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In the first part of the diagram, a donor fluorophore (D) is held within 
100 Å of an acceptor group (A) by a linker chain. Internal quenching occurs 
when the acceptor is absorbing energy at the donor emission wavelength, 
which results in limited fluorescence from the donor group across the 
spectrum. Enzymatic cleavage of the linker enables the two groups to move 
further apart so that internal quenching no longer occurs, and emission from 
the donor is restored.  
2.2.7.2. FRET substrate 
The substrate used to investigate the cleavage by Lss of the pentaglycine 
sequence is shown in Figure 20. It consists of a pentaglycine chain that has a 
N-(2-aminobenzoyl) (Abz) group on one end, and N-(2,4-dinitrophenyl) 
ethylene diamine (EDDnp) group on the other. It was synthesised by Dr R. 
Warfield (Centre for Biomolecular Sciences, University of Nottingham, 
Nottingham) (Warfield et al., 2006). The Abz group is a fluorophore that acts 
as a donor (Ȝmax (absorption) = 325nm, Ȝmax (emission) = 420 nm) and the 
EDDnp group acts as a quencher (Ȝmax (absorption) = 365 nm), for the FRET 
studies. 
 
 
 
 
 
The substrate used to investigate the cleavage of the pentaglycine 
sequence by LssEdom and its mutants, LssEdomW80F and 
LssEdomW59/80F, was MV11 (section 2.2.5.1). 
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Figure 20: FRET assay substrate Abz-Gly5-EDDnp: pentaglycine chain with an N-(2-
aminobenzoyl) (Abz) group on one end and N-(2,4-dinitrophenyl) ethylene diamine 
(EDDnp) group on the other 
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2.2.7.3. Initial study into kinetic parameters 
Fluorescence experiments were carried out using a Perkin Elmer 
LS50B luminescence spectrophotometer with a 5 mm quartz cuvette 
pathlength under the control of FLWinlab software. The temperature was 
maintained at 37ûC throughout these experiments, using a circulating water 
bath. The buffer/substrate solution was allowed to equilibrate for 5 min before 
addition of protein.  
For the initial studies into Vmax for the cleavage of Abz-Gly5-EDDnp 
by Lss, the excitation wavelength used in each case was 325 nm (obtained 
with a xenon discharge lamp excitation source) and scans were run to measure 
the emission at 420 nm (excitation slit 4.0 nm). Runs that were 20 min in 
length were performed with 10 scans at 2 min intervals for each concentration 
of substrate. The substrate concentrations used were 10 PM, 20 PM, 30 PM, 
40 PM, 50 PM and 70 PM, taken from a 0.39 mM stock solution in dimethyl 
sulfoxide (DMSO). The concentration was confirmed by UV absorbance at 
20°C at Ȝ 359 nm (İ359nm=17700 M-1.cm-1) and 365 nm (İ365nm=17100 M-1.cm-
1). The Beer-Lambert equation: A=İ.l.C, was applied to deduce the 
concentration (C) of the substrate from the absorbance value, with a calculated 
pathlength for the spectrophotometer cell of 1 cm. The protein concentration 
used in each case was 0.833 PM in 25 mM sodium phosphate (pH 7.0) and 
150 mM sodium chloride buffer. 
For the initial studies into Vmax for the cleavage of MV11 by the 
lysostaphin endopeptidase domain and mutants W80F and W59/80F, the 
excitation wavelength used in each case was 475 nm and scans were run to 
measure the emission at 508 nm (excitation slit 5.0 nm). Runs that were 10 
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min in length were performed with 4 scans at 10 sec intervals for each 
concentration of substrate. The substrate concentrations used were 0.2 PM, 0.4 
PM, 0.5 PM, 1.0 PM, 1.5 PM and 2.0 PM taken from a 0.19 mM stock 
solution in 1 mM sodium phosphate (pH 7.0) buffer. The protein concentration 
used in each case was 0.100 PM in 1 mM sodium phosphate (pH 7.0) buffer. 
The Grafit© **data-fitting program was used to calculate KM and Vmax. 
2.2.7.4. Inner filter effect correction 
For Abz-Gly5-EDDnp, absorbance readings were taken at 37ûC, at 325 
nm and 420 nm, for the different substrate concentrations in assay buffer. The 
correction factor was calculated from the optical density data (OD), measured 
for a 5 mm pathlength cuvette, by the equation (Bagui et al., 1996, Lakowicz, 
1999): 
 
 
2.2.8. Determination of physico-chemical parameters 
2.2.8.1. Differential Scanning Calorimetry (DSC) 
The VP-DSC high sensitivity scanning calorimeter (MicroCal, Inc.) 
was used to study the thermal stability of untagged LssEdom. Prior to the 
injection in the calorimeter cell, all the solutions were filtered and degassed. 
The reference cell was filled with an identical solution to that in the sample 
cell, but without the protein. The protein concentration was 12.7 µM in 10 mM 
HEPES (pH 7.0) with added sodium chloride, 150 mM. The up-scanning 
experiments were performed under an extra constant pressure of 2 atm and 
with a scan rate of 20ºC.h-1. The thermograms were processed with Origin 7.0. 
                                                 
** http://www.erithacus.com/grafit 
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The calorimetric enthalpy was determined by integrating the area under the 
peak after subtraction of the buffer-buffer baseline and by integrating the area 
under the peak after adjusting the pre- and post-transition baselines.   
2.2.8.2. Circular Dichroism (CD) spectroscopy 
CD measurements were performed on an Applied Photophysics Pi-
Star-180 spectrophotometer, employing constant N2 flushing. The temperature 
was regulated using a Neslab RTE-300 circulating programmable water bath 
and a thermoelectric temperature controller. CD spectra were recorded at 25 or 
85ºC using a 1 mm quartz cuvette. Protein samples were prepared at 26 µM 
concentration. The secondary structure was studied in 1 mM sodium phosphate 
(pH 7.0) buffer. Spectra were recorded from 210 to 260 nm, at 0.5 nm 
intervals with an integration time of 2 s, and are the averages of three scans, 
with the appropriate background buffer spectrum subtracted. CD 
measurements were converted into mean residue molar ellipticity [Ĭ] reported 
in deg.cm2.dmol-1, to reflect the fact that the peptide bond is the absorbing 
species in this case, using the formula:  
> @ )10( nClobs uuuy4 4  
where Ĭobs is the observed ellipticity in millidegrees, l is the optical 
pathlength in centimetres, c is the molar protein concentration, and n is the 
number of peptide bonds in the protein.   
Thermal denaturation curves were recorded over the temperature range 25-
85ºC using a 26 µM protein solution in a 1 mm quartz cuvette. Single 
wavelength data were recorded at 224 nm over a single accumulation. The 
sample was required to reach thermal equilibrium at each temperature for a 
period of at least 30 s with a tolerance of ± 0.2ºC before recording each data 
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point. The temperature was increased every 4ºC and decreased every 6ºC. 
Ellipticity data were corrected to mean residue molar ellipticity using the 
above formula.  
2.2.8.3. Attenuated Total Reflection (ATR) 
spectrometry 
Mid-infrared (IR) spectroscopy is one of the classical methods for 
structure determination of molecules. The absorption of infrared radiation 
excites vibrational transitions of molecules. Vibrational frequency depends on 
the strength and polarity of the vibrating bonds, the masses of the vibrating 
atoms and is influenced by intra- and inter-molecular effects. The infrared 
spectrum is plotted against the inverse of the wavelength, the wavenumber Ǌ, 
which is proportional to the transition energy and has the unit cm-1. 
In Fourier transform infrared (FT-IR) spectrometers, the light emitted 
from the light source is split between two beams that generate a variable 
optical path difference; it gives a detector signal that contains the spectral 
information. The optical path difference generates an interference measured by 
the instrument, called an interferogram, which is the Fourier transform of the 
spectrum. A second Fourier transform performed by a computer converts the 
measured data back into a spectrum.  
Attenuated total reflection (ATR) is a sampling technique used in 
conjunction with infrared spectroscopy which enables samples to be examined 
directly in the solid or liquid state. ATR uses the property of total internal 
reflection called the evanescent wave (Harrick, 1967). An attenuated total 
reflection accessory is illustrated Figure 21 (Barth, 2007). It operates by 
 63
measuring the changes that occur in a totally internally reflected infrared beam 
when the beam comes into contact with the sample.  
 
 
 
 
 
 
An infrared beam is directed onto an optically dense diamond crystal 
with a high reflective index at a certain angle. This internal reflectance creates 
an evanescent wave that extends beyond the surface of the crystal into the 
sample held in contact with the crystal. In regions of the infrared spectrum 
where the sample absorbs energy, the evanescent wave will be attenuated or 
altered. The attenuated energy from each evanescent wave is passed back to 
the IR beam, which then exits the opposite end of the crystal and is passed to 
the detector in the IR spectrometer. The system then generates an infrared 
spectrum.  
The protein samples (100 µl) dialysed in 1 mM sodium phosphate (pH 
7.0) buffer were deposited on the attenuated total reflection (ATR) crystal for 
FT-IR measurements. All IR spectra were collected at room temperature with 
an Equinox 55 Fourier transform infraRed (FT-IR) spectrometer (Bruker 
Optics, Inc., Billerica, MA) with a Bio-ATR II attachment (Bruker Optics, 
Inc.) equipped with a diamond ATR crystal. For each protein spectrum, 100 
interferograms repeated 10 times were accumulated and Fourier transformed to 
yield infrared spectra with a nominal resolution of 2 cm-1. ATR spectra were 
Figure 21: A typical ATR setup. 
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automatically converted to absorption spectra using the Opus 4.2 software 
(Bruker Optics, Inc.). Solvent spectra obtained under the same conditions were 
subtracted from all sample spectra. Baseline correction was performed by the 
Opus 4.2 software. All IR spectra were normalised for easier comparison.  The 
amide I region (1700-1600 cm-1) was used for protein structure determination. 
The regions of the Tyr and His (1518 and 1602 cm-1 and 1594 cm-1, 
respectively) were also used to monitor changes in protein conformation 
(Noguchi et al., 1999, Venyaminov and Kalnin, 1990). Due to the composite 
character of the amide I band, overlapping infrared bands were resolved 
according to Fourier self-deconvolution procedures as described previously 
(Kauppinen et al., 1981). The presence of certain protein secondary structure 
elements was determined based on the positions of the component bands 
(Byler and Susi, 1986, Goormaghtigh et al., 1994). In order to quantify the 
approximate amount of each protein secondary structure, a curve fitting of 
deconvolved amide I band contour was performed with Gaussian function 
(Surewicz et al., 1993). The resulting fractional areas of the bands assigned to 
different types of secondary structure (i.e., Į-helix, ȕ-sheet, turn and irregular 
structure) were assumed to represent the percentages of these structures in a 
given protein (Byler and Susi, 1986, Surewicz and Mantsch, 1988, 
Goormaghtigh et al., 1990).  
2.3. Crystallogenesis and attempts at structure 
resolution 
2.3.1. Principles of protein crystallisation 
Crystallisation is a phase transition phenomenon as illustrated in Figure 
22 (Chayen, 2004). Nuclei form from an aqueous protein solution when the 
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solution is brought into supersaturation, which is achieved by varying certain 
parameters such as protein concentration, nature of precipitant and solvent, 
pH, temperature, and the presence of additives such as ligands and ions. Once 
nuclei have formed, which can be studied by electron microscopy, actual 
crystal growth can begin. 
 
 
 
 
 
 
 
 
 
In the supersaturated region of the phase diagram, nucleation is easy 
but haphazard, and subsequent crystal growth rapid and hard to control. 
However, in the “metastable” region, at concentrations slightly above the 
saturation limit, small nuclei are unstable but larger nuclei may grow at the 
expense of smaller ones.  
The most popular method that has been developed to aid 
macromolecular crystal formation is that of vapour diffusion, which has two 
major variants: sitting and hanging drop, pictured in Figure 23. The small 
Figure 22: Phase diagram illustrating the effects of salt or other precipitant
concentration on protein solubility. 
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drop, containing protein, stabilizing buffer, precipitant and other additives, is 
placed in vapour equilibrium in a closed system with a much larger reservoir 
volume. The reagent concentration in the reservoir is much higher than in the 
drop and therefore pulls water from the drop into a vapour phase until 
equilibrium between them is reached. During this process, the sample in the 
drop is concentrated, increasing its relative super saturation. Once nuclei have 
formed, the concentration of protein in the solute will drop, thereby leading the 
system into the metastable zone, where a few single crystals will grow.  
 
To obtain good structural data, crystals need to be single and have 
dimensions of at least 10 µm3. Crystallisation experiments are based mainly on 
trial and error. The ability to dispense crystallisation trials by way of 
automating and miniaturising, with the HYDRA II robot dispenser 
(Matrixtechcorp), reduce the time needed to set up the series of experiments. 
Such procedures are very valuable for finding the initial conditions for 
crystallisation. 
In addition, as seed-grown crystals avoid some of the problems 
inherent to spontaneously nucleated crystals, this method was tested. Indeed, it 
is said to be profitable to stimulate nucleation by seeding with crystals of the 
Figure 23: Method for protein crystallisation. 
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same protein grown under other conditions. This seeding method is called 
epitaxial jump and is used to obtain crystals under conditions which may be 
significantly different from those in which the original seed was obtained. In 
our case, streak seeding shown on Figure 24 was utilised (Bergfors, 1999).  
 
The well is gently opened and the crystal seeds are picked up with a 
whisker. This is streaked across a pre-equilibrated drop which allows growth 
of well-formed crystals. 
2.3.2. Crystal screening trials 
Protein crystallisation studies on cleaved His-tag LssEdom were 
carried out in collaboration with Dr Max Paoli (Centre for Biomolecular 
Sciences, University of Nottingham, Nottingham) after unsuccessful trials 
on Lss and LssEdom domain C-terminally His-tagged.   
High throughput crystallisation screens were carried out using the 
sitting-drop vapour-diffusion method in 96-well Intelliplates (Hampton 
Research) and the Hydra II micro dispensing system (Robertson Scientific). 
The crystallisation screens tested from NextalBiotechTM were: the 
ClassicsTM, the AmSO4
TM (ammonium sulphate), the anionsTM, the 
Figure 24: Streak seeding method. 
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cationsTM, the PEGsTM, the pHClearTM, and the MPDTM (3-methyl-1,5-
pentadiol). The volume of the reservoir solution was 60 µl and for the three 
drops its volume was 1.0 µl. The robot placed, in each well, different 
concentrations (27, 55, 66 PM) of the same preparation of LssEdom 
dialysed in buffer Tris-HCl, 10 mM, pH 7.0 with sodium chloride, 150 mM. 
It was placed on the corresponding reservoir solution droplet at a ratio of 
1:1 (v/v). The plates were sealed carefully with tape (Henkel) and placed in 
the incubator at 19ºC. Every 5 days the droplets were examined under a 
microscope for the presence of crystals and the “Hit conditions” were 
marked.  
Crystallisation conditions were then reproduced manually with the 
sitting drop vapour diffusion method in Libro plates (Hampton Research). 
Various ammonium sulphate concentrations (1.4 M to 2.4 M) were 
screened against different PEG 400 concentrations (1% to 11%) with 0.1 M 
MES sodium salt buffer pH 6.5. The drops were obtained by mixing 2.0 µl 
of protein at different concentrations (37, 100 and 219 PM) with 2.0 µl of 
solvent, with a reservoir volume of 1 ml.  
As no reproducibility was observed, the effect of the buffer solution 
was tested. The same conditions were reproduced, with the exception of the 
replacement of MES sodium salt buffer by Tris-HCl buffer (0.1 M, pH 6.5). 
The salt concentration potential effect was investigated as well by applying 
the protein against the same conditions in which was added 100 mM or 200 
mM sodium chloride. To test whether or not the lack of reproducibility was 
due to a problem in the preparation of the solutions used, NextalBiotechTM 
solutions of MES sodium salt pH 6.5, ammonium sulphate, PEG 400 were 
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used. The drops were obtained by mixing 1 Pl of 60, 113 and 169 PM of the 
protein with 1 Pl of the reservoir solution.    
In parallel, seeding experiments were performed. A crystal wand 
was made by cutting a cat’s whisker, threading it into a white pipette tip and 
fixing it with glue. Three pre-equilibrated drops were prepared with 1.70 M 
ammonium sulphate, 3% PEG 400 and 0.1 M0(S sodium salt pH 6.5, 
mixed Pl:2 Pl with 37, 100 and 219 PM of LssEdom. The seed source 
well containing needles grown under the same conditions was opened 
gently. Seeds were picked up with the whisker and the crystal growth wells 
were streaked with the whisker across the pre-equilibrated drop. In addition, 
the seed source well, containing crystals grown under the following 
conditions: 2.0 M ammonium sulphate, 5% PEG 400 and 0.1 M0(S 
sodium salt pH 6.5, was opened gently for mounting experiments and then 
used for streak seeding experiments. Seeds were picked up with the 
whisker. The crystal growth wells were streaked with the whisker across the 
pre-equilibrated drop. 
2.3.3. Crystal cryo-mounting 
The crystal cryo-mounting experiment was carried out in 
collaboration with Dr Max Paoli (Centre for Biomolecular Sciences, 
University of Nottingham, Nottingham). The crystals were suspended in a 
film of an “antifreeze” solution (a “cryo-protected” solution forming a 
frozen vitrified water in which the crystal is stable) held by surface tension 
across a small diameter loop of fiber (Hampton Research) and quickly 
plunged into a liquid cryogen.  
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Different “cryo-protectant” solutions were tested:  
x 100 mM MES pH 6.5, 150 mM NaCl, 10 mM Tris-HCl pH 6.5, 2.08 M 
ammonium sulphate, 6% (w/v) PEG 400; 
x 100 mM MES pH 6.5, 2.08 M ammonium sulphate, 6% (w/v) PEG 400, 
320 mM sodium malonate; 
x 100 mM Tris-HCl pH 6.5, 2.08 M ammonium sulphate, 6% (w/v) PEG 
400, 740 mM sodium malonate; 
When observed under the microscope, those solutions showed that there 
was a problem of phase separation. Thus, the amount of PEG 400 was lowered 
and a loop was dipped with a “cryo-protectant” solution made of 100 mM 
MES pH 6.5, 2.08 M ammonium sulphate, 2.5% (w/v) PEG 400, 0.96 M 
sodium malonate. It was flash-frozen and placed on the gionometer. The 
solution was glassy and was used to immerse the crystal for 30 seconds prior 
to being speedily flash-frozen. Two crystals were mounted.  
2.3.4. Nuclear Magnetic Resonance (NMR) 
spectroscopy preliminary studies 
All NMR spectra were collected by Dr J. Long (Centre for 
Biomolecular Sciences, University of Nottingham, U.K.) at 298 K on a Brüker 
AV-600 spectrometer operating at 600 MHz. The spectrometer was equipped 
with a triple-resonance probe using the standard library of pulse sequences 
available with XWINNMR 3.51 (Bruker). The LssEdom sample (uniformly 
15N-labelled) was buffered in 10% D2O solution 10 mM sodium phosphate 
(pH 7.4), 150 mM sodium chloride, 0.04% sodium azide, to give a final 
protein concentration of 75 µM. The 2D 15N-HSQC spectrum was collected 
over-night using XWINNMR version 3.51.  
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2.3.5. Computational techniques 
2.4. Hierarchical clustering 
Multiple alignments with hierarchical clustering were performed using 
Multalin††. Multalin created a multiple sequence alignment from a group of 
related sequences using progressive pairwise alignments. The method used is 
described by Corpet (Corpet, 1988).  Protein sequences (Fasta format) were 
rearranged with postulated gaps so that similar residues were juxtaposed. A 
positive score was attached to identities and a penalty to gaps was subtracted 
from the alignment score of two clusters each time a new gap was inserted in 
one cluster. The program maximised the total score, taking account of all 
possible alignments and allowing for any length gap at any position.  
2.5. General homology procedure 
The amino acid sequence of the target protein, lysostaphin, was 
obtained from GenBank (Accession AAB53783) in which 239 residues were 
involved. The template proteins used were LytM (PDB code 2B44) (Odintsov 
et al., 2004, Firczuk et al., 2005), and ALE-1 (PDB code 1R77) (Lu et al., 
2006), deposited in Protein Data Bank. 
The BLAST search algorithm was used for the search online‡‡ 
(Altschul et al., 1997). Program Modeller 8v2 (Sali and Blundell, 1993), 
which is an implementation of an automated approach to comparative 
modelling by satisfaction of spatial restraints, was employed to build the 3D 
structure of lysostaphin. All sequences were imported in ClustalW program§§ 
(Thompson et al., 1994). The ribbon illustration was made using PyMol 
                                                 
†† http://bioinfo.genopole-toulouse.prd.fr/multalin/multalin.html 
‡‡ http://www.ncbi.nlm.nih.gov 
§§ http://www.ebi.ac.uk/clustalw/ 
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software. The structure with the lowest energy was checked using MolProbity 
software (Davis et al., 2007). SYBYL 7.3 software§ was used to calculate the 
root mean square deviation (RMSD) comparing backbone structures with each 
others. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
§ http://www.tripos.com/data/SYBYL 
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3. Lysostaphin secondary structure prediction 
3.1. Secondary structure 
Proteins are amino acid-based compounds and the composition of 
amino acids in a protein gives it its unique structure. The backbone geometry 
of a protein is defined by the dihedral angles Phi (ĭ) and Psi (Ȍ) angles of 
individual residues (Figure 25). Certain combinations of these angles in 
consecutive residues result in a specific secondary structure motif (Karplus, 
1996). These structures are stabilised by intermolecular hydrogen bonds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 http://cmgm.stanford.edu/biochem201 
Figure 25: Peptide torsion angle. Definition of the Phi (ĭ ) and Psi (Ȍ) angles.  
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Protein chains form frequently observed structural motifs in their 
native state. The most frequently observed secondary structure elements are Į-
helices and parallel and anti-parallel ȕ-sheets. Į-Helices (Figure 26) are helix-
like structures and ȕ-sheets (Figure 27) are pleated sheet-like structures 
connected by ȕ-turns (in the case of anti-parallel ȕ-sheets), as their names 
suggest. Every region remaining in the protein after all the Į-helix, ȕ-sheet and 
ȕ-turn regions are assigned is called a loop region.  
 
 
 
 
 
 
 
 
 
 
 
The right-handed Į-helix results when the nth peptide unit forms 
hydrogen bonds between its C-O and the N-H of the (n+4)th peptide unit and 
between its N-H and the (n-4)th C-O; there is a 1.5 Å translation and 100º turn 
between two consecutive peptide units, giving 3.6 amino acid residues per 
turn.   
 
Figure 26: The right-handed Į-helical secondary structure of human vimentin coil 2B 
fragment (PDB code 1GK4).  
 75
 
 
 
 
 
 
 
 
 
 
Typically the strands of an anti-parallel ȕ-sheet are linked by ȕ-turns 
where the nth peptide unit forms hydrogen bonds with the (n+3)rd peptide unit.  
3.2. Prediction strategies 
Determination of protein secondary structure is not an exact science. 
There are a number of methods of varying resolution to determine the structure 
of proteins. There are both laboratory based methods and theory based 
methods for the determination of secondary structure. Laboratory based 
methods can be used to guess the secondary structure content without knowing 
the tertiary structure. The percentage of common motifs in a protein can be 
determined by means of circular dichroism spectroscopy (CD) (Fasman, 1996) 
or Fourier transform infrared spectroscopy (FT-IR) (Byler and Susi, 1986). In 
another method, the scientist first determines the tertiary structure of the 
protein using a method such as X-ray crystallography (Rupp and Wang, 2004) 
and then specifies the regions of different secondary structure by careful 
Figure 27: Anti-parallel ȕ-sheet secondary structure from pyruvate kinase (PDB code 
1PKN).  
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inspection of the structure. If the structure of a protein is known, the secondary 
structure determination is a pattern recognition problem using algorithms 
developed for this purpose.  
3.3. Protein expression, purification and quality 
assessment 
LssEdom was expressed and purified to near homogeneity by means of 
immobilised metal-affinity chromatography (IMAC) as described in the 
Materials and Methods section (cf. sections 2.1.8. and 2.2.1.). In order to 
obtain the structure of the active form of LssEdom it was necessary to assess 
its activity. A biological substrate, MV11, containing a pentaglycine cleavage 
site was used to primarily observe the cleavage activity of LssEdom. In 
addition, a quantitative measurement to compare the activity of different Lss 
preparations (zinc- or nickel- IMAC purified) was performed by Fluorescence 
Resonance Energy Transfer (FRET) assay.  
The recombinant proteins were found to be active on the MV11 
biological substrate, cleaving MV11 at the Gly5 sequence, as determined by in 
vitro activity assay and observed for LssEdom on SDS-PAGE (Figure 28).   
 
 
 
 
   
Quantitative measurement of Lss activity was performed by (FRET) 
assay. An internally quenched pentaglycine with an ortho-aminobenzoic acid 
Figure 28: LssEdom activity test on MV11 substrate observed on SDS-PAGE.  
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fluorophore (Abz) and a (2,4-dinitrophenyl)ethylene diamine (EDDnp) 
quenching group was used as a substrate (Figure 29) (Warfield et al., 2006). 
 
 
 
             
    
The samples of lysostaphin used in the assays up to this point had been 
purified using a nickel(II)-affinity chromatography column, charged with 50 
mM NiSO4. It was suggested that this might lead to replacement of the zinc(II) 
ion by a nickel(II) ion in the active site of the metallo-enzyme, and hence lead 
to a decrease in enzyme activity. This theory was tested by comparing 
activities obtained after nickel(II) or zinc(II)-affinity chromatography 
purification of lysostaphin samples.  
Titration of the Abz-Gly5-EDDnp FRET substrate with lysostaphin 
resulted in a concentration dependent cleavage of the pentaglycine and 
quantitative emission of the fluorescence. At high substrate concentrations, 
initial rates appeared to decrease due to the inner filter effect. In order to 
overcome this effect a correction factor was calculated as described in the 
Materials and Methods section (cf. section 2.2.7.4.) and applied for each 
concentration of substrate. Three assays were performed at each substrate 
concentration and the mean value of the reaction rates was determined for each 
set. The corrected rates could be fitted to the following Michaelis-Menten 
equation:  
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Figure 29: FRET substrate: internally quenched pentaglycine with ortho-aminobenzoic 
acid fluorophore (Abz) and a (2,4-dinitrophenyl)ethylene diamine (EDDnp) quenching 
group. 
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V0 = Vmax [S0] / ([S0] + KM) 
where:  V0 = intial rate 
Vmax = maximum rate possible at a given enzyme concentration 
   [S0] = initial substrate concentration 
 KM = Michaelis-Menten constant 
 
The Grafit©***data-fitting program was used to calculate KM and Vmax. 
Figure 30 displays the Michaelis-Menten plot from the lysostaphin purified on 
nickel(II) results and Figure 31 displays the Michaelis-Menten plot from the 
lysostaphin purified on zinc(II) results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
*** http://www.erithacus.com/grafit 
nickel-purified Lss Value Std. Error 
Vmax (RFU.s-1) 0.259 0.063 
KM (mM) 0.7 0.2 
Figure 30: Grafit
©
 Michaelis-Menten plot for data collected using nickel-purified 
lysostaphin. 
 79
 
 
 
 
 
 
 
 
 
 
Grafit© estimated the values of Vmax to be 0.26 (± 0.06) RFU.s
-1 for Lss 
purified on nickel(II) and 0.33 (± 0.06) RFU.s-1 for Lss purified on zinc(II). 
Estimated values for KM were 0.7 (± 0.2) mM and 0.2 (± 0.05) mM 
respectively for Lss purified on nickel(II) and on zinc(II). The values 
calculated for the Vmax and KM are only approximate as the usable substrate 
concentration range is not sufficiently wide enough to adequately cover the 
range required to obtain accurate kinetic constants with small errors associated 
with them.  
At a substrate concentration of 10 µM, the relative rates were 
calculated to be 0.0179 (± 0.0002) RFU.s-1 for Lss purified on zinc(II) and 
0.0051 (± 0.0002) RFU.s-1 for Lss purified on nickel(II). Thus, the observed 
cleavage ability was greater than 3.5 fold for the zinc-purified sample. These 
results indicated that protein activity was enhanced when purification was 
performed with zinc(II) rather than nickel(II). Indeed Lss is a zinc 
zinc-purified Lss Value Std. Error 
Vmax (RFU.s-1) 0.330 0.064 
KM (mM) 0.2 0.05 
Figure 31: Grafit
©
 Michaelis-Menten plot for data collected using zinc-purified 
lysostaphin. 
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metalloprotease that contains a zinc ion in its activity site which is important 
for the cleavage reaction. 
3.4. Circular Dichroism (CD) spectroscopy 
Circular dichroism (CD) is defined as the differential absorbance of left 
circularly polarized light (LCPL) and right circularly polarized light (RCPL): 
CD = Abs (LCPL) – Abs (RCPL). To be “CD optically active”, a molecule 
must interact differently with left- and right-handed photons. Asymmetry can 
come from chiral molecules such as the peptide backbone of proteins or their 
aromatic amino acid side chains (all amino acids except glycine contain a 
chiral carbon, thus are asymmetrical). In the far-UV region, the peptide bond is 
the major absorbing group.  
Five common secondary structure motifs (Į-helix, parallel ȕ-sheet, 
antiparallel ȕ-sheet, ȕ-turns, and other (e.g. random coil conformation)) exhibit 
distinctive CD spectra in the far-ultraviolet region (170-260 nm) (Johnson and 
Tinoco, 1972). Based on these and the spectra of standard proteins, there are 
many algorithms currently available for protein secondary structure analysis 
(Compton and Johnson, 1986, Johnson, 1999). These algorithms use a basic 
set of model protein structures. The shape of the spectrum is compared to the 
basis spectra and five structural contributions are extracted (Į-helix, parallel ȕ-
sheet, antiparallel ȕ-sheet, ȕ-turns, and other (e.g. random coil conformation)). 
However, it has limited value due to over-simplification. 
CD is reported in units of absorbance or ellipticity. CD data are 
typically reported in ellipticity (ș), which is related to absorbance by a factor 
of 32.98ș = 33.98ǻAbs. Ellipticity is usually reported in millidegrees (mdeg), 
which are one thousandth of a degree. Molar ellipticity ([ș]) is CD corrected 
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for concentration. Conversion from molar extinction (absorbance corrected for 
concentration) to molar ellipticity uses a factor 3298 ([ș] = 3298ǻİ).  
3.4.1. Exciton coupling phenomenon 
CD spectra of active LssEdom were obtained in order to predict its 
secondary structure to assess if it was a suitable protein for crystallisation 
studies by determining amount of random coil.  Shown in Figure 32 is the 
LssEdom CD spectra recorded at 25ºC and then 85ºC and again 25ºC after 
denaturation at 85ºC. Activities of LssEdom before and after denaturation 
were assessed by FRET assay (cf. Appendix 1). The thermal curves on 
denaturation and attempt at renaturation for LssEdom are provided in section 
4.3.2. CD data have been corrected for concentration and are reported as the 
mean residue molar ellipticity. All solutions of protein used exhibited similar 
spectra with maxima near 224 nm.  
 
 
 
 
Figure 32: Far-UV CD spectra of LssEdom recorded at 25ºC (blue), 85ºC (pink) and 
25ºC after denaturation (orange). The protein concentration was 0.30 mg.ml-1. The buffer 
employed was 1 mM sodium phosphate, pH 7.0.   
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LssEdom is 48% identical to LytM186-314. Thus, the predicted amount 
of secondary structure elements for LssEdom should be in agreement with 
LytM186-314 (PDB codes 2B44, 2B0P, 2B13) content, knowing that a given 
sequence of amino acids always folds into almost the same structure under the 
same environmental conditions. The main part of the secondary structure of 
LytM186-314 is dominated by a ȕ-sheet (42%) that extends throughout the entire 
molecule; some Į-helical conformation (13%) is also present in the structure 
(Firczuk et al., 2005). The CD spectra of ȕ-proteins having similar secondary 
structures and little Į-helix vary widely (Manning and Woody, 1987), which 
complicates estimations of the amounts of the various types of secondary 
structure. Contributions from aromatic side chains, tryptophan residues in 
particular, are considered to be an important source of these variations in the 
far-UV region. LssEdom contains a large fraction of tryptophan residues (4 
Trp, 2.7%). An average protein has a tryptophan content of 1.7% (Singh and 
Thornton, 1992), which suggests that the tryptophan residues in LssEdom may 
make important contributions to the far-UV CD spectra recorded. Some of the 
tryptophan residues are located in aromatic clusters as shown on the LssEdom 
model (cf. section 4.6.3) displayed in Figure 33.  
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Several proteins have strong positive CD bands in the 225-230 nm 
region, probably attributable to aromatic side chains. For ȕ-proteins possessing 
a CD spectrum of low intensity, tryptophan residue CD bands can markedly 
influence the far-UV region, especially in proteins containing several 
tryptophan residues (Grishina and Woody, 1994). The complexity of the far-
UV spectrum most probably arises from exciton splitting of transitions from 
tryptophans. If two identical chromophores are sufficiently close, their excited 
states will interact. This phenomenon is referred to as exciton effect (Davydov, 
1971). The CD bands overlap, giving rise to a characteristic band called 
couplet (Schellman, 1968). The exciton coupling observed probably arises due 
to the highly asymmetrical environment of the aromatic residues in LssEdom. 
Since exciton coupling between aromatic groups increases when they are in 
close proximity, perturbation of the CD spectra thwarts attempts to estimate 
Figure 33: Polypeptide backbone of LssEdom including the side chains of aromatic 
residues. Tryptophan are shown in red, tyrosine in green, phenylalanine in orange and 
histidine in pink.  
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the amounts of the various types of secondary structure in LssEdom. These 
problems might also be emphasized in this protein because of its relatively low 
contents of Į-helix. Together these characteristics make this protein a good 
model for studying contributions to the CD spectrum made by structural 
elements other than secondary structure.  
The complex band pattern observed in the far-UV CD spectrum of the 
native protein has changed in the corresponding spectrum of denatured 
LssEdom recorded at 85ºC and 25ºC after denaturation. This indicates that the 
asymmetric environment around the various aromatic amino acid residues in 
the native state was disrupted upon unfolding, resulting in a CD spectrum 
typical for an unordered polypeptide chain.   
3.4.2. Strategy for mutations 
In order to study the contribution of tryptophan residues to the CD 
spectrum and to predict the secondary structure of LssEdom, mutations were 
performed on residues that were predicted to contribute to the exciton coupling 
phenomenon observed. Of the four tryptophan and ten tyrosine residues in 
LssEdom sequence, only tryptophan residues were considered, as they were 
thought to make the major contribution to the exciton coupling phenomenon 
(Grishina and Woody, 1994). In the model of LssEdom structure (cf. section 
4.6.3.), tryptophan residues were highlighted to evaluate their distances and 
respective orientations (Figure 34). The side chains of tryptophan at position 
59 and 80 in the LssEdom model were in the most parallel orientation, with 
one ring rotated by less than 90º relative to the other and within the shortest 
distance (13 Å) of the all four tryptophan residues. Tryptophan 80 is located 
on a ȕ-sheet buried in the interior of the enzyme molecule and is close to the 
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essential amino acid histidine 83 (Warfield et al., 2006). It is surrounded by 
tyrosine 34 and 62, histidine 83 and 116 and phenylalanine 124. In this case, 
coupling of tryptophan transitions is not necessarily dominant over Tyr-Trp, 
Tyr-Tyr, Phe-Trp, etc. transitions. Tryptophan 59 is located in a ȕ-turn and is 
exposed to the solvent. It is unknown which residues are responsible for such 
spectroscopic properties and to what extent individual tryptophan residues 
affect the tertiary structure and function of LssEdom, because no mutation 
studies have been performed on any of the tryptophan residues.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Looking at substitution preferences in the literature (Betts and Russell, 
2003, Livingstone and Barton, 1993), it was reported that replacing tryptophan 
by phenylalanine by site directed mutagenesis was the most favoured 
substitution in order to minimise the destabilisation of the native state as a 
consequence of the substitution. Based on the above information, tryptophan 
Figure 34: Model of LssEdom structure (cf. Section 4.6.3.). Ribbon representation with 
Trp shown as sticks and highlighted in red. Relative distances between Trp residues are 
shown in yellow: 13.0, 16.0, 17.4, 20.7 Å for W80-W59, W59-W103, W103-W11, W11-W80 
distances, respectively.    
 86
residues W80, on one hand, and W80 with W59, on the other hand, were 
chosen to be mutated into phenylalanine residues by site-directed mutagenesis 
to lower the exciton coupling phenomenon observed by circular dichroism and 
thus allow secondary structure prediction of LssEdom.  
3.4.3. LssEdom mutants 
Ms W. Chen, a final year project student under my supervision, 
constructed a W80F mutant and a W59/80F mutant of LssEdom. The W80F 
substitution in LssEdom was achieved by site-directed mutagenesis in 
pETedom. Two megaprimers were generated by PCR with primers T7F and 
WC2 for the first reaction, and T7R and WC1 for the second reaction 
(sequences for each of the primers are displayed in the Material and Methods,  
section 2.1.5.). The two megaprimers generated were used to polymerise the 
complete DNA sequence with the desired mutation. The products of 
amplification are shown in Figure 35.  
 
 
 
 
Cutting the pETedom DNA template with NdeI and XhoI resulted in 
the excision of a 600 bp insert which was replaced by the above PCR product 
purified and digested with the same enzymes. The clones were confirmed by 
PCR on the recombinant plasmid pWC3 and by DNA sequencing; using T7F 
(forward) and T7R (reverse) primers. DNA sequencing data returned from the 
QMC DNA sequencing laboratory (E1T7F) were translated and compared to 
Figure 35: PCR products: (1) megaprimer generated with primers T7F and WC2 on 
pETedom, (2) megaprimer generated with primers T7R and WC1 on pETedom, (3) LssEdom 
DNA sequence with W80F substitution generated with megaprimer 1 and 2. 
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the LssEdom sequence with the ClustalW program. The results confirmed the 
presence of W80F substitution in the pWC3 plasmid (Figure 36).  
Translation of pWC3 sequencing data compared with LssEdom sequence 
 
 
E1T7F       MAATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWS 60 
Edom        MAATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWS 60 
            ************************************************************ 
 
E1T7F       NYGGGNQIGLIENDGVHRQFYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRM 120 
Edom        NYGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRM 120 
            ******************* **************************************** 
 
E1T7F       NSFSNSTAQDPMPFLKSA 138 
Edom        NSFSNSTAQDPMPFLKSA 138 
    ****************** 
Figure 36: ClustalW homology analysis showing sequence alignment of LssEdom and 
E1T7F sequence, identified by nucleotide sequencing and translated. Stars indicate a 
perfect match in between the theoretical sequence and the sequencing data.    
 
 
The W59/80F substitution in LssEdom was achieved by site-directed 
mutagenesis in pWC3. Two megaprimers were generated by PCR with primers 
T7F and WC4 for the first reaction, and T7R and WC3 for the second reaction. 
The two megaprimers generated were used to polymerise the complete DNA 
sequence with the desired mutation. The products of amplification are shown 
in Figure 37.  
 
 
 
 
 
 
Cutting pWC3 with the restriction enzymes NdeI and XhoI resulted in 
the excision of a 600 bp insert which was replaced by the above PCR product 
Figure 37: PCR products: (1) megaprimer generated with primers T7F and WC4 on pWC3,
(2) megaprimer generated with primers T7R and WC3 on pWC3, (3) LssEdom DNA 
sequence with W59/80F substitutions generated with megaprimer 1 and 2. 
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purified and digested with the same enzymes. The clones were confirmed by 
PCR on the recombinant plasmid pWC5 and by DNA sequencing; using T7F 
(forward) and T7R (reverse) primers. DNA sequencing data returned from the 
QMC DNA sequencing laboratory (E2T7F) were translated and compared to 
the LssEdom sequence with the ClustalW program. The results confirmed the 
presence of W59/80F substitution in the pWC5 plasmid (Figure 38).  
 
Translation of pWC3 sequencing data compared with LssEdom sequence 
 
E1T7F       MAATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGFS 60 
Edom        MAATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWS 60 
            ************************************************************ 
 
E1T7F       NYGGGNQIGLIENDGVHRQFYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRM 120 
Edom        NYGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRM 120 
            ******************* **************************************** 
 
E1T7F       NSFSNSTAQDPMPFLKSA 138 
Edom        NSFSNSTAQDPMPFLKSA 138 
    ****************** 
Figure 38: ClustalW homology analysis showing sequence alignment of LssEdom and 
E1T7F sequence, identified by nucleotide sequencing and translated. Stars indicate a 
perfect match in between the theoretical sequence and the sequencing data.    
 
The recombinant plasmids: pWC3 or pWC5, were transformed into the 
host, E.coli BL21 (DE3), and addition of isopropyl E-thiogalactoside (IPTG) 
induced the overexpression of bands of approximately 16 kDa molecular 
weight, corresponding to the LssEdomW80F-H6 and LssEdomW59/80F-H6 
fusion protein. The proteins were overexpressed in soluble form in the 
cytoplasm.  
LssEdom, LssEdomW80F and LssEdomW59/80F were purified to near 
homogeneity, observed on SDS-PAGE, using twice the same affinity 
chromatographic step on zinc agarose (Figure 39).  
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Protein size studies on LssEdom, LssEdomW80F and 
LssEdomW59/80F (C = 13 µM, [protein] = 0.2 mg.ml-1) were conducted by 
dynamic light scattering on a Malvern Nanosizer (Figures 40 and 41).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: SDS-PAGE showing the fractions containing LssEdom (1), LssEdomW80F
(2) and LssEdomW59/80F (3) purified by metal affinity chromatography. 
Figure 40: Dynamic light scattering size distribution by intensity of LssEdom (red), 
LssEdomW80F (green) and LssEdomW59/80F (blue).  
Figure 41: Dynamic light scattering size distribution by volume of LssEdom (red), 
LssEdomW80F (green) and LssEdomW59/80F (blue). 
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All samples showed the same size distribution. Peaks were centred on 
6.53 nm. The Z average was 659 nm, 722 nm, 616 nm in diameter for 
LssEdom, LssEdomW80F and LssEdomW59/80F, respectively. The 
substitutions performed on LssEdom tryptophan residues 80 and 59 did not 
lead to an increased state of aggregation, which generally occurs when 
proteins are unfolded.  
3.4.4. Kinetic data 
In principle, substitution of a specific tryptophan residue might 
influence not only the point of mutation but also other parts of the protein 
structure, and if this is the case, such substitution might also alter the native 
environment of the remaining tryptophan residues. In order to determine if the 
mutated lysostaphin endopeptidase domains (LssEdomW80F and 
LssEdomW59/80F) were correctly folded and maintained the structure of the 
active form of LssEdom, it was necessary to assess their activities. A 
biological FRET substrate, MV11, containing a pentaglycine cleavage site was 
used to measure quantitatively the cleavage activities of LssEdom, 
LssEdomW80F and LssEdomW59/80F.  
The mutation of tryptophan (Trp, W) into phenylalanine (Phe, F) at 
position 80 in the LssEdom sequence was believed to lead to a certain loss of 
activity as it was just three residues from histidine 83, an essential residue for 
lysostaphin activity (Warfield et al., 2006). This theory was tested by 
comparing the relative activities of LssEdom and its mutants LssEdomW80F 
and LssEdomW59/80F.  
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The recombinant proteins were found to cleave the MV11 biological 
substrate at the Gly5 sequence, as determined by in vitro activity assay and 
observed on SDS-PAGE (Figure 42).   
 
 
 
 
 
 
 
 
 
Titration of the MV11 FRET substrate with LssEdom, LssEdomW80F 
and LssEdomW59/80F resulted in a concentration dependent cleavage of the 
pentaglycine and quantitative emission of the fluorescence. Three assays were 
performed at each substrate concentration and the mean value of the reaction 
rates was determined for each set (Table 5).  
Table 5: Relative rates of cleavage for different concentration of MV11 for LssEdom, 
LssEdomW80F and LssEdomW59/80F.  
[MV11] (µM) Rate (RFU.s-1) 
LssEdom 
Rate (RFU.s-1) 
LssEdomW80F 
Rate (RFU.s-1) 
LssEdomW59/80F 
0.2 0.18 0.06 / 
0.4 0.55 0.28 0.11 
0.5 0.72 0.33 0.12 
1.0 1.24 / 0.16 
1.5 1.50 / 0.18 
2.0 1.54 0.55 / 
 
 
The rates obtained could be fitted to the Michaelis-Menten equation 
(cf. section 3.3.). The Grafit© data-fitting program was used to calculate KM 
Figure 42: LssEdom, LssEdomW80F , LssEdomW59/80F and Lss activity test on MV11
substrate observed on SDS-PAGE. Negative control showing MV11 partly cleaved by
zoocin A.  
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and Vmax. The Michaelis-Menten plot for LssEdom is shown in Figure 43, the 
plot for LssEdomW80F is shown Figure 44 and the plot for LssEdomW59/80F 
is shown Figure 45.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Grafit
©
 Michaelis-Menten plot for data collected with LssEdomW80F.  
 
LssEdom Value Std. Error 
Vmax (RFU.s-1) 2.9 0.6 
KM (µM) 1.6 0.6 
LssEdomW80F Value Std. Error 
Vmax (RFU.s-1) 0.8 0.2 
KM (µM) 0.9 0.5 
Figure 43: Grafit
©
 Michaelis-Menten plot for data collected using LssEdom. 
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Figure 45: Grafit
©
 Michaelis-Menten plot for data collected with LssEdomW59/80F.  
 
 
Grafit© estimated the values of Vmax to be 2.9 (± 0.6) RFU.s
-1 for 
LssEdom, 0.8 (± 0.2) RFU.s-1 for LssEdomW80F and 0.24 (± 0.01) RFU.s-1 
for LssEdomW59/80F. Estimated values for KM were 1.6 (± 0.6) µM, 0.9 (± 
0.5) µM and 0.51 (± 0.07) µM respectively for LssEdom, LssEdomW80F and 
LssEdomW59/80F. The values calculated for the Vmax and KM are only 
approximate as the usable substrate concentration range is not sufficiently 
wide enough to adequately cover the range required to obtain valid kinetic 
constants with small errors associated with them.  
These results indicated that the mutations performed on LssEdom were 
affecting the protein activity. Among the mutants, W80F has the highest 
activity, about 28% of that of the wild-type, and W59/80F has the lowest 
activity, about 8% of that of the wild-type. Fulfilment of the activity criterion 
by LssEdomW80F mutant was a strong indication that the specific native 
LssEdomW80F Value Std. Error 
Vmax (RFU.s-1) 0.24 0.01 
KM (mM) 0.51 0.07 
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conformation was formed and maintained. In order to determine if 
LssEdomW59/80F was an inactive mutant its structure had to be assessed. It 
was possible that the loss of activity was owing to an unfolding of the mutant’s 
structure, caused by the mutation of tryptophan into phenylalanine in position 
59 and 80.  
3.4.5. Circular Dichroism spectra 
As a first step in the assignment of the contribution of the tryptophan 
residues to the native CD spectrum, spectra in the far-UV region were 
recorded for LssEdomW80F and LssEdomW59/80F at 25ºC (Figure 46). The 
CD data have been corrected for concentration and are reported as the mean 
residue molar ellipticities.  
 
 
 
 
LssEdomW80F exhibited a similar spectrum to LssEdom, with a 
maximum near 224 nm. The spectrum of LssEdomW59/80F in the far-UV 
region has a comparatively low intensity, which is to be expected from a 
Figure 46: The far-UV CD spectra of LssEdom (blue), LssEdomW80F (pink) and 
LssEdomW59/80F (orange) recorded at 25ºC.  The protein concentration was 0.30 mg.ml-1. 
The buffer employed was 1 mM sodium phosphate, pH 7.0.   
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protein with a low Į-helical content (Kabsch and Sander, 1983). There is a 
negative band at 212 nm ([ș] = - 1803 deg.cm2.dmol-1) that is in accordance 
with ȕ-sheet structure (Manning and Woody, 1987). In addition, the intensities 
of the bands are most likely affected by both positive and negative 
contributions from other secondary structures, as well as contributions from 
aromatic residues. The intensity of the CD band below 210 nm was not 
informative. This and the contribution from aromatic residues to the CD 
spectra, even in the double mutant LssEdomW59/80F, hindered attempts to 
estimate the amounts of the various types of secondary structure elements in 
LssEdom.  
The complex band pattern observed in the far-UV CD spectra of the 
native proteins has changed in the corresponding spectra of denatured 
LssEdomW80F and LssEdomW59/80F recorded at 85ºC and 25ºC after 
denaturation (Figure 47). This indicates that the asymmetric environment 
around the various aromatic amino acid residues in the native state was 
disrupted upon unfolding, resulting in CD spectra typical for an unordered 
polypeptide chain.   
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All the tryptophan residues in LssEdom contribute to the CD spectrum 
over essentially the entire far-UV spectral range. The contribution of the 
deleted tryptophan residue can be obtained by subtracting the tryptophan 
mutant spectra from the wild type spectra. The results from such calculations 
are shown in Figure 48.  
 
 
 
 
 
 
 
 
Figure 47: The far-UV CD spectra of LssEdom (blue), LssEdomW80F (pink) and 
LssEdomW59/80F (orange) recorded at 85ºC.  The protein concentration was 0.30 mg.ml-1. 
The buffer employed was 1 mM sodium phosphate, pH 7.0.   
Figure 48: Contribution of individual Trp residues to the far-UV CD spectrum of 
LssEdom. These spectra were obtained as difference spectra: LssEdom minus
LssEdomW80F (W80, pink), LssEdom minus LssEdomW59/80F (W59 W80, orange) and 
LssEdomW80F minus LssEdomW59/80F (W59, blue).  
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The wavelength maximum of the CD spectra of the individual 
tryptophan residues W80 and W59 is 224nm. The accompanying ellipticities 
are respectively 2407, 1804 and 4211 deg.cm2.dmol-1 for W80, W59 and both 
W59/80. The magnitude of those bands indicates that both tryptophan 
contribute very largely to the far-UV CD spectrum of LssEdom. This means 
that tryptophan residues will interfere with predictions of the contents of 
various types of secondary structure based on algorithms using ellipticity data 
in the wavelength region 210-260 nm. Interestingly, tryptophan 59, which is 
exposed to the solvent, contributes least to the CD spectrum. For the 
phenylalanine-substituted mutants, putative contributions from the inserted 
phenylalanine residues are of course included in the corresponding tryptophan 
CD spectrum. 
3.5. Attenuated Total Reflection (ATR) 
spectrometry 
3.5.1. Lss versus LytM 
Fourier Transform infrared spectroscopy (FT-IR) experiments were 
carried out to investigate the secondary structure of LssEdom248-385. FT-IR was 
also performed on the control protein LytM186-314, which is 50% homologous 
in sequence to LssEdom248-385 (Figure 49). Indeed, the LytM186-314 structure 
has been solved (Firczuk et al., 2005) and thus could serve to determine the 
accuracy of the secondary structure element assignments for LssEdom248-385. 
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LytM          186 -------ASWLTSRKQLQPYGQYHG---GGAHYGVDYAMPENSPVYSLTDGTVVQAGWSN  
Lss           248 AATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWSN  
                         *.**.. *:   ** *     ** *****: *  .:** :::.*.:*:***** 
 
LytM          YGGGNQVTIKEANSNNYQWYMHNNRLTVSAGDKVKAGDQIAYSGSTGNSTAPHVHFQRMS  
Lss           YGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMV  
              ******: : * :. : ***** .: .*..** ****: *.:***** *****:*****  
 
LytM          GGIGNQYAVDPTSYLQSR 314 
Lss           NSFSNSTAQDPMPFLKSA 385 
              ..:.*. * ** .:*:*  
Figure 49: Sequence alignment of LytM and LssEdom using Clustal W.   
 
The proteins, LssEdom248-385 and LytM186-314, were analysed at 112 µM 
concentration in 1 mM sodium phosphate (pH 7.0) buffer. Infrared spectra of 
the amide I and II bands were obtained for both proteins. The spectral region 
that is most sensitive to the protein secondary structural components is the 
amide I band (1700-1600 cm-1), which is due almost entirely to the C=O 
stretch vibrations of the peptide linkages (approximately 80%). The amide II 
band, in contrast, derives mainly from in-plane N-H bending (40-60% of the 
potential energy) and from the C-N stretching vibration (18-40%) (Krimm and 
Bandekar, 1986), showing much less protein conformational sensitivity than 
its amide I counterpart. As with many other proteins, the amide I contour is a 
composite of overlapping component bands that represent different elements 
of the protein secondary structure. Some of these components are usually 
resolvable by the computational procedure of band narrowing by Fourier self-
deconvolution. The deconvolved spectra of LssEdom248-385 and LytM186-314 in 
solution are shown in Figure 50. 
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The spectra displayed the characteristics of a predominantly ȕ-sheet 
structured protein, with a maximum at 1638 cm-1 for LytM186-314 and 1642 cm-1 
for LssEdom248-385. For both spectra there is a distinctive peak at 1518 cm
-1, 
with a width of 8 cm-1, representative of the high level of tyrosine residues in 
both proteins (11 tyrosines in LytM186-314 and 10 tyrosines in LssEdom248-385). 
The peak for the histidine (1594 cm-1) is less evident as it is broader. The 
LytM186-314 and LssEdom248-385 spectra do not superimpose. The difference 
seen at 1600 cm-1 is not significant as this region of the spectrum is very 
variable between proteins. This could be due to the contribution of lateral 
chains. Nonetheless, the differences observed at 1620 and 1670 cm-1 are 
significant and are certainly related to differences in ȕ-sheets conformation.       
Figure 50: Infrared deconvolved spectra of LytM186-314 (blue) and LssEdom248-385 (red). 
The spectra are overlaid to show the similarities between them.   
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The presence of certain peptide secondary structure elements was 
determined based on the positions of the component bands. In order to 
quantify the approximate amount of each protein secondary structure, a curve 
fitting of deconvolved amide I band contour was performed with Gaussian 
function. The assignments of the main infrared absorption bands are given in 
Table 6, where the percentage of the area of a component band assigned to a 
certain conformation in the total area of all bands was considered to reflect the 
approximate amount of each structure.  
Table 6: Infrared absorption band positions (in wavenumbers, cm
-1
) determined with the 
aid of a Fourier self deconvolution procedure for amide I for LssEdom248-385 and LytM186-
314.  Assignments are given based on the literature data (Byler and Susi, 1986, Goormaghtigh 
et al., 1994). Italic numbers in brackets show tentative percentage of each structure obtained 
from curve fitting.  
Protein Turns ȕ-sheets Unordered 
LssEdom248-385 1668 (29) 
1689 (3) 
1629 (47) 1642 (21) 
LytM186-314 1662 (51) 
1689 (4) 
1616 (3)  
1634 (42) 
 
 
According to the Protein Database (PDB) the structure of LytM186-314 
(PDB code 2B44, 2B0P, 2B13) contains 13% helical feature (3 helices, 17 
residues) and 42% of ȕ-sheet (12 strands, 55 residues). As shown by the 
fitting, the FT-IR spectra have curves at 1616 and 1634 cm-1, representative of 
ȕ-sheet backbone conformation, and curves at 1662 and 1689 cm-1, which can 
be assigned to ordered features like turns (Byler and Susi, 1986, Goormaghtigh 
et al., 1994). The proportion of ȕ-sheet (45%) is in agreement with the X-ray 
structural data. The same fitting process was applied to LssEdom248-385 spectra 
using Gauss curves. The curve at 1629 cm-1 is representative of ȕ-sheet 
backbone conformation, those at 1668 and 1689 cm-1, are representative of 
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ordered features such as turns. As shown on this fitting, there is a band at 1642 
cm-1 that contributes for 21% and may originate from unordered features.  
We can observe a net difference between the spectra of LytM186-314 and 
LssEdom248-385. There is a change in the conformation backbone, which, 
according to the fitting, is due to a weakening of the ȕ-sheet structure in 
LssEdom248-385. Its contribution could be explained by the presence of a 
flexible tail at the extremity of the activity domain (LssEdom) that is not 
present in the fragment of LytM studied. 
3.5.2. Is LssEdomW59/80F an inactive mutant? 
LssEdomW80F and LssEdomW59/80F are mutants of the lysostaphin 
endopeptidase domain. LssEdomW59/80F activity was dramatically reduced 
compared to LssEdom, as shown in the different activity test run on MV11 (cf. 
section 3.4.4.). LssEdomW80F and LssEdomW59/80F conformations were 
investigated employing infrared. The native conformation of LssEdom served 
as a control to measure any change in conformation in the mutants 
LssEdomW80F and LssEdomW59/80F. The proteins were analysed at 112 µM 
concentration in 1 mM sodium phosphate (pH 7.0) buffer. Infrared 
deconvolved spectra of the amide I and II bands for the three proteins are 
displayed in Figure 51. 
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A visual comparison of the infrared spectra of LssEdomWT, 
LssEdomW80F, LssEdomW59/80F indicates the absence of major changes in 
the protein secondary structure upon mutation of tryptophan into 
phenylalanine. All traces represent a single amide I band with a maximum at 
1642 cm-1. A significant absorbance can also be observed at 1518 cm-1. It is 
indicative of the presence of 10 tyrosines in all the protein sequences.  
The difference observed at 1670 cm-1 is representative of a weakening 
in the ȕ-sheets conformation. Also, this could imply LssEDW59/80F is not an 
inactive mutant as its structure is slightly different from the WT, showing 
signs of denaturation. 
The amide I region was used for peptide structure determination. The 
assignments of the main infrared absorption bands are given in Table 7. 
Figure 51: Infrared deconvolved spectra of LssEdomWT (green), LssEdomW80F (blue) 
and LssEdomW59/80F (orange). The spectra are overlaid for comparison.   
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Table 7: Infrared absorption band positions (in wavenumbers, cm
-1
) determined with the 
aid of Fourier self deconvolution procedure for amide I for LssEdomWT, LssEdomW80F 
and LssEdomW59/80F. Assignments are given based on the literature data (Byler and Susi, 
1986, Goormaghtigh et al., 1994). Italic numbers in brackets show the tentative percentage of 
each structure obtained from curve fitting.  
Protein Turns ȕ-sheets Unordered 
LssEdomWT 1668 (29) 
1689 (3) 
1629 (47) 1642 (21) 
LssEdomW80F 1670 (18) 
1688 (8) 
1616 (7) 1641 (67) 
LssEdomW59/80F 1670 (24) 
1688 (4) 
1616 (7)  
 
1641 (65) 
 
 
The same fitting process was applied to LssEdomWT, LssEdomW80F 
and LssEdomW59/80F spectra using Gauss curves. The comparison of the 
band positions for the three traces show a shift from 1629 cm-1 for the wild 
type protein to 1616 cm-1 for the mutants. This could reflect an aggregated 
state with intermolecular ȕ-sheets (Surewicz et al., 1990). In addition, the 
dominance of the 1641 cm-1 band in LssEdomW80F and LssEdomW59/80F 
spectra points to a relatively high proportion of poorly defined structure. This 
is in clear contrast to the LssEdomWT which gives rise to a weaker component 
band in the spectral region characteristic of an unordered structure. 
Although it can be contested, the fitting show more unordered features 
for the mutants compared to the wild-type, which leads to the conclusion that 
the reduction of activity might be due to a fraction of the proteins in solution 
that are aggregated after mutation. Consequently, it can be argued that 
LssEdomW59/80F is an inactive mutant as the mutations performed on 
LssEdom might have led to destabilisation of the structure.   
3.5.3. Is LssEdom suited for crystallisation studies? 
Fourier Transform infrared spectroscopy (FT-IR) experiments were 
carried out to investigate the conformation of LssTdom, LssEdom and full 
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length Lss to determine which candidate was best for crystallisation studies. 
For each protein spectrum (112 µM for LssEdom, 30 µM for Lss and 
LssTdom) 100 accumulations repeated 10 times were collected at room 
temperature with a resolution of 2 cm-1. Infrared deconvolved spectra of the 
amide I and II bands for the three proteins are displayed in Figure 52. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Lss, LssEdom and LssTdom spectra do not superimpose. The 
difference seen at 1600 cm-1 is not significant as this region is very variable. 
This could be due to the contribution of lateral chains. However, the 
differences observed at 1620 and 1670 cm-1 are significant and are certainly 
related to differences in ȕ-sheet conformation.       
Figure 52: Infrared deconvolved spectra of Lss (pink), LssEdom (red) and LssTdom 
(blue). The spectra are overlaid for comparison. 
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The amide I region was used for peptide structure determination. The 
assignments of the main infrared absorption bands are given in Table 8. 
 
Table 8: Infrared absorption band positions (in wavenumbers, cm
-1
) determined with the 
aid of Fourier self deconvolution procedure for amide I for Lss, LssEdom, LssTdom. 
Assignments are given based on the literature data (Byler and Susi, 1986, Goormaghtigh et al., 
1994). Italic numbers in brackets show tentative percentage of each structure obtained from 
curve fitting.  
Protein Turns ȕ-sheets Unordered 
Lss 1662 (56) 
1689 (4) 
1630 (35) 1641 (5) 
LssEdom 1668 (29) 
1689 (3) 
1629 (47) 1642 (21) 
LssTdom 1662 (39) 
1687 (2) 
1620 (2)  
1627 (49) 
1635 (8) 
 
 
 
The same fitting process was applied to Lss, LssEdom and LssTdom 
spectra using Gauss curves. For Lss spectra, the curve at 1630 cm-1 is 
representative of ȕ-sheet backbone conformation, those at 1662 and 1689 cm-1, 
are representative of ordered features such as turns. As shown on this fitting, 
there is a contribution of 5% of unordered features, which could be explained 
by the presence of the linker in between the endopeptidase domain (LssEdom) 
and the targeting domain (LssTdom) in full length Lss. For LssEdom spectra, 
the curve at 1629 cm-1 is representative of ȕ-sheet backbone conformation, 
those at 1667 and 1688 cm-1, are again representative of ordered features such 
as turns. As shown on this fitting, there is a contribution of 21% of unordered 
features. Its contribution could be explained by the presence of a flexible tail at 
the extremity of LssEdom. The fitting of LssTdom spectra showed curves at 
1620, 1627 and 1635 cm-1, representative of ȕ-sheet backbone conformation, 
and curves at 1661 and 1686 cm-1, representative of ordered features such as 
turns. ALE-1 and LssTdom are 80% homologous, as shown by the alignment 
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in Figure 53. The structure of ALE-1260-361 deposited at the Protein Database 
(PDB code 1R77) contains 5% helical feature (1 helice, 5 residues out of 101) 
and 50% of ȕ-sheet (8 strands, 50 residues out of 101). The proportions are in 
agreement with the X-ray structural data. 
 
 
ALE-1     260 DYKTNKYGTLYKSESASFTANTDIITRLTGPFRSMPQSGVLRKGLTIKYDEVMKQDGHVW 
LssTdom   401 GWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVW    
               :*****************.******* *************: * **:************ 
 
ALE-1         VGYNTNSGKRVYLPVRTWNESTGELGPLWGTIK 361 
LssTdom       VGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK 493 
              ***. ***:*:********:**. ** ****** 
Figure 53: Sequence alignment of ALE-1 and LssTdom using Clustal W.   
 
 
Curve fitting analysis shows limitations for the quantitative assessment 
of the “absolute” content of protein secondary structure. However it provides a 
sensitive tool for monitoring, in relative terms, the nature of changes in the 
conformation of protein backbone (Surewicz et al., 1993). It seems, according 
to the fitting, that the conformation of full length Lss is more ordered than that 
of the LssEdom. This could be due to cooperation in between the two domains, 
LssEdom and LssTdom, maintaining a certain conformation for substrate 
docking.  
It can be argued that the difference in shape of the spectra for LssTdom 
is due to the difference in concentration of the proteins used. Nevertheless, 
LssTdom fitting is in good agreement with ALE-1 X-ray structure and the 
prediction of backbone structure show an ordered protein.  
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3.6. Conclusions 
Circular dichroism (CD) spectroscopy was used empirically to estimate 
the amounts of various types of secondary structure in the LssEdom, in order 
to evaluate the suitability of this protein for crystallisation studies. However, 
the CD spectra of ȕ-proteins having little or no Į-helix is reported to vary 
widely (Manning and Woody, 1987). Despite both the wealth of information 
available on protein structures and the increasing use of CD, the contribution 
of aromatic side chains to the CD spectrum has not yet been fully resolved. 
The sign, the magnitude and the wavelength are aspects of the aromatic CD 
bands that are poorly understood. This complicated estimations on the amounts 
of various types of secondary structure in the LssEdom.  
Therefore, an empirical approach to allow estimations of the effects of 
tryptophan side chains on the far-UV CD spectrum of LssEdom was to use 
site-directed mutagenesis and replace the tryptophan residues by 
phenylalanine. The first crucial step toward this goal was to construct 
tryptophan mutants of LssEdom. It was important to assess the stability and 
enzymatic activity of these mutants to ensure that the native conformation of 
the three-dimensional structure had not been changed. Results showed that 
contributions from tryptophan residues were an important source of variations 
in the far-UV region. It was demonstrated that there is a considerable 
interference of CD bands from the tryptophan residues in the far-UV region 
spectrum of LssEdom making it difficult to assign changes in ellipticity to 
changes in secondary structure content.  
  Fourier transform infrared (FT-IR) spectroscopy was a good 
alternative to circular dichroism (CD) spectroscopy for the detection of 
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conformational changes in related proteins. The IR spectral data of proteins are 
interpreted in terms of the vibrations of a structural repeat unit and are highly 
sensitive. The computerised FT-IR instrumentation improved the signal-to-
noise ratio and allowed data manipulation. The band-narrowing method, 
Fourier self-deconvolution, has not only enriched the qualitative interpretation 
of the infra-red spectra, but also provided a basis for the quantitative 
estimation of protein secondary structure (Kauppinen et al., 1981). 
Despite a well-recognised conformational sensitivity of protein infrared 
bands, the analysis of the spectra in terms of protein secondary structure was 
not straightforward. Particularly controversial was the “quantitative” aspect of 
the infrared method. The FT-IR studies of peptides and proteins have made 
efforts in identifying characteristic frequencies and determining their relations 
to the structures of protein molecules. Nonetheless, FT-IR spectra are 
complicated in that different ambient circumstances, including side-chain 
absorbance, make it difficult to precisely assign the secondary structure and 
frequency. The estimation of secondary structure elements in Lss (and 
truncated forms) with the FT-IR method should be considered only as a good 
approximation (Venyaminov and Kalnin, 1990).   
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4. Lysostaphin tertiary structure prediction 
4.1. Tertiary structure 
Proteins are complex organic compounds that consist of amino acids 
joined by peptide bonds. The composition of amino acids in a protein defines 
the three dimensional form that the protein folds to. These structures are 
unique in the sense that a given sequence of amino acids always folds into 
almost the same structure under the same environmental conditions (pressure, 
temperature, pH, etc.). The tertiary structure is the native state, or folded form, 
of a single protein chain. This form is also called the functional form. The 
tertiary structure of a protein includes the coordinates of its residues in three 
dimensional space.  
There are a number of methods with varying resolution to determine 
the structure of proteins. X-ray crystallography and NMR are the most 
commonly used methods to determine protein structure (Branden and Tooze, 
1998). There are also less frequently used techniques like electron microscopy 
(Rhodes, 2006). These methods require time and effort to obtain good 
resolution. There are certain drawbacks for each method. For example, during 
X-ray crystallography, the protein is crystallised, and on rare occasions this 
distorts portions of a structure (Rhodes, 2006). Additionally, different 
laboratories using different methods may publish different structures for the 
same protein.    
Despite their drawbacks there is still no acceptable alternative to the 
laboratory based methods. The next best methods for protein structure 
determination are theory based methods such as homology modelling. This 
method is referred to as a structure prediction method. It can briefly be 
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described as fitting a known sequence to the experimentally determined three 
dimensional structure of a protein that is similar in sequence (Rhodes, 2006).   
4.2. Further purification steps for X-ray 
crystallography and NMR purposes 
In order to obtain a pure sample of LssEdom protein, at high 
concentration and without His-tag (sometimes known to prevent 
crystallisation), pSGAT2-based plasmids were constructed. The LssEdom 
sequence was sub-cloned in a pSGAT2 vector downstream of sequences 
encoding for a His-tag and a thrombin cleavage site. Likewise, Lss sequence 
was sub-cloned in pSGAT2 vector. 
4.2.1. Sub-cloning in pSGAT2 
Lss and LssEdom sequences sub-cloning in the pSGAT2 vector was 
achieved using a PCR method. pET21a(+)-Lss248-493 (pEA3) was used as a 
template along with LssForw (forward) and LssRev (reverse) primers to 
amplify the Lss sequence, and with LssForw (forward) and LssEdomRev 
(reverse) primers to amplify the LssEdom sequence. The products of 
amplification, named Lss (762bp) and LssEdom (438bp) PCR products are 
shown in Figure 54.  
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Restrictions of pSGAT2 with BamHI and HindIII resulted in the 
excision of a 1.1 kb insert observed by agarose gel electrophoresis, shown in 
Figure 55. Lss and LssEdom PCR products digested with BamHI and HindIII 
were purified and cloned into pSGAT2 and used to transform DH5Į cells.  The 
clones were confirmed by PCR on recombinant plasmid (pSGAT2-Lss and 
pSGAT2-LssEdom) and by DNA sequencing, using T7PP (forward) and T7TP 
(reverse) primers. DNA sequencing data were compared to Lss and LssEdom 
sequences with the ClustalW program. The results confirmed the presence of 
Lss and LssEdom inserts in BamHI-HindIII fragment.  
 
 
 
 
 
 
 
Figure 54: PCR amplification of Lss and LssEdom DNA template from pET21a(+)-
Lss248-493 (pEA3). L: Ladder, 1: Lss PCR product (762 bp), 2: LssEdom PCR product (438 
bp). NC: Negative Control . NC1: presence of LssForw and LssRev primers, absence of 
template, NC2: presence of LssForw and LssEdomRev primers, absence of template, NC3: 
presence of pEA3 template, absence of primers. 
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Subsequent to pSGAT2-Lss and pSGAT2-LssEdom constructions, two 
modifications of the DNA sequences were made. First, the codon 
corresponding to the third glycine of the pentaglycine sequence, which is 
downstream of the starting codon in pSGAT2, was mutated by PCR to code 
for a serine residue, in order to obtain a translated sequence that could not be 
cleaved by the lysostaphin activity domain. Secondly, a stop codon was 
inserted at the end of LssEdom DNA sequence.  
For the first round of PCR, site-directed mutants were constructed from 
pSGAT2-Lss and pSGAT2-LssEdom vectors by PCR, using the 
sense/antisense primer pair: T7PP (forward)/Gly3mutpSGAT2 (reverse) 
primers. The purified PCR-amplified DNA fragment was digested with BamHI 
and XbaI, gel-purified, and sub-cloned into pSGAT2-Lss and pSGAT2-
LssEdom plasmids digested with the appropriate restriction endonucleases. For 
the second round of PCR, a site-directed mutant was constructed from 
pSGAT2-LssEdom vector by PCR, using the sense/antisense primer pair: 
pSGAT2edomFOR (forward)/pSGAT2edomREV (reverse). The purified 
Figure 55: Restriction of pSGAT2, Lss and LssEdom PCR products with BamHI and 
HindIII. 1: Supercoiled pSGAT2, 2: Digested pSGAT2 (4429 bp), 3: Digested Lss PCR 
product (748 bp), 4: Digested LssEdom PCR product (427 bp). 
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PCR-amplified DNA fragment was digested with BamHI and HindIII, gel-
purified, and sub-cloned into pSGAT2-LssEdom plasmid backbone digested 
with the appropriate restriction endonucleases. A stop codon was inserted at 
the end of LssEdom DNA sequence using the sense/antisense primer pair: 
pSGAT2EdomFor (forward)/pSGAT2EdomRev (reverse). The PCR product 
was digested with BamHI and HindIII and sub-cloned into pSGAT2-LssEdom 
plasmids. In each case, the fidelity of the PCR-amplified DNA fragments was 
established by nucleotide sequencing after sub-cloning into the expression 
vector (Figure 56). 
Translation of pSGAT2-Ser3-LssEdom sequencing data compared with LssEdom 
sequence 
 
E1T7PP       EGDISMNTIHHHHHHNTSGSGGSGGRLVPRGSAATHEHSAQWLNNYKKGYGYGPYPLGIN 60 
Edom         -------------------------------MAATHEHSAQWLNNYKKGYGYGPYPLGIN 29 
                                             **************************** 
 
E1T7PP      GGMHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNV 120 
Edom        GGMHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNV 89 
            ************************************************************ 
 
E1T7PP      KVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSA 179 
Edom        KVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSA 138 
            **************************************************  
 
Translation of pSGAT2-Ser3-Lss sequencing data compared with Lss sequence 
 
L1T7PP       EGDISMNTIHHHHHHNTSGSGGSGGRLVPRGSAATHEHSAQWLNNYKKGYGYGPYPLGIN 60 
Lss          -------------------------------MAATHEHSAQWLNNYKKGYGYGPYPLGIN 29 
                                             **************************** 
 
L1T7PP       GGMHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNV120 
Lss          GGMHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSKYNV 89 
             ************************************************************ 
 
L1T7PP       KVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGGTVT180 
Lss          KVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLKSAGYGKAGGTVT149 
             ************************************************************ 
 
L1T7PP       PTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQ240 
Lss          PTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQ209 
             ************************************************************ 
 
L1T7PP       DGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK 277 
Lss          DGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK 246 
             ************************************** 
 
Figure 56: ClustalW homology analysis showing sequence alignment of E1T7PP and 
L1T7PP sequences, identified by nucleotide sequencing, and LssEdom or Lss sequence 
respectively. Stars indicate a perfect match in between the theoretical sequence and the 
sequencing data.    
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To summarise, for this study two vectors were built: pSGAT2-Ser-Lss 
and pSGAT2-Ser-LssEdom. The difference between those plasmids occurs in 
the nucleotide sequence they carry: Lss and LssEdom, respectively. The 
expression of Lss and LssEdom is under the control of the T7 promoter 
inducible by IPTG. After expression, the His-tag sequence is fused to the N-
terminal region of the protein and can be removed by thrombin cleavage. For 
future studies, a pSGAT2GlyĺSer vector with a substitution of a glycine in a 
serine residue in position 3 of the pentaglycine sequence was also built. 
4.2.2. His-tag removal 
The recombinant plasmids: pSGAT2-Ser-Lss or pSGAT2-Ser-
LssEdom, were  transformed into the host, E.coli BL21 (DE3), and addition of 
isopropyl E-thiogalactoside (IPTG) induced the overexpression of a band of 
approximately 30 and 18 kDa molecular weight, corresponding respectively to 
H6-Lss and H6-LssEdom fusion proteins, when compared to the uninduced 
control in SDS-PAGE.  The proteins were overexpressed in soluble form in the 
cytoplasm.  
The H6-Lss and H6-LssEdom were purified to near homogeneity, 
observed on SDS-PAGE, using a single affinity chromatographic step on zinc 
agarose. In order to obtain a pure sample of LssEdom, without His-tag, known 
to help obtain highly ordered crystals, the His-tag was removed by enzymatic 
cleavage and separated by chromatography. Thrombin recognised the 
consensus sequence Leu-Val-Pro-Arg-Gly-Ser and cleaved the peptide bond 
between arginine and glycine. Such a protease cleavage site allowed removal 
of an upstream domain “His-Tag”. Kinetic experiments were run with different 
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concentrations of thrombin (1U, 3U, 5U of thrombin per mg of protein), for 
different incubation times (1h, 4h, 16h) and at different temperatures (19ºC, 
4ºC). As shown by SDS-PAGE (Figure 57), cleavage was completed following 
a 16 h treatment, at 19ºC, with 3 units per mg of protein, in iexA buffer (10 
mM Tris pH 7.0, 50 mM NaCl, 5% (v/v) glycerol).    
 
4.2.3. Further purification of LssEdom 
Thrombin removal was performed by ion-exchange chromatography. 
The selected program permitted the specific adsorption of LssEdom on a 
cation-exchange column under low salt concentration conditions and the 
elution of LssEdom under high salt concentration conditions. Thrombin, 
negatively charged under the pH condition selected, was not retained on the 
column. Samples collected during the elution step were loaded on a SDS-
PAGE (Figure 58). 
Figure 57: Thrombin His-tag cleavage optimisation. 1: Edom + 1U thrombin, 3: Edom + 
3U thrombin, 5: Edom + 5U thrombin. 
Figure 58: LssEdom purification by ion-exchange chromatography: chromatogram 
and SDS-PAGE showing the fractions containing LssEdom (1-5). 
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To prove that thrombin was removed from solution by the ion-
exchange chromatography described above, a test was done on the unstable 
LssEdom expressed from pSGAT2-Ser-LssEdom vector without a stop codon 
at the end of the DNA sequence. H6-LssEdom  was dialysed in buffer A (20 
mM sodium phosphate (pH 7.4), 5 mM imidazole, 0.5 M sodium chloride, 5% 
(v/v) glycerol), then 5U of thrombin per mg of protein were added. Ion-
exchange chromatography was run directly and the supernatant left for 3 days 
at 19ºC. The negative control, where H6-LssEdom in bufferA was not exposed 
to thrombin, did not show any degradation after 3 days at 19ºC. On the 
contrary, for the positive control, in which was added 5U of thrombin per mg 
of protein after chromatography in accordance with the test, H6-LssEdom was 
completely degraded after 3 days at 19ºC. Proteins were loaded on SDS-PAGE 
as shown Figure 59. 
 
 
 
 
 
 
 
 
 
 
Figure 59: Verification of thrombin removal by ion-exchange chromatography by 
cleavage assay on unstable LssEdom expressed from pSGAT2-Ser-LssEdom vector 
without a stop codon at the end of the DNA sequence. 1: Thrombin cleavage prior ion-
exchange chromatography, 2: Negative control, 3: Positive control. 
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The H6-LssEdom and removed His–tag were physically separated from 
LssEdom using a single affinity chromatographic step on zinc agarose. 
LssEdom was homogeneous as observed on SDS-PAGE, shown in Figure 60.   
 
LssEdom was further purified by gel filtration chromatography as 
detailed in Materials and Methods (cf. section 2.2.1.). Protein concentration 
was determined by UV spectroscopy as detailed in Materials and Methods (cf. 
section 2.2.5.). The protein solution was concentrated to obtain suitable 
crystals for X-ray diffraction. For this purpose a vertical filter tube was used 
and the protein concentration was determined after ultra filtration. The results 
showed that the maximal solubility of the lysostaphin endopeptidase domain, 
when expressed in 2YT medium, was reached and the concentration value 
remained as: CLssEdom = 220 PM.  
 
 
 
 
Figure 60: LssEdom purification by zinc-affinity chromatography. 1: LssEdom without 
His-tag eluted with the flowthrough on zinc-NTA agarose, 2: H6-LssEdom retained on zinc-
NTA agarose. 
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4.3. Stability studies 
4.3.1. Differential scanning calorimetry (DSC) 
We considered using differential scanning calorimetry (DSC) to define 
the thermal stability of untagged LssEdom. The DSC thermal denaturation 
profile of untagged LssEdom, purified on zinc, in 10 mM HEPES pH 7.0 and 
150 mM NaCl (Figure 61) displayed a single peak centered at 62.8ºC (12.7 
PM LssEdom, v = 20ºC.h-1) and denaturation proceeded with an enthalpy 
range, ǻH, of 21.8 ± 0.3 kcal.mol-1. Therefore, LssEdom is stable at room 
temperature, at which structural studies were run.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61: Exprimental heat capacity profile of untagged LssEdom.  
The trace shows the thermal denaturation of LssEdom (12.7 µM) dialysed in 10 mM HEPES
pH 7.0, 150 mM NaCl, at a scan rate of 20ºC.h-1. 
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4.3.2. Circular Dichroism (CD) 
Circular dichroism (CD) is commonly used in denaturation 
experiments in which the CD signal of a protein is monitored while the protein 
is perturbed in some fashion (e.g., increasing temperature or chemical 
denaturant). Changes in CD signal reflect changes in the protein structure. 
Information about protein stability or folding intermediates can be obtained 
(Woody, 1996). We employed the circular dichroism (CD) technique to define 
the thermal stability of LssEdom-H6. Shown in Figure 62 are the spectra of 
LssEdom-H6 subjected to a scale up (UP) and scale down (DN) of 
temperature. Spectra were recorded at 224 nm using 26 µM LssEdom in 1 mM 
sodium phosphate buffer, pH 7.0. These studies indicated that LssEdom-H6 
denaturation occurred above 60ºC, as shown by previous DSC experiments run 
with untagged LssEdom, and that LssEdom does not refold spontaneously. 
 
 
 
Figure 62: LssEdom-H6 CD denaturation experiment monitored while increasing the
temperature (scale UP) or deacreasing the temperature (scale down DN).  Thermal 
denaturation recorded at 224 nm. The protein concentration was 0.30 mg.ml-1. The buffer 
employed was 1 mM sodium phosphate, pH 7.0.   
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Those informations are corroborated by Zygmunt and Tavormina 
(1972) that demonstrated inactivation of lysostaphin by heating at 75ºC for 15 
minutes.   
4.4. LssEdom crystallisation 
4.4.1. Crystal screening 
In initial high throughput crystallisation trials, 2016 different 
conditions were tested on freshly purified untagged LssEdom. About ten 
small, individual diamond shaped crystals could be observed with the 
condition described in Figure 63, which was considered as the “Hit condition”. 
This condition came from the NextalBiotechTM AmSO4
TM screen and was 
made of 0.1 M MES sodium salt pH 6.5, 2.0 M ammonium sulphate and 5% 
(w/v) PEG 400. No significant crystalline material could be observed with any 
other condition.  
 
 
 
 
 
 
Screens were performed manually around the “Hit condition” of the 
high throughput screens, using the sitting-drop vapour-diffusion technique. 
The effect of various concentrations of ammonium sulphate and PEG on the 
protein crystallisation, were tested. A control was made with student-prepared 
Figure 63: Diamond shape crystals of LssEdom in H3.3 NextalBiotech
TM 
AmSO4
TM 
screen.  LssEdom dialysed in 10 mM Tris pH 7.0 and 150 mM sodium chloride buffer (1 µl
in the drop): 66 µM. Reservoir solution (1 µl in the drop, 60 µl in the reservoir): 0.1 M MES
sodium salt pH 6.5, 2.0 M ammonium sulphate and 5% (w/v) PEG 400. 
 121
solutions and with commercial solutions. No crystals were observed for the 
different conditions.  
The experiments made previously with tagged LssEdom-H6 indicated 
that salts (ammonium sulphate, magnesium sulphate and sodium acetate) 
helped the protein to crystallise. As a consequence, in addition to 0.1 M MES 
sodium salt pH 6.5, 2.0 M ammonium sulphate and 5% (w/v) PEG 400, 100 
mM and 200 mM sodium chloride was also added. However, no significant 
crystalline material was observed. 
Therefore, screens were performed with the streak seeding technique. 
This technique is utilised for epitaxial jumps to obtain crystals under 
conditions which may be significantly different from those in which the 
original seed was obtained. A whisker cat was used to gently touch a rod and 
dislodge seeds. The seeds were transferred to a new protein-precipitant drop 
composed as the seed source drop: 1.70 M ammonium sulphate, 3% PEG 400, 
0.1 M MES sodium salt pH 6.5.  The only difference consisted in the 
concentration of protein used:  219, 100 and 37 M. As no significant 
crystalline material was observed, another streak-seeding experiment was 
performed with the solution that contained residual crystals after cryo-
mounting operation. The seeds were placed into pre-equilibrated drops that 
were prepared with commercial solutions and 54 µM of untagged LssEdom 
(ratio 4µl:4µl). Only phase separation of the solution and precipitation of the 
protein were observed.  
4.4.2. X-ray diffraction 
Data collection was carried out at the EMBC Grenoble outstation. One 
crystal mounted on a 0.05 mm loop was found. With the highest magnification 
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a very weak and disordered diffraction was observed, limited to 3.0-3.2 Å. No 
work was carried on with these data.  
4.5. Nuclear Magnetic Resonance (NMR) of 
LssEdom in solution 
Considering the difficulties encountered in crystallising LssEdom, 
another strategy to obtain its structure was investigated. Nuclear magnetic 
resonance (NMR) spectroscopy was explored as a replacement for X-ray 
crystallography, for the determination of protein structure in solution. To be 
suitable for NMR spectroscopy, the protein must be small (below 16 kDa), 
highly pure, stable at room temperature and very soluble. In preliminary 
studies, differential scanning calorimetry (DSC) and circular dichroism (CD) 
techniques were used to determine LssEdom stability at room temperature. 
Thus, optimisation of LssEdom expression in a minimal medium, purification 
and solubility were required prior to NMR spectroscopy studies.  
4.5.1. Effects of temperature and additives on LssEdom 
expression level 
To perform NMR spectroscopy studies, proteins must be expressed in a 
minimal medium (MM) to be able to 15N and 13C label them. The level of 
expression of LssEdom is very much dependent on the medium used. As 
shown Figure 64, LssEdom expressed in MM at 30°C gave mostly insoluble 
proteins.  
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ZnCl2 was also added to MM at a final concentration of 1 mM, which 
is lower than the concentration that inhibits lysostaphin activity (Szweda et al., 
2005). LssEdom contains a Zn2+ ion in its activity site and it was believed that 
addition of zinc cation in solution would help the protein to fold, and thus, go 
into the soluble fraction. No changes were observed in protein solubility. Thus, 
the effects of salt and temperature were tested on the expression of LssEdom 
in the soluble fraction. By increasing the amount of salt in MM to 5 g.l-1 and 
10 g.l-1, and decreasing the temperature to 27ûC and 20ûC, we observed that 
the expression of LssEdom in the soluble fraction was largely improved as 
shown in Figure 65.  
 
 
 
 
 
Figure 64:  LssEdom expression in MM at 30ûC. 
Out of all protein expressed in MM (1,2), LssEdom is mostly detected  in the 
insoluble fraction (5,6) rather than in the soluble one (3,4). 
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In consequence, for the next experiments, LssEdom was expressed in 
MM containing 0.5 g.l-1 NaCl as no significant changes were observed when 
adding higher amounts of salt, and was incubated at 20°C rather than 30°C, as 
this had been shown to improve folding of the protein.  
4.5.2. Effects of buffers, pH and additives on LssEdom 
solubility 
To perform NMR spectroscopy studies, proteins must be dialysed in a 
solution containing no element that could give a distinct signal. A good choice 
of buffer is reported to be sodium phosphate buffer and the amount of NaCl 
should be kept relatively low.  
At first, LssEdom expressed in MM containing 0.5 g.l-1 NaCl and 
incubated at 20°C, was purified by affinity chromatography on zinc agarose 
and dialysed in a buffer containing 10 mM sodium phosphate, pH 7.4 and 150 
mM NaCl. The highest concentration of LssEdom obtained was 55 µM which 
was too low for NMR studies. Thus, different dialysis buffers were tested, 
Figure 65: LssEdom expression in MM at 20ºC with added in solution different amounts 
of salt (0.5, 5, 10 g.l
-1
).  Under those conditions, LssEdom is mostly detected in the soluble
fraction (S) rather than in the insoluble one (P).  
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HEPES and MES, at the same concentration and with the same amount of salt 
in solution. No improvement was observed. Therefore, additives were tested to 
improve protein solubility. According to Golovanov and coworkers, 
simultaneous addition of charged amino acids, L-arginine (L-Arg) and L-
glutamic acid (L-Glu) at 50 mM to the buffer could dramatically increase 
maximum achievable concentration of soluble protein (Golovanov et al., 
2004). LssEdom that had been expressed and purified was dialysed in a buffer 
containing 10 mM sodium phosphate, pH 7.4, 100 mM NaCl, 50 mM L-Arg 
and 50 mM L-Glu.  A slight improvement in protein concentration was 
measured: 75 µM, compared to the initial 55 µM , which was far from the 8.7 
times increase reported in the literature. Also, different pHs were tested to test 
their effect on protein solubility. Sodium phosphate buffer at pH 6.5 and pH 
8.5 with 100 mM NaCl, 50 mM L-Arg and 50 mM L-Glu presented no 
differences. Addition in the dialysis buffer of an uncleavable LssEdom 
substrate (Gly3 is believed to be the product of pentaglycine cleavage by 
lysostaphin) at a ratio 1:1, enzyme:substrate, did not help the protein to fold 
and go into solution. Finally, transfer of transformed bacteria from LB medium 
for growth culture at 30°C to MM for LssEdom expression at 20°C (to 
enhance chaperone production and help folding of the protein) did not help to 
obtain a better concentration of the protein after purification and dialysis in 10 
mM sodium phosphate, pH 7.4, 100 mM NaCl, 50 mM L-Arg and 50 mM L-
Glu.  
Therefore, the maximal concentration obtained for LssEdom expressed 
in minimum medium at 20°C, purified to near homogeneity as described for 
crystallisation studies (cf. section 4.2.3.) and dialysed in a buffer containing 10 
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mM sodium phosphate, pH 7.4, 100 mM NaCl, 50 mM L-Arg and 50 mM L-
Glu, was 75 µM. It is well below the 1mM working concentration used in 
NMR spectroscopy studies on a Brüker AV-600 spectrometer operating at 600 
MHz.  
It was suggested that a chaperone was missing in the minimum 
medium used for protein expression as higher concentration of protein (220 
µM) could be obtained when the protein was expressed in rich 2YT medium. 
The pro-region of lysostaphin was reported by Baba and Schneewind to 
potentially function as an intramolecular chaperone for folding (Baba and 
Schneewind, 1996), as was also reported for refolding of subtilisin by Zhu and 
coworkers (Zhu et al., 1989).     
4.5.3. Heteronuclear Single Quantum Coherence 
(HSQC) 
The NMR preliminary studies, carried out in collaboration with Dr J. 
Long (Centre for Biomolecular Sciences, University of Nottingham, 
Nottingham) showed a lower molecular weight impurity, and so, LssEdom 
was further purified by size-exclusion chromatography. To determine the 
nature of the impurity, mass spectrometry (MS) studies were achieved in 
collaboration with G. Coxhill (Chemistry, University of Nottingham, 
Nottingham) on LssEdom samples before and after purification by size-
exclusion chromatography. Examination by MS (ESI positive ion) on the 
MicroToF did show some peaks additional to the multiply charged ions of the 
protein, in particular a relatively intense singly charged ion at m/z=719 (cf. 
Appendix 2). On the contrary, in the spectra produced on the Apex FTMS 
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the intensity of the ion at m/z=719 is dependent on the voltage difference 
between the Capillary Exit and the Skimmer 1. This dependency suggested 
that this peak was probably a single charged fragment from the protein. Thus, 
no differences were found between the “before size-exclusion 
chromatography” and the “after size-exclusion chromatography” spectra and 
no impurity was detected by MS (ESI positive and negative ions). 
The NMR preliminary HSQC study, carried out in collaboration with 
Dr J. Long (Centre for Biomolecular Sciences, University of Nottingham, 
Nottingham) was run with 15N labelled LssEdom at a concentration of 0.44 mg 
in 600 µl of 10 mM sodium phosphate, pH 7.4, 150 mM NaCl, 0.04% azide, 
10% D2O in ddH2O. The experiment was run over-night. The spectrum was 
dispersed and no impurity was detected (Figure 66). Nonetheless, the maximal 
concentration of LssEdom obtained, 75 µM, is well below the 1 mM working 
concentration necessary for structure generation on a Bruker AV-600 
spectrometer operating at 600 MHz.   
It was later found that the presence of zinc cations in solution, in the 
different steps of purification and dialysis, were responsible for the 
precipitation of the LssEdom and Lss proteins. By adding Chelex© resin, and 
thus chelating divalent ions in the solutions used for the dialysis of the protein 
solutions, the concentration of both proteins was greatly increased achieving a 
maximum level of 500 µȂ. These improvements in the maximal 
concentrations found for LssEdom may have been factors enabling the 
performance of NMR studies into the structure of LssEdom in interaction with 
the Gly-Gly-L-Ser-Gly-L-Ser peptide that is not cleavable by the glycinase 
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action of LssEdom; this in collaboration with Dr F. Guerlesquin at the IMR02, 
IBSM, Marseille.  
 
 
 
4.6. Lysostaphin tertiary structure modelling 
4.6.1. Sequence to structure 
The primary structure (i.e., amino acid sequence) of a protein is much 
easier to determine than its tertiary structure. The gap between the number of 
proteins of known sequence and number of proteins of known tertiary structure 
is increasing in an accelerating manner. This stems from the limitations of 
laboratory based methods exploited in this chapter. In order to close this gap, 
there have been many searches on how to determine the tertiary structure of a 
Figure 66: The NMR preliminary HSQC spectrum was obtained with a 600MHz Bruker
Spectrometer, on a N
15
 labelled LssEdom peptide at a concentration of 75 µM in 10 mM
sodium phosphate, 150 mM NaCl, pH 7.4, 0.04% azide, 10% D2O in ddH2O.   
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protein from its sequence. Tertiary structure prediction methods come into 
picture at this point.   
The CASP (Critical Assessment of techniques for protein Structure 
Prediction) experiment is an international platform where researchers try to 
predict tertiary structures of proteins whose structure are not available (PSPC, 
2008). Automated structure prediction provides models of reasonable quality 
to researchers who are not themselves structure prediction experts (Marti-
Renom et al., 2000).  
The method used for the construction of an atomic-resolution model of 
Lss was homology modelling, also known as comparative modelling. Protein 
structures (“templates”) that likely resemble the structure of the query 
sequence (“target”), from the basis of the resemblance with its primary 
sequence, were selected and used to produce an alignment that maps residues 
in the target sequence to residues in the template sequence. The sequence 
alignment and the template structure were then used to produce a structural 
model of the target.     
4.6.2. Template selection 
There are a few exceptions to the general rule that proteins sharing 
significant sequence identity will share a fold. For example, a judicious set of 
mutations of less than 50% of a protein can cause the protein to adopt a 
completely different fold (Dalal et al., 1997). However, such a massive 
structural rearrangement is unlikely to occur in evolution, especially since the 
protein is usually under the constraint that it must fold properly and carry out 
its function in the cell.  
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In silico analysis of lysostaphin gene from S. simulans biovar 
staphylolyticus showed that LytM (GI: 49482513) and lysostaphin (GI: 
3287967) were sharing the same traits (Sharma et al., 2006).   
In a subsection of the MEROPS peptidase database (Rawlings et al., 
2008) which searches for protein homologues in a genome, ALE-1 from S. 
capitis (Uniprot code O05156), LytM from S. aureus (UniProt code Q8NYG1) 
and Millericin B from S. milleri (MEROPS code MERO13517) were very 
close in evolution to lysostaphin from S. simulans and S. staphylolyticus 
(Uniprot code P10547 and P10548, respectively) (Figure 67). 
 
The outcome of a BLAST search with entry of the subfamily M23B is 
a list of proteins that are homologous to lysostaphin from S. staphylolyticus 
(UniProt code P10548):  
- ALE-1 from S. capitis (UniProt code O05156),  
- ORF013 from S. aureus phage3A (UniProt code Q4ZCS7),  
- NMB1333 from Neisseria meningitidis (UniProt code Q9JZ20),  
- LytM from S. aureus Mu50 (UniProt code Q8NYG1),  
- IscS from Buchnera aphidicola (UniProt code Q89A19),  
Figure 67: MEROPS phylogenetic tree with entry lysostaphin. 
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- ZooA from Haemophylus influenzae (UniProt code P44693), 
-  YebA from Shigella flexneri (UniProt code P0AFT1), 
-  LytH from Bacillus subtilis (UniProt code O32130),  
- two other putative peptidases whose Uniprot code were Q4A0H0 
and Q4L983.  
The sequences of these proteins were used as input to construct a phylogenetic 
tree using MULTALIN software. The outcome is shown Figure 68.  
 
 
 
 
 
 
 
 
 
From these data it can be observed that ALE-1 and LytM are very close 
to Lss on the evolutionary tree, showing similarities in sequence.  
4.6.3. Structure prediction with Modeller 8v2 
Lysostaphin (Lss253-493) protein sequence was submitted to the Protein 
Homology/analogY Recognition Engine (PHYRE) (Bennett-Lovsey et al., 
2008), which searched for three-dimensional protein structures available in the 
Brookhaven protein databank (Bernstein et al., 1977). Three-dimensional 
structural homologues became fortuitously available for the homology model 
Figure 68: Phylogenetic tree constructed with MULTALIN software with M23B 
subfamily peptidase proteins as input sequences. (PAM, rule line to count the position in 
the alignment). 
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of Lss during the course of my PhD. Two reference proteins, LytM (PDB code 
2B44) and ALE-1 (PDB code 1R77), were used to model the structure of Lss. 
The identity scores compared to the target protein were 48% and 83% for 
LytM186-314 and for ALE-1272-365 respectively (Figure 69). 
(A) 
 
LytM          ---HAKDASWLTSRKQLQPYGQYHG---GGAHYGVDYAMPENSPVYSLTDGTVVQAGWSN  
LssEdom       AATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWSN  
                 * :.*.**.. *:   ** *     ** *****: *  .:** :::.*.:*:***** 
 
LytM          YGGGNQVTIKEANSNNYQWYMHNNRLTVSAGDKVKAGDQIAYSGSTGNSTAPHVHFQRMS 
LssEdom       YGGGNQIGLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMV  
              ******: : * :. : ***** .: .*..** ****: *.:***** *****:*****  
 
LytM          GGIGNQYAVDPTSYLQSR  
LssEdom       NSFSNSTAQDPMPFLKSA  
              ..:.*. * ** .:*:*  
 
 
(B) 
 
ALE-1         -YKTNKYGTLYKSESASFTANTDIITRLTGPFRSMPQSGVLRKGLTIKYDEVMKQDGHVW  
LssTdom       GWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVW  
               :*****************.******* *************: * **:************ 
 
ALE-1         VGYNTNSGKRVYLPVRTWNESTGELGPLWGTIK  
LssTdom       VGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK  
              ***. ***:*:********:**. ** ****** 
 
Figure 69: Amino acid sequence alignment of target with template proteins using 
ClustalW. (A)  LssEdom aligned with LytM. (B) LssTdom aligned with ALE-1.  
 
It should be noted that the amino acid sequence determines the tertiary 
structure of a protein (Anfinsen et al., 1954). On one hand, accurate alignment 
between the target sequence and template structure with a high level of 
sequence homology can guarantee better homology modelling. On the other 
hand, the tertiary structures of proteins are tightly coupled with their activities 
and functions and might not only be determined by their primary sequences. It 
was reported in sections 1.5.1 and 1.5.2 that LytM and ALE-1 possessed a 
similar function to Lss.  
The linker region between the N-terminal and C-terminal domains of 
Lss was also submitted to a subsection of the Brookhaven protein databank 
(Bernstein et al., 1977) which searched sequences that had published three-
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dimensional structures. The search result indicated that no PDB sequence was 
identical to the one submitted, nevertheless, the best match for this linker 
region appeared to be one of the loops in the carboxypeptidase A structure 
starting from amino acid 148 and finishing with amino acid 165 (Greenblatt et 
al., 1998).  The identity scores compared to the target protein was 45% (Figure 
70).  
 1ARL            DAGFGKAGASSSPCSETY  
 Lsslinker       SAGYGKAGGTVTPTPNTG  
                 .**:****.: :* .:*  
 
Figure 70: Amino acid sequence alignment of target (Lss linker A.A. 383-400) with 
template protein (1ARL A.A. 148-165) using ClustalW.  
 
Given the above cited templates, an alignment was generated with the 
Lss target (Figure 71).  
>P1;2B44ZN 
structureX:2B44ZN:253::::::: 
AKDASWLTSRKQLQPYGQYHGGGAHYGVDYAMPENSPVYSLTDGTVVQAGWSNYGGGNQV 
TIKEANSNNYQWYMHNNRLTVSAGDKVKAGDQIAYSGSTGNSTAPHVHFQRMSGGIGNQY 
AVDPTSYLQ* 
 
>P1;1ARLlinker 
structureX:1ARLlinker:383::::::: 
------------------------------------------------------------ 
------------------------------------------------------------ 
---------DAGFGKAGASSSPCSETY* 
 
>P1;1R77 
structureX:1R77:401::::::: 
------------------------------------------------------------ 
------------------------------------------------------------ 
---------------------------YKTNKYGTLYKSESASFTANTDIITRLTGPFRS 
MPQSGVLRKGLTIKYDEVMKQDGHVWVGYNTNSGKRVYLPVRTWNESTGELGPLWGTIK* 
 
>P1;Lss 
sequence:Lss:::::::: 
AQWLNNYKKGYGYGPYPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQI 
GLIENDGVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNST 
AQDPMPFLKSAGYGKAGGTVTPTPNTGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRS 
MPQSGVLKAGQTIHYDEVMKQDGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIK* 
 
Figure 71: Alignment of the complete Lss sequence target with core structural 
fragments identified in closely related solved structure: LytM (PDB code 2B44) and 
ALE-1 (PDB code 1R77), and with variable region: carboxypeptidase A (PDB code 
1ARL).  
 
Given the above alignment of the cited templates with Lss target, this 
information was used to generate a three-dimensional structural model of the 
target, represented as a set of Cartesian coordinates for each atom in the 
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protein (Baker and Sali, 2001). The unsolved protein structure of Lss could be 
modelled using MODELLER 8v2. The input file is shown in Figure 72.  
 
#Homology modelling by automodel class  
  
from modeller.automodel import *  #Load the automodel class 
 
log.verbose()   #request verbose output 
env = environ()  #create a new MODELLER environment to build this model in 
 
#directories for input atom files 
#env.io.atom_files_directory='../atom_files' 
 
a=loopmodel(env, 
alnfile ='lss.ali',   #alignment filename 
knowns =('2B44','1ARLlinker','1R77'), #codes of the templates 
sequence = 'Lss')      #code of the target 
a.starting_model= 1                 # index of the first model  
a.ending_model  = 1                 # index of the last model 
         #(determines how many models to calculate) 
a.md_level=None      #No refinement of model 
 
a.loop.starting_model = 1     # First loop model 
a.loop.ending_model   = 1     # Last loop model 
a.loop.md_level = refine.fast 
 
a.make()                   # do modeling and loop refinement 
 
Figure 72: Script input file containing commands for MODELLER 8v2 for automated 
comparative modelling. 
 
All the files were transferred to the C:\Program 
Files\Modeller8v2\examples\automodel directory for the program to run. 
MODELLER 8v2 treated the aligned residues as structurally equivalent. 
Distances and dihedral angles restraints on the target sequence were calculated 
from the alignment with template three-dimensional structures. The spatial 
restraints were obtained empirically from a database of protein structure 
alignments. The model was obtained by optimising the spatial restraints. The 
output file was a 3D model for the target sequence containing all mainchain 
and sidechain non-hydrogen atoms. Representations of the model are shown in 
Figure 73.  
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Similar to the crystal structure of LytM186-314 (PDB code 2B44), we can 
see from Figure 74 that LssEdom has 8 ȕ-sheets and 2 Į-helices that will 
superimpose. The Zn2+ chelating residues (i.e., H33, D37 and H116) in 
LssEdom active site show strong spatial resemblances with those in LytM.  
Figure 73: The predicted structure of Lss based on automated comparative
modelling using MODELLER 8v2, shown as surface (top) and cartoon (bottom).  
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Figure 74: The three-dimensional structure of LytM186-314 obtained by X-ray 
crystallography (green) superimposed with the predicted structure of LssEdom based on 
automated comparative modelling (yellow). The calculated RMSD comparing backbone 
structures is 2.618.  Also indicated are the Zn
2+
 chelating residues in LssEDom active 
site.  
 
Similar to the crystal structure of ALE-1272-365 (PDB code 1R77), we 
can see from Figure 75 that LssTdom has 8 ȕ-sheets that will superimpose. 
 
 
 
 
 
 
 
 
 
 
 
Figure 75: The three-dimensional structure of ALE-1272-365 obtained by X-ray 
crystallography (green) superimposed with the predicted structure of LssTdom based on 
automated comparative modelling (yellow). The calculated RMSD comparing backbone 
structures is 5.170.   
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4.6.4. Evaluation of prediction accuracy 
The aim of the evaluation is to predict whether or not a model is 
acceptable. If the model violates restraints, it might be because the optimiser 
used in the modelling program did not find a good optimum of the objective 
function. The integrity of the model was checked using MolProbity software, 
which analyses the bond angles of each residue in the protein. Ramachandran 
has shown that all combinations of phi and psi angles cannot exist in nature, 
simply because of steric collisions of residue atoms (Ramachandran and 
Sasisekharan, 1968). Ramachandran has taken into account only phi and psi 
angles of alanine dipeptides and has shown that there are certain 
conformations an alanine dipeptide cannot conform to (Karplus, 1996). These 
restrictions stem from the collision of two atoms in the disallowed 
conformations. Ramachandran (Ramachandran et al., 1963) has chosen to 
represent the distribution of angle pairs in a single chain or multiple chains 
with a scatter plot, which is today called a Ramachandran plot. Some of the 
regions are more populated than others and some of the regions are observed 
in secondary structure elements like Į-helices or ȕ-sheets. The accuracy of the 
Lss three-dimensional structure model has been assessed by measuring the 
percentage of the number of correct predictions over all predictions for each 
atom. The Ramachandran plot (Figure 76) showed 84.8% (201/237) of all 
residues in the favoured regions and 92.8% (220/237) of all residues in the 
allowed regions. 
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Figure 76: MolProbity Ramachandran plot of Lss model. The X-axis shows the phi 
angles and the y-axis shows the psi angles. Grid lines are placed every 60 degrees,
showing the phi and psi angle combination (-180,180) degrees. The light blue areas 
indicate favoured regions; the dark blue areas indicate allowed regions.  
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The outcome of this search is a list of identified outliers that are listed 
in Table 9 and localised on the Lss model structure as shown in Figure 77.  
 
Table 9: List of outliers in the MolProbity Ramachandran analysis of Lss model. 
Outliers (Residue as numbered on 
the model) 
phi, psi angles 
Pro 17 -22.0, 89.3 
Leu 18 -170.6, 103.4 
Ser 77 -91.4, -132.2 
Ser 117 155.2, 162.8 
Ser 130 91.7, 154.4 
Ala 131 -177.8, -136.4 
Ala 136 -69.6, -148.1 
Gly 138 -155.2, 95.3 
Thr 139 126.2, -142.9 
Val 140 -19.9, 75.2 
Trp 148 178.5, -151.8 
Thr 150 155.3, -134.4 
Thr 155 140.7, 159.1 
Leu 156 87.9, 162.4 
Tyr 157 -158.5, -119.6 
Asp 202 26.1, 48.9 
Ser 213 150.6, -165.4 
  
 
 
 
 
Figure 77: Localisation on the Lss model of outlier residues (residues highlighted in 
purple). 
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Outliers were mainly localised in the linker connecting LssEdom to 
LssTdom. This region is flexible and is likely to take different conformations 
in solution. It is of interest to understand how the linker folds in the presence 
of substrate accommodated by LssEdom and LssTdom in full length Lss.  
Models of lysostaphin were later found in the SwissModel repository 
of the Expasy server (Kopp and Schwede, 2004, Kopp and Schwede, 2006). 
Two models were displayed, one predicting the structure for Lss N-terminal 
domain (AA 238-371) based on LytM structure (PDB code 2B13), the other 
predicting the structure for Lss C-terminal domain (AA 389-480) based on 
ALE-1 structure (PDB code 1R77). These models were superimposed with the 
Lss model predicted from MODELLER 8v2 automodel and with the LytM 
(PDB code 2B13) and ALE-1 (1R77) structures.   
SYBYL 7.3 software was used to calculate the RMSD comparing the 
backbone structures of the SwissModel for LssEdom and LytM (PDB code 
2B13). The RMSD for the SwissModel (0.97) is better than for the automodel 
MODELLER 8v2 (2.62) predicting LssEdom structure when compared to 
LytM structure (PDB code 2B13). In addition, SYBYL 7.3 software was used 
to calculate the RMSD comparing the backbone structures of the SwissModel 
for LssTdom and ALE-1 (PDB code 1R77). The RMSD for the SwissModel 
(0.08) is better than for the automodel MODELLER 8v2 (5.17) predicting 
LssTdom structure when compared to ALE-1 structure (PDB code 1R77).      
In Figure 78 and in Figure 79 the similarities in the secondary 
structures (ȕ-sheets) and the variabilities in the structures of the loops can be 
seen. These regions are flexible and likely to adopt different conformations in 
solution and in the presence of ligand so as to accommodate it.   
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Figure 78: Swissmodel (light blue), LytM (PDB code 2B13) (green) and LssEdom model 
predicted from MODELLER 8v2 automodel (yellow) were superimposed to show 
variable regions.  
Figure 79: Swissmodel (light blue), ALE-1 (PDB code 1R77) (green) and LssTdom model 
predicted from MODELLER 8v2 automodel (yellow) were superimposed to show 
variable regions.  
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4.7. Conclusions 
Even with highly pure and correctly folded protein, good structural 
data for LssEdom has not been obtained, this is in spite of the fact that the 
homologous LytM186-314 protein structure has been solved (Firczuk et al., 
2005). This could be due to weakening of the ȕ-sheet structure in the protein 
worked on, as shown in the FT-IR spectra (cf. section 3.5.3.). A model of the 
lysostaphin structure was built to circumvent the problems encountered; the 
reliability of which was tested using MOLProbity software.  
The compact structure of full length Lss compared with LssTdom was 
demonstrated by size exclusion chromatography, where Lss was retained 
longer in the gel-filtration column than LssTdom (data not shown). This could 
be indicative of an interaction between LssEdom and LssTdom in the full 
length structure of Lss, bringing both domains together to accommodate the 
substrate. We look forward for the crystal structure of Lss in complex with its 
substrate (i.e., the Gly-Gly-L-Ser-Gly-L-Ser peptide that is not cleaved by 
glycinase activity of lysostaphin) to give more insight in this matter.   
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5. Interaction studies 
The target specificity of lysostaphin is dependent on its C-terminal 
targeting domain (Baba and Schneewind, 1996). Studies on the lysostaphin 
and ALE-1 cell wall targeting domains, which are very similar, have shown 
that these targeting domains bind purified peptidoglycan from staphylococci in 
a manner that required the presence of pentaglycine cross-bridges (Grundling 
and Schneewind, 2006). It was also said that increased linearised 
peptidoglycan structure greatly enhanced binding of the targeting domain 
(Baba and Schneewind, 1996). A question that arose from those studies was to 
identify the receptors for the targeting domain of lysostaphin in the cell wall of 
S. aureus. Our studies aimed at identifying the receptors of lysostaphin to 
uncover the molecular interactions of the lysostaphin targeting domain 
(LssTdom) to components of the cell wall of staphylococci (Gly5, N-
acetylmuramyl-Ala-D-isoglutaminyl-Nİ-stearoyl-Lys, acetyl-Lys-D-Ala-D-
Ala). Indeed, knowing the selectivity of the lysostaphin targeting domain for 
certain components of the cell wall of different staphylococci, would aid the 
evolution of the ligand-binding properties of lysostaphin targeting domain 
using the phage display technique (Smith and Petrenko, 1997).  
The conventional techniques used for direct detection of non-covalent 
complexes [e.g. gel permeation chromatography (GCP), centrifugation, 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
infrared spectroscopy (Liu and Barth, 2003)] provide limited or no information 
about the mass and binding stoichiometry of the complex. Advanced 
spectroscopic techniques such as X-ray and NMR methods have been used for 
molecular interaction studies, but these methods require good quality crystals 
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and considerable time and effort to obtain good resolution structures. Methods 
that do not require labelling of any of the interacting molecules, such as 
surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), and 
electrospray ionisation mass spectrometry (ESI-MS), are mostly preferred. 
Mass spectrometry (MS), with recent advances in ionisation methods, can 
directly provide the molecular mass and stoichiometry of a complex and allow 
the quantification of the interaction strength (Ganem et al., 1991, Veros and 
Oldham, 2007, Peschke et al., 2004). This technique is relatively simple, 
robust and easily automated (Tjernberg et al., 2004). 
5.1. Attenuated Total Reflection (ATR) 
spectrometry 
LssH114A is a lysostaphin inactive mutant and its stability was 
investigated employing FT-IR. The activity test run with LssWT on MV11 
substrate signified that LssWT was in its native conformation. Thus LssWT 
served as a control protein to measure any change in conformation in the 
mutant LssH114A. The proteins, LssH114A and LssWT, were analysed at 30 
µM concentration in 1 mM sodium phosphate (pH 7.0) buffer. Infrared spectra 
of the amide I and II bands were obtained for both proteins. The most sensitive 
spectral region of protein secondary structure in the infrared is the amide I 
band (1700-1600 cm-1), which is due almost entirely to the C=O stretch 
vibrations of the peptide linkages (approximately 80%). The amide II band, in 
contrast, derives mainly from in-plane NH bending (40-60% of the potential 
energy) and from the CN stretching vibration (18-40%) (Krimm and Bandekar, 
1986), showing much less protein conformational sensitivity than its amide I 
counterpart. As with many other proteins, the amide I contour is a composite 
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of overlapping component bands that represent different elements of the 
protein secondary structure. Some of these components are usually resolvable 
by the computational procedure of band narrowing by Fourier self-
deconvolution. The deconvolved spectra of LssH114A and LssWT in solution 
are shown Figure 79. 
 
 
 
Both traces represent a broad band contour with a maximum at 1640 
cm-1. A significant absorbance can also be observed at 1518 cm-1. It is 
indicative of the presence of 16 tyrosines in both protein sequences.  
The presence of certain peptide secondary structure elements was 
determined based on the positions of the component bands. In order to 
Figure 79: Infrared deconvolved spectra of LssWT (green) and LssH114A (red) in H2O 
medium. The spectra are overlaid to show the similarity.   
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quantify the approximate amount of each protein secondary structure, a curve 
fitting of deconvolved amide I band contour was performed with Gaussian 
function. The assignments of the main infrared absorption bands are given in 
Table 10, where the percentage of the area of a component band assigned to a 
certain conformation in the total area of all bands was considered to reflect the 
approximate amount of each structure.  
Table 10: Infrared absorption band positions (in wavenumbers, cm
-1
) determined with 
the aid of Fourier self deconvolution procedure for amide I for LssWT and LssH114A.  
Assignments are given based on literature data (Byler and Susi, 1986, Goormaghtigh et al., 
1994). Italic numbers in brackets show the tentative percentage of each structure obtained 
from curve fitting.  
Protein Turns ȕ-sheets Unordered 
LssWT 1662 (56) 
1689 (4) 
1630 (35) 1641 (5) 
LssH114A 1665 (34) 
1688 (2) 
1621 (2)  
1624 (47) 
1639 (15) 
 
For LssWT spectra, the band at 1630 cm-1 is representative of ȕ-sheet 
backbone conformation, while the ones at 1662 and 1689 cm-1, can be 
assigned to ordered features like turns (Byler and Susi, 1986, Goormaghtigh et 
al., 1994). As shown on this fitting, there is a weak band at 1641 cm-1 that may 
originate from unordered features, although the wavenumber at which the band 
occurs is a bit low. Its contribution could be explained by the presence of the 
flexible linker in between the activity domain (LssEdom) and the targeting 
domain (LssTdom) of LssWT.  Similarly for LssH114A spectra, the bands at 
1620 and 1624 cm-1 are representative of a ȕ-sheet backbone conformation; 
those at 1664 and 1688 cm-1 are representative of ordered features such as 
turns. The lower spectral position of the sheet’s main band and the 
contribution of 15% of weak ȕ-sheet backbone conformation in LssH114A 
compared to LssWT could be explained by the mutation of histidine (His) into 
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alanine (Ala) in LssH114A that could cause a fast conformational equilibrium 
between ȕ-sheet and unordered conformation.  
Curve fitting analysis shows limitations for the quantitative assessment 
of the “absolute” content of protein secondary structure. However it provides a 
sensitive tool for monitoring, in relative terms, the nature of changes in the 
conformation of protein backbone (Surewicz et al., 1993). Overall, both 
spectra show strong similarities and this suggested that LssH114A had a native 
conformation, comparable with that of LssWT.  
By concentrating LssH114A by evaporation of the 45 µȂ solution on 
the attenuated total reflection (ATR) diamond, it was possible to see changes 
in conformation with the increase in concentration of the protein. In Figure 80 
shows the spectra from 29 multiple scans that were run with 25 accumulations 
each. The concentration of LssH114A could be estimated by integration of the 
amide I band area. 
 
Figure 80: Infrared spectra of LssH114A at different concentrations. The table is
showing an estimation of LssH114A concentration for the different spectra (i.e., 0-21). 
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Changes in conformation could be observed between 60 µM and 80 
µM and above. When the protein was concentrated above 500 µM, forming a 
film, the sample thickness allowed greater interaction of the protein with the 
evanescent wave. However, the variations observed were compatible with a 
transformation of ȕ-sheets into a compact form (amyloids), which were 
suggestive of an aggregation state (Halverson et al., 1991, Ashburn et al., 
1992). 
Figure 81 shows the deconvolved spectra for LssH114A in the 1580-
1760 cm-1 region, where identical spectra have been averaged for clarity. 
Changes in LssH114A conformation could be observed above 63 µM.  
 
 
From those observations, it seems that LssH114A is unstable at 
concentrations above 70 µM.  
Figure 81: Infrared deconvolved spectra of LssH114A at different concentrations.
Identical spectra were averaged: spectra 0-5 (red), spectra 6-8 (blue), spectra 9 (green), 
spectra 10-20 (grey).  
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 The infrared method was used to probe conformational transitions 
induced by ligand binding. To investigate if the peptidoglycan from 
Staphylococcus aureus was interacting with LssH114A and inducing 
conformational changes in the protein structure, 30 µM of protein was mixed 
with 0.14 mg.ml-1 peptidoglycan and compared with the protein alone. The 
spectra collected (Figure 82) were the result of 500 accumulations repeated 
twice, averaged and deconvolved.  
 
Decomposed amide I band positions, percentage areas and assignment 
of the spectral components for LssH114A and LssH114A in solution with 
peptidoglycan from S. aureus are shown in Table 11.  
Figure 82: Overlaid infrared deconvolved spectra of LssH114A (blue) and LssH114A in 
solution with peptidoglycan from S. aureus (green).  
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Table 11: Infrared absorption band positions (in wavenumbers, cm
-1
) determined with 
the aid of Fourier self deconvolution procedure for amide I for LssH114A and LssH114A 
in solution with peptidoglycan from S. aureus.  Assignments are given based on the 
literature data (Byler and Susi, 1986, Goormaghtigh et al., 1994). Italic numbers in brackets 
show tentative percentage of each structure obtained from curve fitting.  
Protein Turns ȕ-sheets Unordered 
LssH114A 1665 (34) 
1688 (2) 
1621 (2)  
1624 (47) 
1639 (15) 
LssH114A +  
PG S.aureus 
1665 (41) 
1688 (3) 
_1618 (5)  
1637 (51) 
 
 
For LssH114A with added peptidoglycan from S. aureus, the curve at 
1637 cm-1 is representative of ȕ-sheet backbone conformation, the ones at 
1665 and 1688 cm-1, are representative of ordered features like turns. The 
weak band at 1618 cm-1 represents a tyrosine side chain vibration that may be 
enhanced by changes in conformation.  
The shift in the spectral position of the ȕ-sheets to higher wavenumber 
could indicate that there is more order for LssH114A mixed with 
peptidoglycan from S. aureus than for LssH114A alone, which fitting showed 
a contribution of 15% of weak ȕ-sheet backbone conformation. The difference 
in the spectral shape from LssH114A alone and LssH114A in presence of 
peptidoglycan may represent an excess of unsubtracted substrate. It could also 
be that insoluble peptidoglycan is interacting with the protein and orientating it 
on the surface of the diamond, giving more order to the protein orientation, as 
seen for membrane proteins (Rothschild et al., 1980).  
To investigate if the pentaglycine (Gly5) ligand was interacting with 
LssH114A, 45 µM of protein was mixed with 0.14 mg.ml-1 of the ligand and 
compared with the protein alone using infrared. Concentration of LssH114A 
was performed by evaporation of the 45 µȂ solution on the diamond. Seven 
multiple scans were run with 25 accumulations each. The spectra collected are 
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shown in Figure 83. Concentrations were estimated by integration of the amide 
I band. 
Changes in conformation could be observed between 123 µM and 248 
µM and above. When the protein was concentrated above 810 µM, forming a 
film, the sample thickness allowed greater interaction of the protein with the 
evanescent wave. However, the variations observed were compatible with a 
transformation of ȕ-sheets into a compact form (amyloids), which were 
suggestive of an aggregation state (Halverson et al., 1991, Ashburn et al., 
1992) 
Figure 84 and Figure 85 show, in more detail, the infrared deconvolved 
spectra of LssH114A and LssH114A in presence of Gly5; identical spectra 
were averaged for clarity. The spectra for LssH114A and of LssH114A in the 
presence of Gly5 were superimposed to look for evidence of conformational 
changes.  
Figure 83: Infrared spectra of LssH114A in the presence of Gly5 at different 
concentrations. The table shows an estimation of LssH114A concentration for the
different spectra (i.e., 1-6). 
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Figure 85: Overlaid infrared deconvolved spectra of LssH114A (pink) and LssH114A in 
solution with Gly5 (green). Identical spectra were averaged: spectra 10-20 for LssH114A 
alone and spectra 4 for LssH114A with Gly5. 
 
Figure 84: Overlaid infrared deconvolved spectra of LssH114A (blue) and LssH114A in 
solution with Gly5 (purple). Identical spectra were averaged: spectra 0-5 for LssH114A 
alone and spectra 0-2 for LssH114A with Gly5. 
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The difference in the shape of the spectra from LssH114A alone and 
LssH114A in the presence of Gly5 may represent an excess of unsubtracted 
substrate. It could also mean that Gly5 is stabilising LssH114A, forming a 
complex.   
5.2. Mass spectrometry 
Analysis of LssTdom (5 µM) by ESI-MS, in triethylammonium acetate 
(25 mM, pH 7.4), gave a simple spectrum dominated by two peaks at m/z 
2874.7 (77%) (Figure 86A) and 2300.0 (23%) (Figure 86B). These peaks 
correspond to the [M+4H]4+ and [M+5H]5+ ions of LssTdom respectively, 
where methionine has been cleaved from the N-terminal of the protein. 
(measured mass of LssTdom without Met +1 11495.0 Da; calculated mass of 
LssTdom without Met +1 11491.9 Da).  
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This spectrum is complicated by adducts. The peaks at m/z 2879.4 and 
2303.9 may be originated from addition of one ammonium ion (MW 18.04) 
and the ones at m/z 2884.1 and 2307.7 may be originated from addition of two 
ammonium ions (MW 36.08), on the apoprotein (LssTdom without Met +1). 
Distinctive peaks at m/z 2939.2 and 2351.6 could correspond to LssTdom still 
containing methionine on the N-terminus (Met +1) (calculated mass of 
LssTdom 11623.0 Da) with added triethylammonium ion (MW 102.2) and 
most likely a molecule of methanol (MW 32.0).  
The peptide Gly5 is mimicking the cross-bridge found in S. aureus 
peptidoglycan, a target of lysostaphin. Following the addition of 40 µM Gly5 
(G5) (8 molar equivalents), an additional set of signals could be observed at 
m/z 2950.5 (Figure 87A) and 2360.6 (Figure 87B), corresponding to the 
Figure 86: (A) ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
apoprotein signal at m/z 2874.7. (B) ESI mass spectra of the [M+5H]5+ charge state of the 
LssTdom showing the apoprotein signal at m/z 2300.0. 
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[M+4H]4+ and [M+5H]5+ charge states of LssTdom-G5 non-covalent complex 
(measured mass of LssTdom-G5 11796.1 Da; calculated mass of LssTdom-G5 
11795.2 Da). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 87: (A) ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-G5 non-covalent complex signal at m/z 2950.5. (B) ESI mass spectra of the 
[M+5H]5+ charge state of LssTdom showing the LssTdom-G5 non-covalent complex signal at 
m/z 2360.6.  
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In order to observe the apparent dissociation constant KD for LssTdom-
G5 complexes, a series of ESI-MS measurements were made at different 
concentrations of Gly5 (ranging from 2 to 8 molar equivalents). Figure 88 A-D 
shows results for the LssTdom-G5 complex.  
 
A smooth increase in the intensity of the ion at m/z 2950.5 and 2360.6, 
relative to m/z 2874.7 and 2299.9 respectively, is observed as the total ligand 
concentration is increased. Using the relative intensities of the signals in the 
mass spectrum (combined data for [M+4H]4+ and [M+5H]5+ charge states), 
together with the total protein and ligand concentrations, the values of protein 
Figure 88: ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-G5 non-covalent complex signal at m/z 2950.5 at different concentrations: (A) 2 
molar equivalents, (B) 4 molar equivalents, (C) 6 molar equivalents, (D) 8 molar equivalents. 
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concentration free in solution [P], of protein-ligand complex concentration 
[PL] and of ligand concentration free in solution [L] were calculated (Table 
12). The dissociation constant KD was determined from plots of [PL]/[L] vs. 
[L] (Figure 89). Gly5 bound to LssTdom with a dissociation constant of 9 (± 1) 
µM.  
Table 12: Values for [P] (protein concentration), [L] (ligand concentration) and [PL] 
(protein-ligand complex). 
[L] (µM) [P] (µM) [PL] (µM) 
8.93 3.93 1.07 
18.63 3.63 1.37 
28.39 3.31 1.69 
38.23 3.23 1.77 
 
 
 
 
 
 
 
 
 
 
The peptide Gly-Gly-L-Ser-Gly-L-Ser is mimicking the cross-bridge 
found in lysostaphin host bacteria peptidoglycan – S. simulans. Addition of 40 
µM Gly-Gly-L-Ser-Gly-L-Ser (G2SGS) (8 molar equivalents) to the LssTdom 
solution could be observed at m/z 2965.5 (Figure 90A) and 2372.5 (Figure 
90B), corresponding to the [M+4H]4+ and [M+5H]5+ charge states of 
Figure 89: GraFit4 plot of the LssTdom-G5/free ligand concentrations vs. free ligand 
concentrations giving a KD value of 9 (± 1) µM (Chi
2 = 0.0014). 
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LssTdom-G2SGS non-covalent complex (measured mass of LssTdom-G2SGS 
11857.7 Da; calculated mass of LssTdom-G2SGS 11855.3 Da).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to observe the apparent dissociation constant KD for LssTdom-
G2SGS complexes, a series of ESI-MS measurements were made at different 
Figure 90: (A) ESI mass spectra of the [M+4H]4+ charge state of LssTdom showing the 
LssTdom-G2SGS non-covalent complex signal at m/z 2965.5. (B) ESI mass spectra of the 
[M+5H]5+ charge state of the LssTdom showing the LssTdom- G2SGS non-covalent complex 
signal at m/z 2372.5. 
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concentrations of Gly-Gly-L-Ser-Gly-L-Ser (ranging from 2 to 8 molar 
equivalents). Figure 91 A-D shows results for the LssTdom-G2SGS complex.  
 
 
 
A smooth increase in the intensity of the ion at m/z 2965.5 and 2372.5, 
relative to m/z 2874.6 and 2299.9 respectively, is observed as the total ligand 
concentration is increased. Using the relative intensities of the signals in the 
mass spectrum (combined data for [M+4H]4+ and [M+5H]5+ charge states), 
together with the total protein and ligand concentrations, the values of protein 
concentration free in solution [P], of protein-ligand complex concentration 
[PL] and of ligand concentration free in solution [L] were calculated (Table 
13). The dissociation constant KD was determined from plots of [PL]/[L] vs. 
Figure 91: ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-G2SGS non-covalent complex signal at m/z 2965.5 at different concentrations: (A) 
2 molar equivalents, (B) 4 molar equivalents, (C) 6 molar equivalents, (D) 8 molar 
equivalents.  
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[L] (Figure 92). Gly-Gly-L-Ser-Gly-L-Ser bound to LssTdom with a 
dissociation constant of 15 (± 5) µM.  
Table 13: Values for [P] (protein concentration), [L] (ligand concentration) and [PL] 
(protein-ligand complex). 
[L] (µM) [P] (µM) [PL] (µM) 
9.56 4.56 0.44 
19.42 4.41 0.58 
29.32 4.32 0.68 
39.18 4.18 0.82 
 
 
 
 
  
 
 
 
 
 
 
 
A competition experiment between LssTdom and 8 molar equivalents 
of Gly5 and Gly-Gly-L-Ser-Gly-L-Ser showed both receptor-ligand complexes 
at m/z 2950.3 and 2965.5 respectively for the [M+4H]4+ charge state (Figure 
93D). Peak intensities revealed that the LssTdom-G5 complex was 1.3 times 
more abundant than LssTdom-G2SGS, in agreement with the above mentioned 
KD values (i.e., 9.3 µM for the LssTdom-G5 complex and 14.7 µM for the 
LssTdom-G2SGS complex).  The competitive binding experiment measured 
Figure 92: Plot of the LssTdom-G2SGS/free ligand concentrations vs. free ligand 
concentrations giving a KD value of 15 (± 5) µM (Chi
2 = 0.0022). 
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the binding of a single concentration of Gly5 ligand (40 µM) in the presence of 
various concentrations of G2SGS ligand (10 to 80 µM) (Figure 93 A-H).   
 
A smooth increase in the intensity of the ion at m/z 2965.5 and 2372.5, 
and a smooth decrease in the intensity of the ion at m/z 2950.3 and 2360.3, 
relative to m/z 2874.0 and 2299.8 respectively, is observed as G2SGS ligand 
concentration is increased. Using the relative intensities of the signals in the 
mass spectrum (combined data for [M+4H]4+ and [M+5H]5+ charge states), 
together with the total protein and ligand concentrations, the value of 
Figure 93: ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-Gly5 non-covalent complex at m/z 2950.3 at fixed concentration (8 molar
equivalents) and the competitive LssTdom-G2SGS non-covalent complex signal at m/z 2965.5 
at different concentrations: (A) 2 molar equivalents, (B) 4 molar equivalents, (C) 6 molar 
equivalents, (D) 8 molar equivalents, (E) 10 molar equivalents, (F) 12 molar equivalents, (G)
14 molar equivalents, (H) 16 molar equivalents. 
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[LssTdom-G5] was calculated (Table 14). The median inhibition concentration 
(IC50) which is the concentration of G2SGS that reduces the LssTdom-G5 non-
covalent complex formation by 50%, was determined from plots of 
log[G2SGS] concentrations vs [LssTdom-G5] concentrations (Figure 94). The 
concentration of G2SGS that reduces Gly5 binding by half was 59 µM (± 9 
µM), which is very close to [Gly5] + KD (i.e., 40 µȂ + 9 µM (± 1 µM)).  
Table 14: Values for [inhibitor] ([G2SGS] concentration) and response ([LssTdom-G5]). 
[inhibitor] (=[G2SGS]) 
(µM) 
Response (=[LssTdom-Gly5]) 
(µM)) 
20 1.0195 
30 1.0210 
40 0.9763 
50 0.9412 
60 0.9120 
70 0.8788 
80 0.8516 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 94: Plot of log[G2SGS] concentrations vs [LssTdom-G5] concentrations giving an IC50
value of 59 (± 9) µM.  
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Following the addition of 40 µM Gly4 (G4) (8 molar equivalents) to the 
LssTdom solution, two additional peaks could be observed at m/z 2936.3 
(Figure 95A) and 2349.1 (Figure 95B), corresponding to the [M+4H]4+ and 
[M+5H]5+ charge states of LssTdom-G4 non-covalent complex (measured 
mass of LssTdom-G4 11740.9 Da; calculated mass of LssTdom-G4 11738.1 
Da).  
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The additional peaks at m/z 2939.2 and 2351.6 that are present in 
LssTdom spectrum when not associated with Gly4 may be hidden and 
complicate the accurate measurement of the intensities of the peaks at m/z 
2936.3 and 2349.1, corresponding to the [M+4H]4+ and [M+5H]5+ charge 
states of LssTdom-G4 complex. Nonetheless, in order to observe the apparent 
dissociation constant KD for LssTdom-G4 complexes, a series of ESI-MS 
measurements were made at different concentrations of Gly4 (ranging from 2 
to 16 molar equivalents). Figure 96 A-E shows results for LssTdom-G4 
complex.  
Figure 95: (A) ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-G4 non-covalent complex signal at m/z 2936.3. (B) ESI mass spectra of the 
[M+5H]5+ charge state of the LssTdom showing the LssTdom-G4 non-covalent complex 
signal at m/z 2349.1. 
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A smooth increase in the intensity of the ion at m/z 2936.3 and 2349.1, 
relative to m/z 2874.7 and 2300.0 respectively, is observed as the total ligand 
concentration is increased. Using the relative intensities of the signals in the 
mass spectrum (combined data for [M+4H]4+ and [M+5H]5+ charge states), 
together with the total protein and ligand concentrations, the values of protein 
concentration free in solution [P], of protein-ligand complex concentration 
[PL] and of ligand concentration free in solution [L] were calculated (Table 
Figure 96: ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-G4 non-covalent complex signal at m/z 2936.3 at different concentrations: (A) 2 
molar equivalents, (B) 4 molar equivalents, (C) 6 molar equivalents, (D) 8 molar equivalents,
(E) 16 molar equivalents. 
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15). The dissociation constant KD was determined from plots of [PL]/[L] vs. 
[L] (Figure 97). Gly4 bound to LssTdom with a dissociation constant of 38 (± 
5) µM.  
Table 15: Values for [P] (protein concentration), [L] (ligand concentration) and [PL] 
(protein-ligand complex). 
[L] (µM) [P] (µM) [PL] (µM) 
9.49 4.49 0.51 
19.17 4.17 0.83 
28.96 3.96 1.04 
38.74 3.24 1.26 
 
 
 
 
 
 
 
 
 
 
 
Following the addition of 40 µM Gly2 (G2) (8 molar equivalents) to the 
LssTdom solution, two additional peaks could be observed at m/z 2906.6 
(Figure 98A) and 2325.6 (Figure 98B), corresponding to the [M+4H]4+ and 
[M+5H]5+ charge states of LssTdom-G2 non-covalent complex (measured 
mass of LssTdom-G2 11622.4 Da; calculated mass of LssTdom-G2 11624.0 
Da).  
Figure 97: GraFit4 plot of the LssTdom-G4/free ligand concentrations vs. free ligand 
concentrations giving a KD value of 38 (± 5) µM (Chi
2 = 0.0004). 
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Figure 98: (A) ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-G2 non-covalent complex signal at m/z 2906.6. (B) ESI mass spectra of the [M+5H]
5+
charge state of the LssTdom showing the LssTdom-G2 non-covalent complex signal at m/z
2325.6. 
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In order to observe the apparent dissociation constant KD for LssTdom-
G2 complexes, a series of ESI-MS measurements were made at different 
concentrations of Gly2 (ranging from 2 to 12 molar equivalents). Figure 99 A-
G shows results for LssTdom-G2 complex. 
A smooth increase in the intensity of the ion at m/z 2906.6 and 2325.6, 
relative to m/z 2873.5 and 2299.0 respectively, is observed as the total ligand 
concentration is increased. Using the relative intensities of the signals in the 
mass spectrum (combined data for [M+4H]4+ and [M+5H]5+ charge states), 
together with the total protein and ligand concentrations, the values of protein 
concentration free in solution [P], of protein-ligand complex concentration 
Figure 99: ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-G2 non-covalent complex signal at m/z 2906.6 at different concentrations: (A) no 
ligand, (B) 2 molar equivalents, (C) 4 molar equivalents, (D) 6 molar equivalents, (E) 8 molar 
equivalents, (F) 10 molar equivalents, (G) 12 molar equivalents. 
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[PL] and of ligand concentration free in solution [L] were calculated (Table 
16). The dissociation constant KD was determined from plots of [PL]/[L] vs. 
[L] (Figure 100). Gly2 bound to LssTdom with a dissociation constant of 14 (± 
2) µM.  
Table 16: Values for [P] (protein concentration), [L] (ligand concentration) and [PL] 
(protein-ligand complex). 
[L] (µM) [P] (µM) [PL] (µM) 
9.35 4.35 0.65 
19.08 4.08 0.92 
28.97 3.97 1.03 
38.85 3.85 1.15 
48.73 3.73 1.27 
 
 
 
 
 
 
 
 
 
 
 
 
The peptide acetyl-Lys-D-Ala-D-Ala is mimicking part of the stem 
peptide found in S. aureus peptidoglycan. Following addition of 40 µM acetyl-
Lys-D-Ala-D-Ala (KA2) (8 molar equivalents) to the LssTdom solution, two 
additional peaks could be observed at m/z 2957.4 (Figure 101A) and 2365.9 
(Figure 101B), corresponding to the [M+4H]4+ and [M+5H]5+ charge states of 
Figure 100: GraFit4 plot of the LssTdom-G2/free ligand concentrations vs. free ligand 
concentrations giving a KD value of 14 (± 2) µM (Chi
2 = 0.0011). 
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LssTdom-KA2 non-covalent complex (measured mass of LssTdom-KA2 
11825.0 Da; calculated mass of LssTdom-KA2 11822.2 Da).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 101: (A) ESI mass spectra of the [M+4H]4+ charge state of LssTdom showing the 
LssTdom-KA2 non-covalent complex signal at m/z 2957.4. (B) ESI mass spectra of the 
[M+5H]5+ charge state of the LssTdom showing the LssTdom-KA2 non-covalent complex 
signal at m/z 2365.9. 
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In order to observe the apparent dissociation constant KD for LssTdom-
KA2 complexes, a series of ESI-MS measurements were made at different 
concentrations of acetyl-Lys-D-Ala-D-Ala (ranging from 2 to 8 molar 
equivalents). Figure 102 A-D shows results for LssTdom-KA2 complex.  
 
 
 
A smooth increase in the intensity of the ion at m/z 2957.0 and 2365.7, 
relative to m/z 2874.3 and 2299.6 respectively, is observed as the total ligand 
concentration is increased. Using the relative intensities of the signals in the 
Figure 102: ESI mass spectra [M+4H]4+ charge state of the LssTdom showing the LssTdom-
KA2 non-covalent complex signal at m/z 2957.0 at different concentrations: (A) 2 molar 
equivalents, (B) 4 molar equivalents, (C) 6 molar equivalents, (D) 8 molar equivalents. 
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mass spectrum (combined data for [M+4H]4+ and [M+5H]5+ charge states), 
together with the total protein and ligand concentrations, the values of protein 
concentration free in solution [P], of protein-ligand complex concentration 
[PL] and of ligand concentration free in solution [L] were calculated (Table 
17). The dissociation constant KD was determined from plots of [PL]/[L] vs. 
[L] (Figure 103). acetyl-Lys-D-Ala-D-Ala bound to LssTdom with a 
dissociation constant of 19 (± 4) µM.  
Table 17: Values for [P] (protein concentration), [L] (ligand concentration) and [PL] 
(protein-ligand complex). 
[L] (µM) [P] (µM) [PL] (µM) 
9.46 4.46 0.54 
19.23 4.23 0.77 
29.00 4.00 1.00 
38.94 3.94 1.06 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 103: Plot of the LssTdom-KA2/free ligand concentrations vs. free ligand concentrations 
giving a KD value of 19 (± 4) µM (Chi
2 = 0.0015). 
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A competition experiment between LssTdom and 8 molar equivalents 
of Gly2 and acetyl-Lys-D-Ala-D-Ala showed both receptor-ligand complexes at 
m/z 2906.6 and 2956.1 respectively for the [M+4H]4+ charge state (Figure 104 
D). Peak intensities revealed that LssTdom-G2 complex was equivalently 
abundant to LssTdom-KA2, in agreement with the above mentioned KD values 
(i.e., 14.2 µM for LssTdom-G2 complex and 18.7 µM for LssTdom-KA2 
complex). The competitive binding experiment measured the binding of a 
single concentration of Gly2 ligand (40 µM) in the presence of various 
concentrations of KA2 ligand (10 to 100 µM) (Figure 104 A-I). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 104: ESI mass spectra of the [M+4H]4+ charge state of the LssTdom showing the 
LssTdom-Gly2 non-covalent complex at m/z 2906.6 at fixed concentration (8 molar
equivalent) and the competitive LssTdom-KA2 non-covalent complex signal at m/z 2956.1 at 
different concentrations: (A) 2 molar equivalents, (B) 4 molar equivalents, (C) 6 molar 
equivalents, (D) 8 molar equivalents, (E) 10 molar equivalents, (F) 12 molar equivalents, (G)
14 molar equivalents, (H) 16 molar equivalents, (I) 20 molar equivalents.  
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A smooth increase in the intensity of the ion at m/z 2956.1 and 2365.9, 
and a smooth decrease in the intensity of the ion at m/z 2906.6 and 2325.6, 
relative to m/z 2873.5 and 2299.8 respectively, is observed as the amount of 
KA2 ligand concentration is increased. Using the relative intensities of the 
signals in the mass spectrum (combined data for [M+4H]4+ and [M+5H]5+ 
charge states), together with the total protein and ligand concentrations, the 
value of [LssTdom-G2] was calculated (Table 18). The median inhibition 
concentration (IC50) which is the concentration that reduces the LssTdom-G2 
non-covalent complex formation by 50%, was determined from plots of 
log[KA2] concentrations vs [LssTdom-G2] concentrations (Figure 105). The 
concentration of KA2 that reduces Gly2 binding by half was 47 µM (± 1 µM), 
which is very close to [Gly2] + KD (i.e., 40 µȂ + 14 µM (± 2 µM)).  
 
Table 18: Values for [inhibitor] ([KA2] concentration) and response ([LssTdom-G2]). 
[inhibitor] (=[G2SGS]) 
(µM) 
Response (=[LssTdom-Gly5]) 
(µM)) 
20 0.9949 
30 0.9696 
50 0.8338 
60 0.7826 
70 0.7444 
80 0.7367 
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This very same set of experiment was run with LssTdom in complex 
with 8 molar equivalent Gly5, competing for the same binding site with 
different concentrations of acetyl-Lys-D-Ala-D-Ala (from 2 to 20 molar 
equivalents). The resolution on the peaks for LssTdom-G5 (2946.6 and 2360.6 
respectively for [M+4H]4+ and [M+5H]5+ charge states) and LssTdom-KA2 
(2955.6 and 2365.9 respectively for [M+4H]4+ and [M+5H]5+ charge states) 
was poor and did not allow any consistent measure on the intensity of the 
peaks. Nonetheless, a smooth increase in the intensity of the ion at m/z 2946.6 
and 2360.6, and a smooth decrease in the intensity of the ion at m/z 2955.6 and 
2365.9, relative to m/z 2873.5 and 2299.8 respectively, is observed as the 
amount of KA2 ligand concentration is increased. 
Figure 105: Plot of log[KA2] concentrations vs [LssTdom-G2] concentrations giving an IC50
value of 47 (± 1) µM.  
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Following addition of 40 µM Gly-L-Ser (GS) (8 molar equivalents) to 
the LssTdom solution, two additional peaks could be observed at m/z 2915.3 
(Figure 106A) and 2331.6 (Figure 106B), corresponding to the [M+4H]4+ and 
[M+5H]5+ charge states of LssTdom-GS non-covalent complex (measured 
mass of LssTdom-GS 11655.1 Da; calculated mass of LssTdom-GS 11654.0 
Da).  
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Thorough dialysis of LssTdom in milliQ water led to significant 
changes in protein ESI mass spectra. As shown in Figure 107, LssTdom 
unfolded in milliQ water resulted in ions having higher charge states (6+-14+). 
This may be compared with the same experiment performed in 25 mM 
triethylammonium acetate, pH 7.4, which promoted a folded conformation 
with only two charge states (i.e., 4+-5+). Moreover the width of the charge state 
distributions was also larger for unfolded LssTdom due to structural 
heterogeneity of the corresponding states in solution. The denatured state of a 
protein exposes more sites for protonation, resulting in the formation of higher 
charge states (Pramanik et al., 1998). 
  
Figure 106: (A) ESI mass spectra of the [M+4H]4+ Charge state of the LssTdom showing the 
LssTdom-GS non-covalent complex signal at m/z 2915.3. (B) ESI mass spectra of the 
[M+5H]5+ charge state of the LssTdom showing the LssTdom-GS non-covalent complex 
signal at m/z 2331.6. 
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As a negative control LssTdom denatured in milliQ water showed no 
binding to any of the ligands by ESI-MS (Figure 108). This spectrum is 
complicated by adducts. The peak at m/z 1278.0 correspond to the [M+9H]9+ 
ion of LssTdom where methionine has been cleaved from the N-terminal of the 
protein. The peak at m/z 1306.7 could correspond to LssTdom still containing 
methionine on the N-terminus (Met +1), with adducts coming from the 
different commercial ligand solutions.  
 
 
 
 
 
 
 
Figure 107: ESI mass spectra of LssTdom thoroughly dialysed in milliQ water showing
charge state distribution characteristic of an unfolded protein. 
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As a negative control no complexes could be observed between 
LssTdom and Gly3 (Figure 109A) or L-serine (L-Ser) (Figure 109B) or NAM-
Ala-iGlu-Lys (Figure 109C) ligands, following the addition of 8 molar 
equivalents of the ligands. The peptide Gly3 is believed to be the product of 
pentaglycine cleavage by lysostaphin and the peptide NAM-Ala-iGlu-Lys is 
mimicking part of the stem peptide found in S. aureus peptidoglycan. 
 
 
Figure 108: ESI mass spectra of the [M+9H]9+ charge state of denatured LssTdom showing 
the apoprotein signal at m/z 1277.9 (6.) [1. in presence of Gly5 (160 µM); 2. In presence of 
Gly4 (160 µM); 3. In presence of Gly3 (160 µM); 4. In presence of Lys-D-Ala-D-Ala (160 
µM); 5. In presence of NAM-Ala-iGlu-Lys (160 µM)].  
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Figure 109: ESI mass spectra of the [M+4H]4+ charge state of LssTdom showing the 
apoprotein signal at m/z 2874.7 (A) in presence of Gly3 (40 µM); (B) in presence of L-Ser 
(40 µM); (C) in presence of NAM-Ala-iGlu-Lys (40 µM).  
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Table 19 summarises the results obtained by MS on the complexes 
formed by LssTdom with ligands mimicking parts of the S. aureus 
peptidoglycan.  
 
Table 19: Table summarising the results on the complexes obtained by MS. 
Abbreviations used are: KD, constant of dissociation, IC50, median inhibition concentration, 
G, glycine, S, serine, K, lysine, A, alanine, Q, glutamine, NAM, N-acetylmuramic acid. 
Complex KD (µM) IC50 (µM) 
LssTdom.G5 9 (±1) 
LssTdom.G2SGS 15 (±5) 
59 (±9) 
LssTdom.G4 38 (±5) No study 
LssTdom.G3 No binding No study 
LssTdom.G2 14 (±2) 
LssTdom.KA2 19 (±4) 
47 (±1) 
LssTdom.GS Binding No study 
LssTdom.S No binding No study 
LssTdom.NAM-AQK No binding No study 
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5.3. Conclusions 
Gründling and coworkers showed that the lysostaphin targeting domain 
binds to purified peptidoglycan and that intact pentaglycine cross bridges are 
essential for binding (Gründling and Schneewind, 2006). However, in those 
studies, binding of the lysostaphin targeting domain was not inhibited by 
addition of excess amounts of pentaglycine. Our results showed a 
concentration dependent binding of the lysostaphin targeting domain to 
pentaglycine. A reasonable dissociation constant, with a KD value of 9 x 10
-6 
(± 1 x 10-6) M for the LssTdom-G5 complex, was measured. Although ESI-MS 
is specific and sensitive, caution is needed when interpreting results as the 
avidity of the gas-phase complex may not be similar to that found in solution, 
depending on the nature of non-covalent interactions. Complexes where the 
bond in solution involves a significant hydrophobic component have high KA 
values in solution, but low bond strength in the gas-phase. Such complexes 
will readily decompose in the clean up stages and lead to values of KA that are 
too low.   
An increasing association with increasing n (Gly3, Gly4, Gly5) was 
observed. These results suggested the occurrence of a weak, probably specific, 
interaction between LssTdom and Glyn (n>3). Lysostaphin targeting domain 
was shown not to bind Gly3, which is speculated to be very similar to the 
product of pentaglycine cleavage by lysostaphin. Endeed, enzymes have 
evolved to have low affinity to prevent product inhibition. Those results are 
consistent with the results presented by Warfield and coworkers, where a 
triglycine FRET substrate was not cleaved at all and a tetraglycine FRET 
substrate was hydrolysed approximately five times more slowly than a 
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pentaglycine FRET substrate by full length lysostaphin (Warfield et al., 2006). 
Firczuk and coworkers briefly reported the testing of tetraglycine-[N-(2,4-
dinitrophenyl)ethylene diamine] as a fluorescent substrate for LytM (Firczuk 
et al., 2005). They found this compound to be a moderate substrate (KM = 2.3 
mM). The KD value found for the LssTdom-G4 complex by ESI-MS was 38 x 
10-6 (± 5 x 10-6) M, which is tighter than that found previously. An explanation 
would be that the substrate used for the FRET assay is not as well 
accommodated as tetraglycine alone owing to the steric effect of N-(2,4-
dinitrophenyl)ethylene diamine. It could also be that as LytM and lysostaphin 
do not share the same targeting domain, they behave differently regarding the 
substrate.  
Additionally, a non-covalent LssTdom-G2 complex was observed with 
a KD value of 14 x 10
-6 (± 2 x 10-6) M. Gründling and coworkers examined the 
binding of the lysostaphin targeting domain to the S. aureus mutant femAB 
with monoglycine bridges and its isogenic parent with pentaglycine cross-
bridges (Gründling and Schneewind, 2006). A drastic decrease in the binding 
of the lysostaphin targeting domain to the cell wall envelope of femAB mutant 
staphylococci was observed compared with the isogenic wild-type strain.  
Thus, according to these studies, the binding was dependent on the length of 
the interpeptide bridge. The unsuspected interaction of the lysostaphin 
targeting domain to Gly2 ligand observed by ESI-MS might be explained by a 
change in conformation of the lysostaphin targeting domain, accommodating a 
small ligand like Gly-L-Ser and Gly-Gly rather than peptidoglycan from 
staphylococci.  
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Data on the KM (200 x 10
-6 M) of lysostaphin (full length) using the 
FRET assay against the Abz-Gly5-EDDnp FRET substrate (cf. section 3.3) 
gave a 20 times lower association value compared to that observed on ESI-MS 
for the LssTdom-Gly5 complex. An explanation would be that the substrate 
used for the FRET assay is not as well accommodated as pentaglycine alone, 
due to the steric effect of the N-(2-aminobenzoyl) and N-(2,4-dinitrophenyl) 
ethylene diamine groups, which are fluorophore and quencher respectively in 
the FRET substrate.  
In our study, the dissociation constant values for the LssTdom-G5 and 
LssTdom-GGSGS non-covalent complexes were of the same order: 9 x 10-6 (± 
1 x 10-6) M for the LssTdom-G5 complex and 15 x 10
-6 (± 5 x 10-6) M for the 
LssTdom-GGSGS complex. Data from the competition assay showed that the 
concentration of G2SGS that reduced Gly5 binding by half was 59 µM (± 9 
µM). Lu and coworkers compared the binding of the ALE-1 targeting domain 
to various staphylococcal peptidoglycans with genetically modified 
interpeptide bridges and their isogenic parents (Lu et al., 2006). Once Gly5 
became Gly2-Ser-Gly2 within the peptidoglycan, binding was reduced 
considerably but not entirely abolished. The targeting domain showed a strong 
preference for Gly5 in this study. A question that arose was whether the 
LssTdom-GGSGS non-covalent complex signal observed by ESI-MS was 
significant of a specific interaction. Indeed, the lysostaphin targeting domain is 
positively charged at pH 7.4 and is likely to favour Ser association (polar 
interaction) over Gly in the gas-phase.  
Gründling and coworkers suggested that the lysostaphin targeting 
domain binding to peptidoglycan required not only pentaglycine cross bridges 
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but also other structural features of cross-linked peptidoglycan. His studies 
showed that cross-linked peptidoglycan, harbouring murein disaccharides, wall 
peptides, and cross bridges, appeared to serve as a receptor for the lysostaphin 
targeting domain. Our results showed that the lysostaphin targeting domain 
bound to acetyl-Lys-D-Ala-D-Ala but did not bind to N-acetylmuramyl-Ala-D-
isoglutaminyl-Nİ-stearoyl-Lys; both are fragments of the stem peptides in 
staphylococci. Those observations are corroborated by the studies of 
Gründling and coworkers studies (Gründling and Schneewind, 2006) where a 
S. aureus dltB mutant with a higher amount of exposed D-Ala, not linked to 
polyglycerol-phosphate (LTA) or polyribitol-phosphate (WTA), showed 
increased binding to the lysostaphin targeting domain. However, Guan and 
coworkers determined the crystal structure of the C-terminal peptidoglycan-
binding domain of human peptidoglycan recognition protein (PGRP-IĮ) in a 
complex with a N-acetylmuramyl-Ala-D-isoglutaminyl-Nİ-stearoyl-Lys 
representing the conserved core of lysine-type peptidoglycans (Guan et al., 
2005). Human peptidoglycan recognition protein hydrolyses the amide bond 
between the N-acetylmuramyl and L-alanine moieties of peptidoglycan and 
lysostaphin hydrolyses the pentaglycine cross-bridge; this difference of 
function can explain the difference observed in the binding substrates.  
Data from the competition assay showed that the concentration of 
acetyl-Lys-D-Ala-D-Ala that reduced Gly2 binding on that lysostaphin 
targeting domain by half was 47 µM (± 1 µM). These data suggested that 
acetyl-Lys-D-Ala-D-Ala and Gly2 are competing for the same binding site in 
the lysostaphin targeting domain. No quantitative measure was made on 
acetyl-Lys-D-Ala-D-Ala competition with Gly5, but the same tendency was 
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observed: acetyl-Lys-D-Ala-D-Ala and Gly5 seemed to compete for the same 
binding site in the lysostaphin targeting domain. This contradicted our first 
hypothesis which was that lysostaphin targeting domain was accommodating 
both of those compounds in the same binding site rather than accommodating 
one at a time. This would make LssTdom very non specific and able to bind to 
bacteria that do not have the pentaglycine peptidoglycan cross-bridge (i.e, 
Streptococcus mutans which peptidoglycan structure differs from that of S. 
aureus in its interpeptide bridge and contains L-Ala-L-Ala). It is in 
disagreement with what was reported by Lu and coworkers where ALE-1 
targeting domain binding to peptidoglycan of S. mutans was significantly 
lower than to peptidoglycan of S. aureus 209P (Lu et al., 2006).     
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6. Discussion 
 
Lysostaphin is a potential therapeutic antibiotic for Methicillin-
resistant Staphylococcus aureus (MRSA) for which new antibacterials are 
required owing to the widespread occurrence of multi-drug resistant strains. 
lif-encoded resistance to lysostaphin is associated with the site-specific 
incorporation of serine residues into the pentaglycine cross-bridge (Ehlert et 
al., 2000; Bardelang et al., 2008). Thus a structure is desirable to enable 
rationally guided design of lysostaphin variants able to bypass the lif 
mechanism of resistance. The investigations in this thesis raised interrogations 
on the structural requirements for enzymatic activity and on the potential 
targets in the peptidoglycan for the binding of lysostaphin.   
Fourier transform infrared (FT-IR) spectroscopy allowed the detection 
of conformational changes in lysostaphin and its endopeptidase domain. The 
proteins infrared bands showed a more ordered conformation for the full 
length lysostaphin than its endopeptidase domain alone (cf. section 3.5.3.). The 
compact structure of the full length lysostaphin compared with its cell wall 
targeting domain was demonstrated by size exclusion chromatography, where 
lysostaphin was retained longer in the gel filtration column than its targeting 
domain alone (cf. section 4.7.). It was then proposed that the endopeptidase 
domain and the cell wall targeting domain interacted in the full length 
structure of lysostaphin, bringing both domains together to accommodate the 
same substrate (cf. section 4.7.).  
However, in the homology model presented in this thesis (cf. section 
4.6.3.), the linker between LssEdom and LssTdom is modelled in mostly 
extended conformation, bringing the two domains 40 Å apart. Firczuk (2005), 
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Lu (2006) and their coworkers suggested that LytM activity domain and ALE-
1 cell wall binding domain respectively, accommodated the same peptide 
motif, a polyglycine. This would imply that lysostaphin binding to 
peptidoglycan would require cross-linked peptidoglycan with two pentaglycine 
regions separated by at least 40 Å.    
 The initial prediction of lysostaphin structure from its sequence 
information is not very accurate considering the error on the protein linker 
structure prediction that may cause the model not to resemble the native state 
of the protein (cf. section 4.6.4.). Nevertheless, structure prediction is only a 
step in protein structure determination. To obtain good crystals of Lss in 
complex with its substrate (i.e., the non-hydolysable Gly-Gly-L-Ser-Gly-L-Ser 
peptide or a peptide that possess two non-hydrolysable Gly-Gly-L-Ser-Gly-L-
Ser sequences, provided the distance between these motifs is appropriate for 
the enzyme) that would diffract between 2 and 3 Å, would allow the resolution 
of its tertiary structure using the technique of molecular replacement where 
LytM (Firczuk et al., 2005) and ALE-1 (Lu et al., 2006) structures would 
serve as models. Once the structure of lysostaphin solved, it would be 
interesting to compare it with LytM structure to understand better the substrate 
specificity of those two glycyl-glycine endopeptidases.   
The interaction studies performed in this thesis (cf. section 5.2.) aimed 
at defining the potential targets in the peptidoglycan for the binding of 
lysostaphin. Our results showed a concentration dependent binding of the 
lysostaphin targeting domain to pentaglycine, Gly-Gly-L-Ser-Gly-L-Ser, 
tetraglycine, diglycine, acetyl-Lys-D-Ala-D-Ala. Interactions of LssTdom to 
diglycine was unsuspected as it was not in agreement with what had 
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previously been reported in the literature (Lu et al., 2006; Gründling and 
Schneewind, 2006). A question that arose from the binding studies performed 
was whether the interactions observed in the gas phase resembled those 
formed in solution. Indeed, the method makes a number of assumptions 
(Peschke et al., 2004), most notably that complexes are successfully 
transferred from solution to the gas phase without significant perturbation of 
the intermolecular non-covalent forces responsible for their association. A 
limitation with this type of approach is that it is only valid for complexes 
dominated by polar or ionic interactions, where the dissociation of the 
complex in the gaseous phase can be neglected (a compound forming a 
complex that has significant contributions from non-polar interactions is 
thermodynamically favoured as a dissociation molecule in the gaseous phase).  
To define the type of system involved in the association of the 
lysostaphin targeting domain to the peptidoglycan components of 
staphylococci, we looked at the residues likely to be involved in the binding. A 
non-exhaustive list of the residues likely involved in the binding of the ALE-1 
targeting domain to pentaglycine is: tyrosine 276 and 280, isoleucine 293, 
arginine 296 and tryptophan 358 (Lu et al., 2006). As the cell wall targeting 
domain of lysostaphin and ALE-1 share a high degree of homology, it seems 
safe to assume that both enzymes behave similarly. Tryptophan and isoleucine 
are hydrophobic residues, tyrosine is partially hydrophobic and arginine is 
hydrophilic and charged. As those residues are mainly hydrophobic, we can 
predict that the complexes of lysostaphin with peptidoglycan components 
formed were dominated by non-polar interactions and appeared relatively 
weaker in the gas-phase.  
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The data obtained for KD and IC50 for the different complexes were 
under scrutiny, with the question as to whether it was possible to quantify the 
interactions observed. Indeed, the dissociation constants (KD) obtained for the 
binding of the lysostaphin targeting domain are in the µȂ range which is very 
low compared to the nM range expected for high affinity binders. Thus it is 
difficult to assess whether the complexes formed were due to non-specific 
binding. Nonetheless, the value of KM obtained for full length lysostaphin by 
FRET assay measurement showed a very poor binding affinity (KM = 200 
µȂ), in agreement with that which was obtained by ESI-MS. This gives more 
confidence in the reliability of the measures obtained by mass spectrometry.  
To confirm the data obtained by ESI-MS, a potential future approach 
could be to use isothermal titration calorimetry (ITC) to measure non-covalent 
LssTdom-ligand complexes. This would confirm whether or not resistance to 
lysostaphin action due to incorporation of serine residues in the crossbridge is 
a result of the endopeptidase domain being unable to cleave this sequence and 
not due to the targeting domain being unable to bind it. By demonstrating that 
lysostaphin targeting domain presents a difference of affinity between 
pentaglycine and Gly-Gly-L-Ser-Gly-L-Ser in solution using ITC technique 
and thus contradicting the ESI-MS results obtained in the gas-phase, might 
enable the discovery of lysostaphin targeting domain variants that could 
acquire altered binding properties using the phage display technique. Indeed, 
the key aspect of this technique is to find an affinity selection test adapted for 
the discovery of protein variants, which can be resumed by this quote “you get 
what you select for”.  
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Appendix 1 
 
Additional graphic for Chapter 3 (Section 3.4.1.). 
 
Activities of LssEdom before and after denaturation by treatment at 
high temperature (85ºC) were assessed by FRET assay at 37ºC. The MV11 
substrate concentration used was 2.0 PM taken from a 0.19 mM stock solution, 
in 1 mM sodium phosphate (pH 7.0) buffer. The LssEdom concentration used 
in each case was 0.100 PM. 
 
 
 
 
The rate of cleavage is approaching zero when LssEdom is denatured 
by treatment at high temperature (85ºC). 
 
 
 
Cleavage of 2.0 µM MV11 by 0.100 µM LssEdom, before (25ºC) and after 
denaturation at 85ºC.  
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Appendix 2 
 
Additional spectrum for Chapter 4 (Section 4.5.3.). 
 
Examination of LssEdom protein sample by MS (ESI positive ion) on 
the MicroToF did show some peaks additional to the multiply charged ions of 
the protein, in particular a relatively intense singly charged ion at m/z=719. 
Intensity of the ion at m/z=719 is dependent on the voltage difference between 
the Capillary Exit and the Skimmer 1.  
 
 
Mass spectrum (ESI positive ion) at 80 V of LssEdom sample used for NMR studies. 
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Additional spectrum for Chapter 4 (Section 4.5.3.). 
 
Examination of LssEdom protein sample by MS (negative ion) on the 
Apex FTMS system, did not show the ion at m/z=719. 
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